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Ovarian cancer (OC) is one of the most common gynaecological malignancies and a cause
of mortality among western women. Standard-of-care treatment consists of
platinum/taxane-based chemotherapy, but 5-years survival rate remains low.
Germline and somatic mutations in BRCA are present in half of the high grade serous
(HGS) ovarian cancer. Olaparib, a PARP inhibitor affecting DNA damage repair pathway,
has been approved in the treatment of germline-BRCA-mutated patients. The combination
with cediranib, an angiogenesis inhibitor, has shown promising results, increasing
progression-free survival in women with recurrent HGS ovarian cancer.
In this thesis, patient-derived ovarian cancer xenografts (OC-PDX) were used to study
olaparib therapy and mechanisms underlying the observed benefit of the combination.
Next Generation Sequencing and gene expression analysis were performed on OC-PDX to
identify mutations/aberrations in BRCA1/2 and other genes connected to the DNA repair
pathway. A cohort (n=13) of OC-PDX was selected and classified as BRCAness and Not
BRCAness, accordingly to their proficiency or deficiency in DNA damage repair.
Olaparib and cediranib were administered in short-term (4 weeks) or maintenance (until
progression) regimens.
Olaparib showed activity in BRCAness OC-PDX; the effect was improved by cediranib,
inducing durable responses even after treatment suspension. Of note, the combination was
also beneficial in Not BRCAness OC-PDX, promoting stable disease and regression.
The effect of the combination on changes in tumor-associated vasculature and hypoxia
(likely due to cediranib) and DNA damage repair (due to olaparib), together with
preliminary data on gene expression and mutational status, suggested a potential
“cumulative” effect of the combination after 4 weeks of treatment. Studies are ongoing, to




The results obtained compel us to believe that the combination of olaparib with cediranib is
advantageous both in DNA repair proficient and, most importantly, in deficient patients,
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1.1 EPITHELIAL OVARIAN CANCER
1.1.1 Epidemiology and risk factors
Ovarian cancer is the seventh most common gynaecological malignancy and one of the
most significant causes of mortality among women, with an estimated incidence of
239.000 cases per year worldwide and accounting for 152.000 deaths per year (Banerjee et
al., 2010; Banerjee and Kaye, 2013).
The high mortality is due to difficulties in diagnosing early stage disease; indeed the
majority of cases (75%-80%) continue to be diagnosed at advanced stage (Banerjee and
Kaye, 2013).
Cytoreductive surgery plays a key role in the initial treatment of ovarian cancer patients, to
remove the tumor mass in order to achieve either a complete ablation or to leave residual
tumors <1 cm (optimal cytoreductive surgery) (Saitou et al., 2015).
After debulking, the majority of patients are referred to standard of care therapy with
platinum/taxane-based first line chemotherapy, resulting in an 80% response rate. However,
the 5-year survival rate remains at 31%, with the majority of the patients relapsing and
becoming resistant to first line treatment (Jemal et al., 2009; Korkmaz et al., 2016). Stage
at diagnosis deeply influences the progression-free survival (PFS) and overall survival (OS)
of the patients. To date, an effective screening tool for ovarian cancer has not been
identified, mainly because symptoms preceding the diagnosis are neither specific nor
sensitive. Indeed, pelvic and abdominal pain, increasing girth or bloating of the abdomen,
difficulty with eating are all symptoms that could be confused with gastrointestinal
diseases. Moreover, in many cases symptoms may not even be present until the tumor has
reached an advanced stage (Cragun, 2011; Karst and Drapkin, 2010).
An important issue to be addressed for ovarian cancer are risk factors. The most important
is a strong family history of ovarian or breast cancer, although an identifiable genetic
predisposition, such as Breast Cancer Type 1 and 2 Susceptibility Proteins (BRCA1 and
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BRCA2) tumor suppressor gene mutations, is present only in 10-15% of patients (Bast et al.,
2009). Early menarche, late menopause, nulliparity and increasing age are also connected
with increased risk, whereas oral contraceptive usage, pregnancy, breastfeeding and tubal
ligation are associated with reduced risk (Edmondson and Monaghan, 2001). Incessant
ovulation could explain these epidemiological data; the repetitive wounding of the ovarian
surface epithelium and cell proliferation in postovulatory repair could result in a stepwise
accumulation of genomic alterations. The accumulation of ovarian epithelial inclusion
cysts might increase the risk of carcinogenesis by entrapping cells in a hormone- and
growth factor-rich environment (Fathalla, 1971). Gonadotropin could also be involved in
the development of ovarian cancer; its high concentration during ovulation and its
persistence after menopause stimulate the epithelial cells of the ovary, inducing genomic
instability and increasing carcinogenesis risk (Cramer et al., 1983).
Inflammation and changes in the redox potential could also play a role in the setting of
ovulation and surface-epithelium repair, accounting for the increased risk of epithelial
ovarian cancer associated with talc or asbestos exposure, endometriosis, pelvic
inflammatory disease and mumps (Cramer et al., 1983).
In this scenario, an effective screening test might help to decrease mortality from ovarian
cancer.
CA-125 is a glycoprotein produced by the uterus, cervix and Fallopian tubes and released
in serum in case of tissue damage and inflammation. In general, levels of CA-125 higher
than 35 U/ml are considered elevated, even though not unequivocally correlated with
cancer.
Indeed, elevated levels of CA-125 are present also in physiological conditions such as
pregnancy, menstrual cycle, hepatic disease and endometriosis.
Transvaginal ultrasonography has been evaluated as an early screening method, but
resulted not to be a completely reliable screening test (Partridge et al., 2009). Women
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carrying mutations in BRCA1 and BRCA2 genes are recommended to undergo periodical
measurements of levels of CA-125 in association with ultrasonography. Moreover, a
salpingo-oophorectomy is advised after 40 years or after pregnancy in these women (Bast
et al., 2009).
1.1.2 Pathology
The term “ovarian cancer” refers not to a single disease, but to a heterogeneous subset of
malignancies involving the ovary, with different morphology and biological behaviour.
Generally, ovarian cancer may arise from one of three cell types: epithelial cells, sex cord-
stromal cells (i.e. granulosa, theca and hilus cells), or germ cells (i.e. oocytes).
Although approximately 40% of all ovarian tumors are non-epithelial in origin, such
lesions may progress to malignancies, accounting for 10% of ovarian cancer (Chen et al.,
2003). Approximately 90% of ovarian cancers are carcinomas (malignant epithelial tumors)
and considered as a heterogeneous group of neoplastic diseases, exhibiting a wide range of
tumor morphologies, clinical manifestations and genetic alterations (Prat and FIGO
Committee on Gynecologic Oncology, 2015).
According to the International Federation of Gynecology and Obstetrics (FIGO) criteria,
epithelial ovarian tumors can be classified upon the grade of invasion and diffusion at
diagnosis in four stages, from I to IV (Prat and FIGO Committee on Gynecologic
Oncology, 2015), as reported in the following table.
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Stage I: confinement to the ovary.
IA
Tumor limited to one ovary with an intact capsule or
to Fallopian tubes.
IB
Tumor limited to both the ovaries with intact
capsules or to both the Fallopian tubes.
IC
Tumor limited to one or both the ovaries or
Fallopian tubes, but with capsule rupture or the
presence of malignant cells on the epithelial surface.
Malignant cells are also present in the ascites or
peritoneal washings.
Stage II: involvement one or both the ovaries or Fallopian tubes, with pelvic extension or
primary peritoneal cancer.
IIA
Tumor is extended and/or implanted on the uterus
and/or Fallopian tubes and/or ovaries.
IIB
Tumor has extended to other pelvic intraperitoneal
tissues.
Stage III: involvement of one or both ovaries or Fallopian tubes, or primary peritoneal
cancer with spreading to the peritoneum outside the pelvis, and/or metastasis to the
retroperitoneal lymph nodes.
IIIA
Cytologically or histologically proven positive
retroperitoneal lymph nodes only or microscopic
extrapelvic peritoneal involvement.
IIIB
Macroscopic peritoneal metastasis beyond the pelvis
up to 2 cm diameter with or without metastasis to
retroperitoneal lymph nodes.
IIIC
Macroscopic peritoneal metastasis beyond the pelvis
more than 2 cm diameter with or without metastasis
to retroperitoneal lymph nodes.
Stage IV indicates tumors with distant metastasis, with malignant cells present in the
pleural effusion and involving abdominal organs with parenchymal and extra-abdominal
metastasis.
Five main subtypes of epithelial ovarian cancer can be recognized based on their
histopathology: high grade serous (HGS, 70%) and low grade serous (LGS, <5%)
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carcinomas, high grade endometrioid carcinomas (HGE, 10%), clear cell carcinomas (CCC,
10%), mucinous carcinomas (MUC, 3%) (Figure 1.1) (Prat, 2012; Robert J. Kurman et al.,
2014). They differ completely in epidemiologic and genetic risk factors, precursor lesions,
patterns of spread and molecular events during cancer development, other than response to
first line chemotherapy and prognosis (Gilks and Prat, 2009).
1.1.3 Dualistic model
Over the last several years a so-called “dualistic model” has been proposed to explain the
pathogenesis of epithelial ovarian cancer, based on origin, morphological and molecular
features (Bowtell, 2010; Kurman and Shih, 2010; Wu et al., 2013).
Serous carcinomas arise from the Fallopian tube epithelium, while endometriosis is
considered the precursor of endometrioid and clear cell tumors (Kurman and Shih, 2010).
Moreover, low grade serous carcinomas differ from high grade serous on both the
morphological and molecular aspects. Even though they both seem to arise from Fallopian
tubes, the former develops from papillary hyperplasia that invades the ovary forming
benign cysts that evolve later to neoplasia, which are not related to BRCA abnormalities.
The latter arises from the tube and invades the ovary by direct contact. The finding of high
grade serous tubal intraepithelial carcinoma (STIC) in patients with BRCA mutations
drives the idea that STIC cannot be considered a real in situ carcinoma, but rather
metastasizing tubal-origin cells, sharing typical tube Mullerian markers with high grade
serous carcinomas, rather than ovarian epithelial markers (Piek et al., 2001). Accordingly
to these findings, epithelial ovarian tumors can be divided into Type I and Type II.
1.1.4 Classification
1.1.4.1 Type I
The type I group includes low grade serous, clear cell and mucinous carcinomas, which
develop in a stepwise fashion from well-established precursor lesions, such as borderline
tumors and endometriosis. These types of tumor are generally indolent and confined to the
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ovary (stage I), genetically stable and displaying a variety of somatic sequence mutations
but very rarely tumor protein p53 (TP53) (Jones et al., 2010; Shih and Kurman, 2004).
Low grade serous (LGS) carcinomas
LGS are uncommon (less than 5% of all cases of ovarian carcinoma), originate from
papillary hyperplasia of the Fallopian tube, that subsequently colonizes the ovary forming
benign cysts. They are generally associated with a good prognosis. LGS lack chromosomal
instability and the most frequent mutations are on Kirsten rat sarcoma viral oncogene
homolog (KRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) genes.
Low grade endometrioid (LGE) carcinomas
LGE account for approximately 10% of ovarian carcinomas and resemble tumors
encountered frequently in the endometrium. They are diagnosed at early stage and for this
reason prognosis is generally favourable. The most frequent mutation occurs in the Catenin
(cadherin-associated protein) beta 1 (CTNNB1) gene (50% of the cases) and to a lesser
extent phosphatase and tensin homolog (PTEN) is mutated (20% of the cases) or lost
(40%).
Clear cell carcinomas (CCC)
CCC account for approximately 10% of ovarian carcinomas and patients are generally
diagnosed at early stages of disease. These types of tumors are frequently related to
endometriosis and have a good prognosis (Komiyama et al., 1999). From the histological
point of view, a papillary architecture defines this group of tumors. CCC lack BRCA
abnormalities and chromosomal instability (Press et al., 2008), but inactivating mutations
on the AT rich interactive domain 1A (SWI-like) (ARID1A) gene and activating mutations
of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene
are present in ~ 50% of cases.
Mucinous carcinomas (MUC)
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MUC account for 3% of ovarian carcinomas. They are generally associated with a good
prognosis because they are usually confined to the ovary, without the involvement of the
ovarian surface. Tumor cells of MUC resemble those of the endocervix, gastric pylorus
and intestine. KRAS mutations are the most common alterations in this type of tumor.
1.1.4.2 Type II
Type II includes high grade serous and high grade endometrioid carcinomas, malignant
mixed mesodermal tumors (carcinosarcomas), and undifferentiated carcinomas, which
present at an advanced stage (stages II-IV) in more than 75% of cases. These types of
tumors are generally aggressive and rapidly evolving, highly chromosomally unstable,
presenting mutations in TP53 (more than 95% of the cases) and rarely displaying
mutations found in the type I tumors (Kurman and Shih, 2011). BRCA inactivation, either
by mutation or loss of expression, and its downstream genes via promoter methylation,
occurs in up to 40% to 50% of high grade serous carcinoma.
High grade serous (HGS) carcinomas
HGS is the most common type of ovarian carcinoma, arising from the Fallopian tube and
reaching the ovary by direct contact (Piek et al., 2003). This type accounts for
approximately 70% of all cases of ovarian carcinomas and they are usually related to a
poor prognosis, mainly due to their rapid growth and aggressiveness. Primary
cytoreductive surgery is the initial approach in most patients; thereafter tumors are
generally sensitive to platinum/taxane-based first line chemotherapy, but the majority of
the patients eventually experience chemotherapy resistant recurrence.
Up to 50% of HGS show abnormalities in BRCA1 and BRCA2 genes (such as germline and
somatic mutation, deletion, promoter methylation and therefore low expression) and more
than 95% in TP53 (mutation or deletion) (Esteller et al., 2000; Kindelberger et al., 2007;
Leitao et al., 2004; Medeiros et al., 2006; Singer et al., 2005). Moreover, HGS are
characterized by homologous recombination dysfunction and widespread copy number
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changes. All these changes result in a loss of ability to repair DNA double strand breaks
and in an increase in chromosomal instability, that increases intratumoral heterogeneity.
Recently has been reported that germline mutations in BRCA1 and BRCA2 are mutually
exclusive with aberrations in cyclin E1 (CCNE1), one of the few recognized molecular
therapeutic target in HGS.
High CCNE1 expression occurs up to 50% of HGS cases, but only half the cases are linked
to 19q12 locus amplification accordingly to the Cancer Genome Atlas (Cancer Genome
Atlas Research Network, 2011).
The CCNE1-high/amplified subset of tumors has intact BRCA1/2, unfavorable outcome,
since they are poorly responsive to platinum therapy and have limited responsiveness to
PARP inhibitors.
High grade endometrioid (HGE) carcinomas
HGE can barely be distinguished from HGS. Unlike LGE, CTNNB1 and PIK3CA/PTEN
pathways are not defective, but mutations in TP53 are frequently present (Wu et al., 2007).
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Figure 1.1 The major histologic subtypes of epithelial ovarian cancer.
Serous carcinomas mirror fallopian tube epithelium, endometrioid carcinomas resemble
endometrial glands, and mucinous carcinomas look like endocervical epithelium.
Picture shows representative tumor section stained with haematoxylin and eosin. The
shaded circle represents the general anatomical location from which ovarian carcinomas
are thought to arise.
Modified from Karst A.M. and Drapkin R, Ovarian Cancer Pathogenesis: A Model in Evolution, Journal of
Oncology, 2010.
Chapter 1 Francesca Bizzaro
12
1.2 TREATMENT OF OVARIAN CANCER
1.2.1 Cytoreductive surgery
Peritoneal washing and/or paracentesis, hysterectomy, bilateral salpingo-oophorectomy,
pelvic and para-aortic lymph node sampling, diaphragmatic biopsies, omentectomy, biopsy
of suspicious lesions and random biopsies through the peritoneum are used to collect
material for histological analysis to formulate a diagnosis and decide the optimum post-
operative treatment (Ozols, 2003).
Since the majority of ovarian cancers are diagnosed at advanced stage and grade of disease,
chemotherapy alone rarely results in a complete cure. For this reason, optimising surgery
continues to be essential for patients.
Complete surgical debulking is the standard of care for early stage ovarian cancer, whereas
primary cytoreductive surgery followed by platinum/taxane-based chemotherapy is to date
the current management for advanced ovarian cancer. Optimal cytoreduction is one of the
most significant predictors of survival: indeed residual disease < 1 cm is considered
optimal debulking and prognosis correlates with the extent of residual disease (Griffiths,
1975).
Moreover, the timing of cytoreduction is becoming a critical point; cytoreduction at the
time of diagnosis is a standard practice, although only 50% of patients can be effectively
reduced at the initial laparotomy.
Patients in whom the initial cytoreduction is not successful are committed to three cycles
of chemotherapy, and if responsive, undergo another attempt at cytoreduction (interval
cytoreduction) followed by additional chemotherapy (Martinek and Kehoe, 2010). Interval
debulking has generally a significant effect both on time to progression and median
survival for patients (6 months).
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Ovarian cancer is frequently considered a chronic disease, and while cure remains the
ultimate goal of therapy, prolongation of survival, together with palliation of symptoms, is
a clinically meaningful accomplishment.
1.2.2 Chemotherapy
The 2010 consensus meeting defined standard of care treatment in ovarian cancer. The
recommended treatment paradigm for advanced disease has been debulking surgery
followed by platinum-based chemotherapy, initially cisplatin-based and more recently with
carboplatin/paclitaxel (Stuart et al., 2011).
Platinum-derivatives
Platinum-derivatives were introduced as chemotherapeutic agents in the 1960s. Cisplatin
was the first platinum-based drug developed, before oxaliplatin and then carboplatin, a
drug with fewer and less severe side effects introduced in the 1980s and to date the drug of
choice for the treatment of ovarian cancer.
Cisplatin is a cytotoxic drug, classified as an alkylating agent, whose mechanism of action
is the formation of platinum complexes interacting with DNA. The formation of DNA
adducts, primarily intra-strand crosslink adducts, activates several signal transduction
pathways and culminates in the activation of apoptosis.
Several randomized studies have demonstrated the efficacy of platinum-based therapy in
ovarian cancer, particularly when given in combination. Gynaecologic Oncology Group
Trial No.47 (Omura et al., 1986) has compared the efficacy of doxorubicin-
cyclophosphamide (AC) with doxorubicin-cyclophosphamide-cisplatin (PAC); the
progression-free survival and median survival time were significantly increased in the PAC
group.
Taxane-derivatives
Paclitaxel was isolated in 1967 from the bark of the Pacific yew tree, Taxus brevifolia.
Together with docetaxel, it comprised the category of taxanes. Paclitaxel is a mitotic
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inhibitor that stabilizes microtubules (tubulin dimers) and as a result, interferes with the
normal breakdown of microtubules during cell division because chromosomes are thus
unable to achieve a metaphase spindle configuration. This blocks progression of mitosis
and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G-
phase of the cell cycle without cell division.
The consensus meeting in 2010 acknowledged that acceptable variations to the
recommended therapies existed, but their use must be supported by at least one trial
demonstrating superiority or non-inferiority. Initially, improvements to standard
platinum/taxane chemotherapy were seen through the addition of a third chemotherapeutic
agent with demonstrable activity in the relapsed setting. First line trials investigated the
addition of drugs, including pegylated liposomal doxorubicin (PLD), topotecan and
gemcitabine (Bolis et al., 2010; Bookman et al., 2009; du Bois et al., 2010; Hoskins et al.,
2010), but unfortunately demonstrated only increased toxicity without survival benefits.
Other cytotoxic agents
After first line treatment with platinum/taxane-based chemotherapy, patients are monitored
periodically to evaluate the response; tumors are defined as platinum resistant if the relapse
occurs within 6 months from the last dose of treatment. In this case, a second line
chemotherapy is proposed.
Pegylated liposomal doxorubicin is a newly available formulation of doxorubicin, an
anthracycline antibiotic intercalating DNA that is encapsulated in a pegylated liposome.
The size of the liposomes prevents them from entering tissues with tight capillary junctions,
such as the heart and gastrointestinal tract, and in contrast to other nanoparticles, the
pegylation allows these molecules to be protected from destruction by the
reticuloendothelial system (Green and Rose, 2006).
Topotecan is a derivative of camptothecin that inhibits topoisomerase I, thus blocking cell
cycle S-phase (Armstrong, 2004).
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Gemcitabine is a nucleoside analogue of deoxycytidine that replaces cytidine during DNA
replication, thus blocking DNA synthesis and inducing apoptosis (Poveda, 2005).
Recently, trabectedin demonstrated efficacy as a second-line treatment in platinum-
sensitive ovarian cancer. The mechanism of action is binding of the DNA minor groove
and interference with cell division, gene transcription mechanisms and DNA repair
(Colombo, 2011).
A more successful strategy seems likely to be the addition of targeted therapies to
chemotherapy.
1.2.3 Targeted therapies
During recent years the search for new cancer therapies has been addressed to the
development of specifically targeted drugs that block cancer growth and dissemination by
interfering with multiple molecular targets, such as growth factor receptors, signal
transduction pathways, cell cycle regulators, and angiogenic mechanisms specifically
expressed by tumor cells or the tumor environment. For this reason, these therapies are
theoretically very effective against cancer cells and less harmful to normal cells.
Two of the major molecular targeted agents applied to ovarian cancer are inhibitors of
angiogenesis (chapter 1.3.1 Inhibitors of angiogenesis as cancer therapy) and inhibitors of
the poly(ADP-ribose) polymerases (chapter 1.4.1 Poly(ADP-ribose)polymerase (PARP)
inhibitors as cancer therapy) (Grunewald and Ledermann, 2017; Lim and Ledger, 2016).
1.3 ANGIOGENESIS AND TUMOR ANGIOGENESIS
The term angiogenesis refers to all those processes that lead to blood vessel formation and
sprouting, starting from the existing vasculature. In physiological conditions, angiogenesis
plays a key role in embryonal development, formation of the uterus lining prior to
menstruation and of the placenta after fertilization, pregnancy, normal tissue growth and
wound healing (Figure 1.2) (Carmeliet and Jain, 2000).
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Figure 1.2 New blood-vessel formation.
Angiogenic signals lead to the preferential differentiation of certain endothelial cells into
so-called “tip cells”, which start to migrate and exist at the leading front of the growing
vessels.
Number of factors including VEGF receptor (VEGFR)-3 (for lymphatic-endothelial cells),
VEGFR-1 and -2 (for blood endothelial cells), PDGF-B and the Notch ligand delta-like
ligand (Dll)-4 have been shown to contribute to the endothelial tip cell phenotype.
a) Vessel in normal physiological conditions.
b) Detachment of pericytes and dilatation of blood vessels before the basement membrane
and extracellular matrix are degraded.
c)Migration of endothelial cells, following angiogenic stimuli.
d) Proliferation of endothelial cells.
e) Adhesion of endothelial cells to each other, consequently creation of a lumen and
formation of a basement membrane, surrounded by pericytes.
Modified from Bergers and Benjamin, Tumorigenesis and angiogenic switch, Nature Review, 2003.
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Nevertheless, angiogenesis is fundamental in many pathological conditions such as chronic
inflammation and cancer (Folkman, 1971). Angiogenesis is a critical component for the
growth and metastasis of cancer (Ellis and Hicklin, 2008) and it is one of the hallmarks of
cancers that have been extensively studied (Hanahan and Weinberg, 2011). Accordingly to
Folkman et al (Hanahan and Folkman, 1996), endothelial cells switch from a resting state
to a rapid growth phase, induced by factors released by the tumor. The switch depends on
the increased production of positive regulators of angiogenesis such as vascular endothelial
growth factor (VEGF), fibroblast growth factor (FGF), placental growth factor (PlGF),
transforming growth factor beta (TGF-beta), angiopoietins (Angs), interleukin-8 (IL-8) and
others (Bergers and Hanahan, 2008) induced by tumor cells, or released from the
microenvironment upon tumor stimulation. In parallel, the switch involves downregulation
of negative regulators of angiogenesis, such as endostatin, angiostatin and thrombospondin
(Hanahan and Folkman, 1996; Ribatti, 2009). During pathological angiogenesis the tight
balance and control of factors which regulated the process are lost and tumor vessels fail to
remain quiescent (Figure 1.3) (Bergers and Benjamin, 2003).
In this scenario, tumor blood vessels display abnormalities both at the structural and
functional level. Typical tumor vessels are leaky, tortuous and sinusoidal, poorly covered
in pericytes and smooth muscle cells, leading to a poor functionality and perfusion (Hosaka
et al., 2013; Nagy et al., 2012; Xue et al., 2011) and facilitating invasion and metastatic
dissemination of tumor cells (Kassis et al., 2007). Moreover tumor vessel density is highly
heterogeneous within the tumor, resulting in chaotic blood flow, hypoxia,
hyperpermeability that may also influence the delivery and effectiveness of anticancer
therapy (Figure 1.3) (Dowlati et al., 2008; Ghosh et al., 2008; Giavazzi et al., 2003; Yu et
al., 2002) and thus may influence the patients’ outcome (Hollingsworth et al., 1995).
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Figure 1.3 Angiogenic balance and angiogenic switch.
Physiologically, angiogenesis is a process tightly regulated by a multitude of pro- and anti-
angiogenic factors. However, this delicate equilibrium is lost in tumor tissues and pro-
angiogenic factors prevail over angiogenesis inhibitors, thus promoting the angiogenic
switch.
a) “Dormant” tumor nodule.
b) Starting of the “switch”: perivascular detachment and vessels dilatation. Angiogenic
switch occurs to ensure exponential tumor growth.
c) and d) Onset of the sprouting of the new tumor vessels, that continuously grow and
mature, recruiting perivascular cells.
e) Permanent tumor vessels formation to feed hypoxic and necrotic areas of the tumor.
Modified from Bergers and Benjamin, Tumorigenesis and angiogenic switch, Nature Review, 2003.
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1.3.1 Inhibitors of angiogenesis as cancer therapy
An effective antiangiogenic strategy is to block the VEGF / VEGFR (vascular endothelial
growth factor receptor) pathway (Leung et al., 1989). VEGFA, known also as vascular
permeability factor, was first described in the malignant ascites of human ovarian cancer
(Dvorak et al., 1995) and it is mainly induced by hypoxia (Forsythe et al., 1996). To date,
VEGFA is the most studied non-oncogene-specific target that can be blocked directly with
humanized monoclonal antibodies such as bevacizumab. The VEGF receptor family, that
includes VEGFR1, VEGFR2 and VEGFR3, is the target of numerous kinase inhibitors,
such as sunitinib, sorafenib, pazopanib and cediranib (Figure 1.4).
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Figure 1.4 VEGF signaling inhibitors and their targets.
The VEGF family of ligands (VEGFA, PlGF, VEGFB, VEGFC, and VEGFD) bind to their
receptors (VEGFR1; blue, VEGFR2; grey, VEGFR3; green).
VEGF antagonists display their activity:
• interfering with binding of VEGF ligands on the extracellular domain (e.g. Bevacizumab,
VEGF-Trap, Veglin, IMC-18F1, Ramucirumab/CDP791);
• competing for ATP-binding to the intracellular kinase domain (e.g. axitinib, brivanib,
cediranib, linifanib, pazopanib, sorafenib, sunitinib, tivozanib, vandetanib, vatalanib).
Modified from Tugues et al, Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in
the treatment of cancer, Molecular Aspects of Medicine, 2011.
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Bevacizumab (Avastin ®) is a humanized antibody that targets directly VEGF and blocks
its binding with VEGFR (Kim et al., 1992). The antitumor activity of bevacizumab has
been demonstrated in preclinical studies (Gerber and Ferrara, 2005; Hu et al., 2002;
Mabuchi et al., 2008) and in several clinical trials (Burger et al., 2007; Chura et al., 2007;
Nimeiri et al., 2008; O’Malley et al., 2011) on ovarian cancer. Recently, two randomized
controlled clinical trials have been carried out with bevacizumab added to first line
chemotherapy (GOG-0218 and ICON7) (Burger et al., 2011; Perren et al., 2011) and
results led to the approval of bevacizumab in combination with platinum/taxane-based
frontline therapy by EMEA (European Medicines Evaluation Agency).
The AURELIA and OCEANS trials have evaluated the activity of bevacizumab combined
with chemotherapy also in platinum-resistant (Pujade-Lauraine et al., 2014) and platinum-
sensitive (Aghajanian et al., 2012) recurrent ovarian cancer.
Interestingly the AURELIA trial suggested a positive trend in overall survival in patients
treated with bevacizumab combined with dose-dense weekly paclitaxel. Although this
regimen of paclitaxel is considered a reasonable option to enhance antitumor activity and
prolong survival (Katsumata et al., 2009; Pignata et al., 2014) and paclitaxel displays
potent antiangiogenic properties (Miller et al., 2001), the relevance of doses and schedules
of paclitaxel in a combination with bevacizumab was not completely clear. Recently, the
GOG-0262 clinical trial reported that in combination with bevacizumab (and carboplatin),
3-weekly or weekly paclitaxel (PTX) regimens were equally effective (reported as PFS),
with the former giving fewer adverse events (Chan et al., 2016). This study also indicated
similar PFS with weekly paclitaxel without bevacizumab (14.2 months) and with weekly
or every-3-weeks PTX with bevacizumab (respectively 14.9 and 14.7 months), thus
questioning the advantage of adding bevacizumab to the treatment regimens. A further
issue in these trials is that, although the delay in tumor progression (PFS) was a major
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achievement for women with ovarian cancer receiving bevacizumab-containing
chemotherapy, this usually led to a scanty OS increase (Burger et al., 2011; Perren et al.,
2011).
The escape of the tumor from antiangiogenic treatments is well documented in preclinical
studies, including in our models of patient-derived ovarian cancer (OC-PDX) treated with
bevacizumab, which under certain circumstances increased survival but also increased
tumor dissemination (Decio et al., 2015; Oliva et al., 2012; Mitamura et al., 2016).
A number of other antiangiogenic agents have been tested in clinical trials in ovarian
cancer (as reported in the table below, Angiogenesis inhibitors tested in ovarian cancer
clinical trials).
Nintedanib, an oral tyrosine kinase inhibitor (TKI) targeting VEGF receptor 1-3, FGFR 1-3
and PDGFR α and β, has been studied as a first line therapy in chemotherapy-naïve
patients in combination with carboplatin and paclitaxel in the randomised, double-blind,
placebo-controlled phase 3 trial AGO-OVAR 12. A statistically significant improvement in
PFS was noted although the actual magnitude of benefit in median PFS was modest (du
Bois et al., 2016).
Pazopanib, a multi-targeted receptor tyrosine kinase inhibitor (VEGFR 1-3, PDGFR α and
β and c-kit) has also been studied in the first line setting in ovarian cancer. In a randomized,
double-blind, placebo-controlled, phase III trial of maintenance pazopanib (for up to 24
months) following no evidence of progression after surgery and platinum-taxane
chemotherapy, progression-free survival was significantly improved (12.3 vs 17.9 months;
HR 0.766 p=0.021) (du Bois et al., 2014).
Trebananib, a peptide fusion protein (or peptibody), displays its activity by preventing the
binding of angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) to their receptor Tie2.
Trebananib has shown antiangiogenic activity on preclinical models of ovarian cancer
(Coxon et al., 2010) and as a single-agent in relapsed epithelial ovarian cancer in phase I
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trial (Herbst et al., 2009), prolonging progression-free survival in phase II study (Karlan et
al., 2012). Results of a phase III trial investigated the addition of trebananib to paclitaxel,
showing an increase in progression-free survival (7·2 months vs 5·4 months), associated
with higher incidence of oedema (Monk et al., 2016).
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Angiogenesis inhibitors tested in ovarian cancer clinical trials.
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In this scenario, cediranib, a VEGFR tyrosine kinase inhibitor, has a response rate similar
to bevacizumab given as single-agent (Hirte et al., 2015; Matulonis et al., 2009).
1.3.2 Cediranib
Cediranib (AZD2171) is a potent, oral, small molecule tyrosine kinase inhibitor that blocks
the three VEGF receptors (VEGFR1, VEGFR2, VEGFR3), and targets also c-KIT and
PDGFR-alpha and PDGFR-beta (Figure 1.5) (Wedge et al., 2005; Smith et al., 2007;
Heckman et al., 2008; Brave et al., 2011).
Figure 1.5 Structure of cediranib.
[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)
quinazoline maleate (AZD2171).
Modified from Brave et al, Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor,
against VEGFR-1 and Members of the Structurally Related PDGFR Family, Molecular Cancer Therapeutics,
2011.
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Cediranib competes for the ATP-binding site within the receptor kinase domain in
particular of VEGFR2, that predominantly transduce the angiogenic and permeability
activity of VEGFA, but also of VEGFR1 and VEGFR3 (Heckman et al., 2008), preventing
the ATP catalysis and propagation of receptor signaling. Consequently, a reduced
activation of downstream signaling molecules ERK1/2, Akt, and CREB is observed.
The unique structural features adjacent to the ATP-binding site allows the achievement of
selectivity. However, cediranib has additional activity against PDGFR-alpha, PDGFR-beta
and c-Kit. Indeed, these receptors have some structural homologies with the VEGFR
family members, having a kinase-insert sequence in the intracellular domain.
The simultaneous inhibition of multiple kinases may provide additional therapeutic
opportunities, but also impact adversely on tolerability or in combination usage with
concurrent cytotoxic drugs.
Additionally, cellular functions associated with VEGFR activation, including proliferation,
survival, and migration, are all compromised by cediranib. Interestingly, cellular migration
seems to be particularly sensitive to cediranib treatment. Low concentrations of the
compound inhibit blood endothelial cell migration, but only slight inhibition of ligand-
induced receptor phosphorylation at the same concentration was observed. Furthermore,
cediranib compromises the growth of tumor-associated blood vessels and also induces
regression and inhibition of VEGFR3 mediated lymphangiogenesis. The growth of human
non-small cell lung adenocarcinomas in cediranib treated animals is impaired (Heckman et
al., 2008). Cediranib inhibits human umbilical vein endothelial cell (HUVEC) proliferation
and diminishes microvessel density, causing reversible epiphyseal zone hypertrophy in
rodent models (Wedge et al., 2005) and was described effective in reducing lymphatic
metastasis, independent of the effect on blood vessels (Padera et al., 2008), but also
blocking VEGFC-induced VEGFR3 activity and lymphangiogenesis in lung cancer
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(Heckman et al., 2008). Also, cediranib is active in a wide variety of human tumor
xenografts (Decio et al., 2015; Lobo et al., 2015; Melsens et al., 2017). It has demonstrated
single-agent activity in preclinical models of ovarian cancer and activity in combination
with other small molecule inhibitors or chemotherapy, inhibiting tumor progression and
dissemination to metastatic organs even in OC-PDX poorly responsive to platinum (Decio
et al., 2015).
In the randomized, double-blind NCIC clinical trial BR24 in advanced non-small-cell lung
cancer (NSCLC), the addition of cediranib to carboplatin/paclitaxel resulted in improved
response and increased PFS (Goss et al., 2010).
In the double-blind, randomized phase III study (HORIZON III) in advanced metastatic
colorectal cancer, cediranib activity, in terms of PFS and OS, was comparable to that of
bevacizumab when added to mFOLFOX6. However, the predefined boundary for PFS
non-inferiority was not met (Schmoll et al., 2012).
Cediranib monotherapy was studied in a phase II study in patients with recurrent
glioblastoma. Encouraging proportions of radiographic response and an increase in the 6-
month PFS was observed after cediranib treatments (Batchelor et al., 2013).
Cediranib monotherapy demonstrated significant evidence of antitumor activity in a
randomised phase II study in patients with advanced renal cell carcinoma (Mulders et al.,
2012).
In a prospective trial of systemic therapy for metastatic alveolar soft tissue sarcoma, it was
observed that cediranib had substantial single-agent activity, producing an objective
response rate (ORR) of 35% and a disease control rate of 84% at 24 weeks (Kummar et al.,
2013).
In an open-label, phase I study of cediranib in patients with acute myeloid leukemia,
cediranib showed preliminary evidence of activity as a monotherapy (Fiedler et al., 2010).
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In particular, in ovarian cancer cediranib has demonstrated activity as monotherapy in two
phase II single-agent studies with either platinum-resistant or -sensitive recurrent disease;
all the patients that had benefitted from the administration of cediranib were high grade
serous cases with a maximum of one previous line of treatment for relapsed disease
(Matulonis et al., 2009).
Following these phase II trials, studies with cediranib given in combination with
chemotherapy and other targeted therapies were carried out.
A pivotal phase III trial of cediranib in combination with platinum-based chemotherapy
with or without cediranib maintenance demonstrated improved PFS in patients treated with
cediranib compared with placebo and the outcome measure of safety demonstrated that is
feasible to add cediranib to carboplatin/cisplatin (DDP) and paclitaxel chemotherapy
without major unexpected toxicities (Raja et al., 2011).
ICON6, a multi-stage phase III, randomized, placebo-controlled Gynaecological Cancer
InterGroup (GCIG) trial, evaluated the activity of cediranib in combination with
chemotherapy in patients with relapsed-sensitive ovarian, Fallopian tube or primary
peritoneal cancer. Treatment arms were chemotherapy plus placebo then placebo in
maintenance (arm A), chemotherapy plus cediranib once a day then placebo in
maintenance (arm B), chemotherapy plus cediranib once a day then cediranib in
maintenance (arm C). PFS was the primary end-point. Median PFS was 11.0 months in
arm C and 8.7 months in arm A. The majority (90%) of patients in arm B had disease
progression, and median progression-free survival was 9.9 months. ICON 6 was
prematurely interrupted, due to toxic effects, particularly diarrhoea, fatigue and
hypertension, but PFS was greater in the chemotherapy plus cediranib in maintenance
group than chemotherapy plus cediranib followed by placebo (Ledermann et al., 2016).
The promising activity in terms of PFS in ICON6 prompted the investigation of cediranib
in combination with other therapies (such as PARP inhibitors) for ovarian cancer.
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1.4 DNA REPAIR TARGETED THERAPY
DNA repair pathways are intrinsic cell mechanisms that evolved to allow the tolerance and
repair of DNA damage associated with normal cell functions and with the extrinsic injuries
such as environmental radiation, reactive oxygen species and chemical agents.
Genome instability caused by the great variety of DNA damaging agents would be an
overwhelming problem for cells and organisms if it were not for DNA repair systems
(Friedberg et al., 2006; Glazer et al., 2013; Sancar et al., 2004; Wood et al., 2001).
The human genome encodes information to protect its own integrity. DNA repair enzymes
have the role to continuously monitor the chromosome to correct damaged nucleotides
with five main mechanisms of action (Figure 1.6).
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Figure 1.6 DNA damage repair pathways.
The five DNA damage response pathways are presented with key proteins involved and the
critical repair steps within each of the pathways are pictured.
Modified from Jalal et al, DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target,
Clin Cancer Res, 2011.
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Two major forms of injury can occur on DNA: single strand breaks (SSBs) that involve
only one DNA filament, and double strand breaks (DSBs) that involve the double helix.
Direct reversal repair (DDR) directly restores the native nucleotide residues by removing
the non-native chemical modification. Functions for excision repair are base-excision
repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR); the BER
system excises single damaged bases and replaces them, NER mainly removes bulky
adducts and MMR corrects occasional errors of DNA replication as well as abnormalities
formed during recombination.
Homologous (HR) and non-homologous (NHR) recombination pathways, such as non-
homologous end-joining (NHEJ), correct DSBs. The former repairs DNA double strand
breaks using the homologous DNA strand as a template to resynthesize a new filament and
for this is considered a high fidelity repair pathway; the latter ligates the ends resulting
from DNA double strand breaks with an error-prone mechanism of repair.
Interest in targeting DNA repair proteins has increased over the last few decades, in
particular because their impact in platinum resistance is well documented in several types
of cancer, including ovarian (Nguewa et al., 2006).
1.4.1 Poly(ADP-ribose) polymerase (PARP) inhibitors as cancer therapy
PARP inhibitors are the latest class of agents to gain approval in ovarian cancer (George et
al., 2017).
PARP1 and 2 are enzymes that sense the DNA damage and signal transducers that operate
by synthetizing negatively charged poly(ADP-ribose) (PAR) chains, via PARylation, on
target proteins as a form of posttranslational modification (Satoh and Lindahl, 1992).
PARP1 works by binding DNA single strand breaks and other DNA lesions. The
recognition of the damage induces allosteric changes in the structure of PARP1, activating
its catalytic function (Figure 1.7). This leads to the PARylation and recruitment of DNA
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repair effectors (such as BRCA1/2, substrates of PARP) and also to the remodelling of the
chromatin around the site of damage. To shut down the process, PARP1 autoPARylates
itself and it is released from the repaired DNA (Dawicki-McKenna et al., 2015; De Vos et
al., 2012; Krishnakumar and Kraus, 2010; Satoh and Lindahl, 1992).
The rationale to use PARP inhibitors is that tumor cells can be made more sensitive to
conventional treatments that damage DNA, such as chemotherapy or radiotherapy. It was
recently shown that PARP inhibition, as well as blocking the PARylation process, also
induces a “trap” of PARP on the site of DNA damage. This effect induces the block of the
replication forks; in conditions of effective DNA repair systems, such as HR (chapter 1.4
DNA repair target therapy), the activity of the forks is restored and the tumor cell survives.
Conversely, the concept of synthetic lethality is related to the blockade of PARP activity in
the presence of defects in mechanisms of DNA repair. Mutations in DNA repair effector
genes (such as BRCA1/2) and consequent production of a non-functional protein, added to
PARP1 blockade, induce a non-resolution of the DNA damage, driving genomic instability,
mediated by an error-prone mechanism of repair, such as NHEJ, that eventually leads to
death (Ashworth et al., 2011; Terada et al., 1979).
For these reasons, drug discovery efforts led to the development of a plethora of PARP
inhibitors that show different effects in terms of cytotoxicity and ability to “trap” PARP on
DNA.
To date there are five principal PARP inhibitors that have been developed and are used
clinically: veliparib (Abbvie), rucaparib (Pfizer/Clovis), olaparib (KuDOS/AstraZeneca)
and niraparib (Merck/Tesaro) and the second generation, more potent PARPi, talazoparib
(Lead/Biomarin/Medivation/Pfizer) (Shen et al., 2013). Talazoparib is approximately 100
times more potent than niraparib in term of capacity to “trap” PARP on DNA, and
niraparib itself is more potent that olaparib and rucaparib; it has been demonstrated that the
PARP inhibitor with least “trap” ability is veliparib (Murai et al., 2014).
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Preclinical testing of PARP inhibitors demonstrated anti-tumor activity both alone and in
combination with DNA damaging chemotherapy.
Farmer and colleagues (Farmer et al., 2005) showed in vitro and in vivo activity of PARP
inhibitor on BRCA1 and 2 deficient embryonic stem cells (ES). Similarly, De Soto (De
Soto et al., 2006) reported in vivo demonstration of PARP-1 in BRCA1 deficient mammary
tumors, mouse and human breast cells, thus indicating that the inhibition of PARP could
improve the outcome for patients with defects in DNA repair effector genes.
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Figure 1.7 Mechanism of action of PARP inhibitors.
A. PARP1 catalytic cycle.
i) Non-DNA bound state. PARP1 includes three zinc-finger related domains (ZnF1,2,3), BRCA1
C-terminus domain (BRCT), tryptophan-,glycine-, arginine-rich domain (WGR) and the catalytic
domain composed by an helical domain (HD) and an ADP-ribosyltransferase (ART) domain. HD
acts as an autoinhibitory domain preventing the bound to DNA. ii) DNA single strand breaks (SSBs)
make the DNA double helix turn. iii) SSBs are recognized by ZnF1,2,3. iv) HD domain changes
conformation and losses the autoinhibitory activity. v) ART domain drives the PARylation by
mediating the recruitment of DNA repair effectors that are PARP1 substrates. vi) PARP1
autoPARylation causes the restoration of a catalytically inactive state. vii) PARPi, that binds
catalytic domains of PARP1, prevents the release of PARP1 from DNA, by “trapping” it at the site
of damage.
B. PARP inhibitors mechanism of action.
i) When PARP1 is trapped on DNA, it causes the impairment of the progression of replication
forks. ii) Stalled replication forks normally induce DNA damage response. iii) Homologous
recombination (HHR), that involves BRCA1/2, allows the forks to restart and damage is resolved.
iv) Defective HHR induces the cell to switch on error prone DNA damage repair systems, which
cause large-scale genomic rearrangements, which can lead to cell death and synthetic lethality. v)
Resistance to PARP inhibitor can occur also in case of HHR deficiency.
Modified from Lord and Ashworth, PARP inhibitors: Synthetic lethality in the clinic, Science, 2017
B
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1.4.2 BRCA1 and BRCA2 mutations
Breast cancer susceptibility genes (BRCA) 1 and 2 were discovered in the early 90’s (Hall
et al., 1990; Wooster et al., 1995). BRCA1 spans approximately 100 kb on the genomic
DNA and consists of 5592 base pairs in 22 exons, that encodes an 1863 amino acid protein
(Figure 1.8) (Miki et al., 1994). BRCA2 is a large gene of 10524 nucleotides, including 27
exons and encoding for a protein of 3418 amino acids (Figure 1.9) (Tavtigian et al., 1996).
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Figure 1.8 Structure and Binding Partners of BRCA1.
BRCA1 encodes for 24 exons, translating into an 1863 amino acid protein. Main functional
domains are:
- RING finger domain, located at the N-terminus. It mediates the binding with
BARD1, that it is necessary for BRCA1 stability. This domain has also a E3 ligase activity.
- BRCT domains, located at the C-terminus. These two domains are responsible for
the binding with phosphorylated protein to signal the DNA damage response pathway.
- Region between the exon 11 and 13. This region plays a key role in binding Rad50,
Rad51, PALB2 and BRCA2. Moreover it contains two nuclear localization signals (NLS)
and a SQ cluster domain (SQCD) that mediates the binding with ATM and ATR.
Figure 1.9 Structure and Binding Partners of BRCA2.
BRCA2 coding sequence translates for a 3418 amino acid protein. Main functional
domains are:
- RING finger domain, located at the N-terminus. It mediates the binding with
PALB2, BRCA1 and EMSY.
- C-terminus domain. It mediates the binding with multimeric Rad51.
- BRC repeats domains. These eight domains mediate the binding with 6-8
monomeric molecules of Rad51.
- DNA binding domains. These three domains are able to associate with single strand
DNA and double strand DNA.
Modified from Orr and Savage, The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes —
Implications for DNA Damage Response, DNA Repair and Cancer Therapy, Advances in DNA repair,
Chapter 7, 2015. 9
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These two genes are considered tumor-suppressors because germline mutations are
associated with tumor development and predisposition to familial forms of breast, ovarian
and (as more recently discovered) pancreatic cancer (Antoniou et al., 2003; O’Donovan
and Livingston, 2010).
Moreover, the loss of the wild type allele (loss of heterozygosis) is frequently observed in
sporadic breast and ovarian tumors. This is likely due to the fact that both the BRCA1 and
BRCA2 genes adhere to the Knudson “two-hit” hypothesis in which both alleles of a tumor
suppressor gene must be mutated for the pathogenic phenotype to become apparent. Hence
one inherited a copy of mutant BRCA1/2 is the “first hit” and the “second hit” comes from
acquiring a somatic mutation (Knudson, 1971).
BRCA1 and BRCA2 play a key role in maintaining genomic integrity, being involved in the
regulation of DNA repair pathways. Specifically, BRCA1 is a multi-functional protein
involved in transcriptional regulation, ubiquitination, oestrogen metabolism, chromatin
remodelling and mRNA splicing (Turner et al., 2004). The main function of BRCA2
identified to date is to promote the NHEJ recombination pathway.
BRCA1 and BRCA2 are highly mutated in HGS, with a rate of germline mutation of
approximately 8-18% (Pal et al., 2005; Risch et al., 2001). Nevertheless, it is important to
note that germline mutations are reported also in other types of ovarian cancer, including
endometrioid, clear cell and mucinous, with lower mutation rates (5-15%) (Pennington et
al., 2014; Soegaard et al., 2008; Zhang et al., 2011).
HGS tumors display a loss of the second copy of BRCA1/2, thus having a homozygous
deficiency in the HR repair pathway. Germline BRCA-mutated ovarian cancers
demonstrate a specific clinical behaviour, such as earlier stage diagnosis, improved patient
survival, high response to platinum and high sensitivity to PARP inhibitors (Alsop et al.,
2012; Banerjee et al., 2010; Fong et al., 2010; Tan et al., 2013). Even somatic mutations
play a fundamental role; accordingly to The Cancer Genome Atlas Research Network
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(Cancer Genome Atlas Research Network, 2011), an additional 3% of HGS show somatic
mutations on BRCA1/2 genes. Pennington (Pennington et al., 2014) described a 9%
somatic mutation rate in one or more genes belonging to the HR pathway, including
BRCA1 and BRCA2.
To date, the clinical relevance of harbouring germline mutations is widely established, but
the same could not be claimed for somatic abnormalities. Hennessy (Hennessy et al., 2010)
demonstrated that PFS was longer in patients with somatic mutations in BRCA1/2
compared with wild type, but no improvement was seen in OS. No significant differences
in OS were highlighted in somatic mutation carriers compared with wild type cases after
platinum (Pennington et al., 2014). Prospective studies such as ARIEL-3 are planning to
clarify the relevance of somatic mutations in BRCA1/2 as biomarkers for therapy.
Also, the deficiency in HR could be driven by epigenetic alterations that lead to BRCA1
and BRCA2 silencing. BRCA1 promoter hypermethylation (an epigenetic modification that
leads to loss of expression of the protein) was seen in ovarian cancer patients (Baldwin et
al., 2000). Moreover, promoter hypermethylation has been reported to be associated with
loss of heterozygosity (Ledermann et al., 2012).
In this scenario, BRCA1 and BRCA2 are not the only players. Recently it is becoming
evident that a proportion of sporadic ovarian cancers share pathological features of BRCA
mutation-association cases, without BRCA germline or somatic mutations. The concept of
“BRCAness” includes situations where defects in the HR pathway are present but
associated with genes other than BRCA1 and 2 (Turner et al., 2004). This aspect is
becoming increasingly relevant especially relating to the activity of PARP inhibitors in
ovarian cancer (Konstantinopoulos et al., 2010). Indeed, in this project it was decided to
focus on germinal and somatic mutations in BRCA1 and 2 to select OC-PDX for in vivo
trials, but also to take into consideration the mutational status of a panel of HR related
genes (Table 1.1) (Coleman et al., 2017; McNeish et al., 2015).
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Table 1.1 Panel of 31 genes associated with homologous recombination.
Modified from Coleman RL et al, Rucaparib maintenance treatment for recurrent ovarian carcinoma after
response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial,
Lancet, 2017.
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1.4.3 Olaparib
Olaparib (AZD2281) is a potent oral inhibitor of poly(adenosine diphosphate [ADP]–
ribose) polymerase that induces synthetic lethality in BRCA1/2-deficient tumors and
generally in HR deficient tumors (Figure 1.10) (Evers et al., 2008; Rottenberg et al., 2008).
Figure 1.10 Structure of olaparib.
4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-
phthalazin-1-one (Lynparza TM, AZD2281, KU-0059436).
Modified from O’Connor et al, The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3
Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models, Cancer
Research, 2016.
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Olaparib has EMA (European Medicine Agency) approval as maintenance of second or
later therapy for patients with platinum-sensitive relapsed BRCA mutated (germline and
somatic) HGS, who had a complete or partial response to platinum-based chemotherapy.
Moreover, FDA (Food and Drug Administration) approved it as a treatment for patients
with germline BRCA mutated ovarian cancer who have received three or more lines of
chemotherapy.
Olaparib inhibits DNA repair of SSBs, through a catalytic inhibition of the PARP enzyme,
both blocking DNA PARylation and trapping PARP in DNA complexes, leading to
termination of replication forks (Lord and Ashworth, 2017). Eventually, in the case of
repair pathway deficiency, SSBs evolve to DSBs, leading to an accumulation of DNA
damage and tumor cell death.
A comprehensive characterization of 41 ovarian cell lines, sequenced in BRCA1/2 genes,
mRNA expression of BRCA1/2 and gene methylation status, allowed testing of olaparib in
vitro. In this study deleterious mutations, heterozygous mutations and promoter
methylation were correlated to a higher sensitivity to the PARP inhibitor, following long-
term exposure (Stordal et al., 2013).
Indraccolo (Indraccolo et al., 2006) derived two ovarian cancer cell lines from patients
previously treated with chemotherapy, both showing loss of the BRCA1 wild type allele,
accompanied by gain of one or more copies of the mutant allele, thus providing a useful
tool to test the activity of PARP inhibitors.
The efficacy of olaparib was tested in vivo in several studies. Kortman (Kortmann et al.,
2011) investigated the synthetic lethality efficacy in BRCA2 germline mutated xenograft
models, developed directly from ovarian cancer tissue, either alone or in combination with
carboplatin. Results indicated that olaparib greatly delayed tumor growth only in the
BRCA2 mutated xenografts and not in the wild type counterpart, significantly decreasing
proliferation, increasing apoptosis (cleaved caspase 3 and Ki67 stains), and reducing
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PARP1 activity.
Topp (Topp et al., 2014) generated a biobank of patient-derived xenografts, including two
mutated in BRCA1, two mutated in BRCA2 and one BRCA1 promoter methylated,
demonstrating the correlation between an impaired DNA repair pathway and platinum
activity.
Fong (Fong et al., 2009) carried out the first phase I trial of olaparib in 60 patients
including 22 BRCA mutated; the primary end-point was to establish the maximum tolerated
dose as 400 mg twice daily. An additional study on 50 patients with BRCA mutated tumors
showed that there was a significant association between the clinical benefit rate and
progression-free survival across the platinum-sensitive, -resistant and -refractory group;
moreover, an association between platinum sensitivity and extended response to olaparib
was highlighted (Fong et al., 2010).
A Phase II trial in patients with recurrent BRCA mutated ovarian cancer, comparing 400
mg olaparib twice a day versus 100 mg twice a day, showed that the higher dose gave a
better clinical outcome (Audeh et al., 2010). In the phase II trial Study 42 by Kaufman
(Kaufman et al., 2015) olaparib was given as a monotherapy in patients with different
types of cancer, including ovarian, breast, pancreatic and prostate; the response to olaparib
was observed across the different types of tumors, associated with germline mutations in
BRCA1/2. These results led to the FDA licencing of olaparib.
Interesting data on olaparib monotherapy as a maintenance regimen in patients with
platinum-sensitive relapsed HGS were assessed in a pivotal phase II randomized placebo-
controlled study (Study 19), in which patients were not selected accordingly to their BRCA
status (Ledermann et al., 2012); PFS was significantly longer in the olaparib treated group.
PFS benefit was significant in patients with BRCA wild type tumors, suggesting for the
first time the advantage of the administration of the drug also in this group of patients.
Following these results, EMA approved olaparib for maintenance treatment of patients
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with platinum-sensitive relapsed BRCA mutated HGS who have received three or more
lines of chemotherapy.
A variety of phase III trials of olaparib in ovarian cancer are currently in progress, such as
SOLO-1 and SOLO-2, that are evaluating the maintenance of olaparib in patients with
BRCA-mutated cancer who have responded to first line or second or later line platinum-
based chemotherapy (Kathleen N. Moore et al., 2014; Pujade-Lauraine et al., 2017).
PAOLA-1 is evaluating the efficacy of olaparib in patients who have received
platinum/taxane-based chemotherapy plus bevacizumab (Ray-Coquard et al., 2016).
1.5 PARP INHIBITORS IN COMBINATION WITH ANGIOGENESIS
INHIBITORS
Interest in the combination of PARP inhibitors and antiangiogenic strategy is growing.
Enhanced PARP inhibition has been shown under hypoxic conditions and to reduce
VEGF-induced angiogenesis (Pyriochou et al., 2008).
In this scenario, it has been postulated that the dual use of PARP inhibitors and
antiangiogenic agents may have a synergistic effect (Bindra et al., 2005; Tentori et al.,
2007).
A preclinical study led by Lim (Lim et al., 2014) reported that the inhibition of VEGFR3 in
ovarian cancer cells is associated with decreased levels of BRCA1 and BRCA2, inducing a
downregulation of the expression levels of the two genes. In this way cells are restored to
chemosensitivity, suggesting that the downregulation of BRCA genes can be obtained by
inhibiting angiogenesis. Thus, it may be a pharmacologically relevant strategy also for
BRCA wild type patients.
Preclinical antiangiogenic interaction of olaparib and cediranib led to the clinical
investigation of the activity of the combination. A phase I study, aiming to explore
tolerability and safety in patients with ovarian, Fallopian tube, primary peritoneal and
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breast cancers, has been conducted (Liu et al., 2013). In this study, patients were allocated
to receive olaparib plus cediranib in 28-day cycles until disease progression, toxicity or
withdrawal. Activity was observed both in platinum-sensitive and -resistant patients, both
BRCA mutated and wild type.
A following phase II trial evaluated PFS. Patients were randomized to receive olaparib as a
single-agent or in combination with cediranib. PFS was higher in the latter group (17.7 vs
9 months), and there was also a slight increase in OS at 24 months (81% versus 65%).
Subsequently, ad hoc analysis revealed that not only patients with BRCA mutations gained
an advantage from the combination, but the magnitude of improvement was greater in
BRCA wild type/unknown patients, encouraging the administration of the two agents
together also in this population (Liu et al., 2014). Taking together, these results suggest
that the combination of olaparib and cediranib has encouraging activity, regardless of
BRCA mutational status, both in platinum-sensitive and -resistant ovarian cancers, thus
providing a new therapeutic option, especially for BRCA wild type patients.
1.6 ANIMAL MODELS FOR OVARIAN CANCER
The scarcity of in vivo preclinical models that closely reproduce the complexity and
heterogeneity of ovarian cancer has limited - and still limits - the development of new and
effective therapeutic strategies.
In this scenario, clinically-derived cell lines play a critical role, being reproducible and
easy to use, especially if the focus is on specific mechanisms. However, their resemblance
to the original tumor is very limited, thus affecting their therapeutic predictive value
(Domcke et al., 2013).
In vivo animal models more accurately recapitulate the biological and molecular
characteristics of primary tumors, thus being a more valuable preclinical platform. The
development of peritoneal metastasis and ascites, the interaction between tumor and
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microenvironment are crucial to accurately recapitulate the progression of human disease
(Ricci et al., 2014, 2013; Masazza et al., 1991; Massazza et al., 1989; Lengyel et al., 2014).
In recent years, two types of mouse models have expanded the understanding of the
disease, the investigation of tumorigenic mechanisms and the testing of novel therapeutic
strategies.
Genetically engineered mouse (GEM) models are generated by introducing transgenes or
gene mutations into the mouse genetic background, mirroring natural disease initiation,
progression and physiological states.
Two main examples are the tetracycline-inducible system and the Cre/loxP recombinase
system, which ensure gene induction/inactivation in a tissue-specific manner at temporally
regulated points (Gama Sosa et al., 2010; Jaisser, 2000). A major limitation of GEM
models is that they cannot entirely mirror a patient’s disease from the molecular aspect,
because they are generally engineered only with one or a limited number of putative key
alterations/mutations, in genetically homogeneous animals. However, the genetic
background in patients is more heterogeneous and their lifetime exposure to additional
environmental influences renders the clinical situation infinitely more complex. On the
other hand, GEM have a functional immune system that can be exploited to focus on the
role of the microenvironment and especially the innate and adaptive immune systems in
relation to drug response (Chen et al., 2014; Smith et al., 2014).
1.6.1 Patient-derived ovarian cancer xenografts (OC-PDX)
Xenograft models are typically generated by establishing tumor cell lines in vitro and then
injecting them into immunocompromised mice, such as thymus-deficient nude, severe
combined immunodeficient (SCID) and NOD/SCID//IL2Rnull (NSG) strains. However,
the use of an established cell line can result in a population that is not truly representative
of the original tumor, producing responses that are different from those seen in patients
(Ricci et al., 2013).
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In light of this, patient-derived xenograft models are generated by injecting tumors from
patients directly into immunodeficient mice. These models benefit from their limited
diversity from the patient’s tumor, retaining the natural heterogeneity, allowing for further
evolution during progression and following drug treatment (Ricci et al., 2014; Sausville
and Burger, 2006; Siolas and Hannon, 2013; Tentler et al., 2012).
Ovarian cancer patient-derived xenografts (OC-PDX) retain the biological behaviour,
histological and molecular profiles of the original patients, even if it is crucial to use the
OC-PDX within a few in vivo passages in mice, in order to avoid changes in the
phenotypes or acquisition of new mutations.
OC-PDX are a useful tool to test new therapeutic strategies and efficacy can be determined
by mimicking the response of the patients (Weroha et al., 2014). A strong correlation
between patient and OC-PDX responsiveness to therapy has been demonstrated in ovarian
cancer, thus endorsing the reliability of the model to lead translational preclinical and co-
clinical trials (Ricci et al., 2014; Masazza et al., 1991; Massazza et al., 1989; Fiebig et al.,
1984). Unfortunately, the biggest issue with OC-PDX is the lack of a mouse immune
system that makes it impossible to study the effect of the immune system to boost the
therapy. It has been widely demonstrated that the immune system plays a critical role in
cancer initiation and expansion (Colvin, 2014; Hansen et al., 2016; McLean and Mehta,
2017; Pogge von Strandmann et al., 2017).
PDX could nevertheless accomplish this goal thanks to the recent development of
“humanized xenograft” models, which are created by co-engrafting patient’s tumor
fragments with hematopoietic stem cells or human peripheral blood mononuclear cells
(Siolas and Hannon, 2013), ideally derived from the same patient to avoid allogenic and
graft-versus-host phenomena (Shultz et al., 2012).
In the Department of Oncology, where this PhD research has been carried out, a platform
of transplantable patient-derived ovarian tumor xenografts (OC-PDX) has been established
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and some models have been used to perform all of the studies described in this thesis. Our
bio-bank of OC-PDX has been shown to comprise all the main subtypes of ovarian
carcinoma and retain the features of patients’ original tumors, on the histopathological,
molecular and biological behaviour points of view (Ricci et al., 2014).
To summarize, OC-PDX models are a preferred tool for drug discovery and translation,
despite some limitations. These models resemble patients’ biological, histological and
molecular features and enable the identification of predictive biomarkers and novel
therapeutic strategies. Moreover, the possibility to repeat experiments and include
treatment groups not feasible in the clinic, make this a unique and powerful tool.
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CHAPTER 1.
Aim of the study
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Epithelial ovarian cancer is still a leading cause of cancer deaths due to difficulties in
diagnosis and lack of effective therapies.
Thus, there is an ongoing need to identify selective pathways and investigate targets for
therapy.
Preclinical models that more closely recapitulate the heterogeneity of ovarian tumor are
useful for more efficient drug development. To accelerate the process of data integration
and translation between preclinical and clinical efforts, a preclinical trial should be
conducted in OC-PDX established directly from patients, and where possible in parallel to
the clinical trial.
Models of OC-PDX, which are molecularly and biologically representative of patient
tumors, have been recently shown to be a valuable tool in predicting clinical outcome. The
advantage is that freshly xeno-transplanted human tumor, without in vitro manipulation,
maintains the biological and molecular features of the original tumor (Ricci et al., 2014).
To address this goal, in this study specimens from patients were transplanted immediately
after surgical resection into immune-incompetent mice, such as SCID and NSG strains.
OC-PDX were established subcutaneously (s.c. ectopic models) or orthotopically into the
peritoneal cavity (i.p. intraperitoneal models or i.o. intraovarian model ID8).
Because they can be propagated perpetually, these models are an important source of
tumor material for biological and pharmacological studies, overcoming the limitation often
encountered with small biopsies. Patients’ original tumors and corresponding OC-PDX
were analyzed for histopathologic phenotype and for molecular genetic alterations, via the
Next Generation Sequencing technique complemented by traditional Sanger Sequencing.
The molecular characterization is a useful tool to select appropriated OC-PDX for testing
new therapeutic agents, such as poly(ADP-ribose)polymerase inhibitors (e.g. olaparib), in
combination with angiogenesis inhibitors (e.g. cediranib).
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Indeed, germinal and somatic defects in the DNA repair pathways have been proved to be
a promising target of PARP inhibitors, but several preclinical and clinical trials
demonstrated that the combination with angiogenesis inhibitors could be a compelling
strategy for those patients with functional DNA repair pathways, even though no clear
mechanisms of action have so far been determined.
Altogether, the aims of this project were to:
 Enlarge the collection of OC-PDX already established in the Department of
Oncology, where this PhD research has been carried out (Ricci et al., 2014).
Additional patients’ tumor samples have been received during this PhD research
program and established in vivo.
 Profile the expanded platform of OC-PDX and corresponding patient tumor, when
available, at a histopathological and molecular level, exploiting new techniques,
such as Next Generation Sequencing, RNA Sequencing and Fluidigm for gene
expression.
 Take advantage of this improved and properly analyzed biobank to provide insights
into better treatment modalities for ovarian cancer. In particular, based on
histopathological and molecular features, a smaller cohort of ad hoc OC-PDX has
been selected to perform preclinical studies aimed at elucidating the responsiveness
to PARP inhibitor olaparib and to the combination with the angiogenesis inhibitor
cediranib, and explore possible mechanisms of action underlying it.





Chapter 2 Francesca Bizzaro
54
2.1 PATIENT-DERIVED OVARIAN CANCER XENOGRAFTS (OC-PDX)
2.1.1 Models
Clinical specimens (primary ovarian tumors, metastases, ascitic fluid) were obtained from
patients undergoing surgery for ovarian tumor by laparotomy or paracentesis at the San
Gerardo Hospital in Monza (Italy) and IEO Hospital (European Institute of Oncology) in
Milan (Italy). Tumor specimens were engrafted into immunodeficient mice within 24h, as
described below, or stored as frozen stocks (Masazza et al., 1991; Massazza et al., 1989;
Ricci et al., 2014). The study protocol for tissue collection and clinical information was
approved by the institutional review board and patients provided written informed consent
authorizing the collection and use of the tissue for study purposes.
Detailed clinical and follow-up data were obtained from medical records at predefined
intervals: post-surgery, after primary chemotherapy, at six-month intervals up to five years
and annually thereafter. Patients underwent primary surgery of the ovary and disseminated
disease for diagnosis, staging and debulking. Surgical staging was based on the FIGO
(Fédération Internationale des Gynaecologistes et Obstetristes) classification. Optimal
debulking was defined as less than 1 cm (diameter) residual disease, and sub-optimal
debulking as more than 1 cm. Patients were followed up with a physical examination,
including the pelvic examination and serum CA-125 assay. When there were abnormal
findings a CT scan was done, and relapse was defined according to RECIST criteria
(Response Evaluation Criteria In Solid Tumors) (Therasse et al., 2000) as tumor re-growth
after a standard course of platinum-based primary chemotherapy.
A complete clinical response (cCR) was defined as resolution of all clinical and
radiographic evidence of disease, and normal CA-125 after completion of first line
chemotherapy, which was considered the last treatment. Persistent disease was defined as
the lack of complete response to first-line chemotherapy. For patients who achieved a cCR,
progression-free survival (PFS) was defined as the interval between the end of first-line
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chemotherapy and first confirmed sign of disease recurrence. Overall survival (OS) was
defined as the interval between the date of diagnosis and the date of death from any cause.
2.1.2 Animals
For all the studies reported, six- to eight-week-old athymic female NCr-nu/nu and SCID
mice were obtained from Envigo Laboratories (Udine, Italy). NOD scid gamma (NGS)
mice were bred in-house at the Mario Negri Institute. Mice were maintained under specific
pathogen-free conditions, housed in isolated vented cages (IVC), and handled using aseptic
procedures. For the syngeneic intraovarian model ID8, seven-week-old pathogen-free
C57BL/6 were obtained from Envigo Laboratories (Udine, Italy). Procedures involving
animals and their care were conducted in accordance with institutional guidelines that
comply with national (Legislative Degree 26, March, 2014) and international laws and
policies (EEC Council Directive 2010/63, August, 2013), in line with guidelines for the
welfare and use of animals in cancer research (Workman et al., 2010). Animal studies were
approved by the Mario Negri Institute Animal Care and Use Committee and Italian
Ministerial decree no. 84-2013. Additionally, intensive in vivo training is required by
Istituto di Ricerche Farmacologiche Mario Negri IRCCS guidelines to ensure respect of
and compliance with the laws. The training program consists of lectures (12 hours),
concerning animal welfare, and hands-on practical sessions (30 days) under the supervision
of an expert.
2.1.2.1 Anaesthesia and euthanasia in mice
In order to transplant tumor fragments subcutaneously, animals were placed individually in
a transparent acrylic chamber and anaesthetized using an automatic delivery system that
provides a mixture of 3-4% isoflurane (Florane, Abbot Laboratories) in 1% oxygen.
Anaesthetic depth was assessed by testing the pedal withdrawal reflex. At the end of each
study, mice were euthanized by cervical dislocation. This technique used in physical
euthanasia of small animals consists in applying pressure to the neck to dislocate the spinal
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column from the skull or brain. Euthanasia was performed either at predetermined days
(end of short-term treatment, 4 weeks), when subcutaneous tumors reached a volume of
1500 mm3 (maximum 10% of animal body weight) or when animals showed sign of
discomfort (survival). Subcutaneous tumor samples and representative organs of the
peritoneal cavity were then collected.
2.1.3 Ectopic tumor models
Patient-derived solid specimens from tumor masses (ovary and omentum) were dissected
free of necrotic tissue. Working under sterile conditions, tumor fragments (2-4mm3) were
transferred to a petri dish of 100mm, filled with medium RPMI 1640 (BioWest)
supplemented with 50% fetal bovine serum (FBS) (Microgem), then transferred to a
second petri dish containing RPMI 1640 supplemented with 20% FBS. Subsequently,
fragments were rinsed in HBSS (BioWest) and prepared for transplantation (Masazza et al.,
1991; Ricci et al., 2014). The subcutaneous transplant was performed in the right flank of
mice under anaesthesia. Briefly, the skin was disinfected with Betadine and a 1-2 cm
lateral skin incision performed to access the subcutis, where tumor fragments were placed
using a sterile trocar. The incision was then closed with metal wound clips. For these
ectopic models, tumor growth s.c. was measured with a Vernier caliper, and tumor weight
(mg=mm3) was calculated as [length (mm) x width2 (mm2)]/2. Measurements were
acquired with software “Study Director” version 2.5 (Studylog System, Inc.)
To store and enlarge the biobank of OC-PDX, s.c tumors from 3-5 mice were collected,
minced (2-4 mm3) and pooled together to avoid selection of subpopulations and to
maintain heterogeneity. Fragments were then frozen in a solution containing 50%
Cryoprotective Medium (Lonza) with 15% DMSO and 50% FBS and then stored in liquid
nitrogen for future experiments, or transplanted serially in mice for further studies (i.e
therapy).
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2.1.4 Orthotopic tumor models
2.1.4.1 Intraperitoneal models
Patient-derived ovarian cancer cells from were obtained from patients’ ascites.
Working under sterile condition, ascites fluids were centrifuged at 8000 g for 10 minutes at
4°C. Pellets of cells were resuspended in HBSS (BioWest) and again centrifuged. Then
viable cells were counted by trypan blue exclusion with the aid of a Bürker chamber and
resuspended in HBSS at the concentration of 5 x 107 cells/ml.
A suspension of 0.2 ml (10 × 106 cells) was injected intraperitoneally in the lower right
quadrant of the mouse abdomen using a syringe with a 21 gauge needle. Animals were
checked at least twice a week for tumor formation (abdominal distension) in the peritoneal
cavity and killed when they presented signs of discomfort (survival), ascites was harvested
and the volume recorded.
To store and enlarge the biobank of OC-PDX, ascites from 3-5 mice were collected, pooled
and frozen in a solution containing 50% Cryoprotective Medium (Lonza) with 15% DMSO
and 50% FBS and then stored in liquid nitrogen or transplanted serially in mice for further
studies (i.e. therapy).
2.1.4.2 Intraovarian model ID8
Cell culture conditions
The murine ID8 cell line was obtained from MOSEC (mouse ovarian surface epithelial
cells), isolated from the ovaries of virgin wild type mice and cultured repeatedly before
transplantation into syngeneic recipient mice of seven weeks age (Greenaway et al., 2008).
Cells were resurrected from the cell bank by rapidly thawing the vial (to 37° in a water
bath) and the viable cells counted by Trypan blue exclusion dye (Fluka Analytical) with
the aid of a Burker chamber and transferred to a fresh tube. About 10 ml of fresh medium
containing 10% of heat-inactivated FBS (Microgem) was added. After centrifugation, cells
were transferred to a T25 tissue culture flask in 5 ml fresh culture medium containing
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Dulbecco's Modified Eagle Medium (DMEM), 10% v/v FBS and 1% v/v L-glutamine.
Cells were maintained in 5% CO2 in air incubator and were passaged routinely twice a
week to maintain logarithmic growth. Cell culture procedures were carried out aseptically
in class II laminar flow cabinet and the cells were tested for Mycoplasma contamination,
with qPCR, upon thawing. Cell lines were not maintained in culture for long periods in
order to avoid changes in their growth and biological behaviour.
Four or five days before each study, cell cultures were split (1:10 to 1:20) and plated in 75
cm2 flasks ensuring that they did not develop beyond semi-confluence. The culture
medium was changed 24h before harvesting cells for injection into mice.
On the day of the injection, the medium was removed and the monolayer washed once with
phosphate-buffered saline (PBS). PBS was then removed and the monolayer was overlaid
with Trypsin–EDTA solution (0.05% w/v trypsin and 0.02% w/v EDTA in Ca2+/Mg2+-
free PBS, Bio-West) and then poured off. After few minutes, the flask was tapped until the
cells lifted away from the surface. Approximately 10 mL of complete medium containing
FBS (to neutralize the trypsin) were added, and the suspension pipetted up and down in
order to obtain a single-cell suspension. Cells were then transferred into a 50 mL
polypropylene conical tube, pelleted by centrifugation (8000 g for 10 min), washed twice
again with Ca2+/Mg2+-free Hank’s balanced salt solution (HBSS) and pelleted each time.
Cells were counted using Trypan blue exclusion dye with the aid of a Bürker chamber and
resuspended in HBSS at the concentration of 2 x 108/ml.
Orthotopic intrabursa transplant
Cell suspensions were obtained from cell lines as described above.
Pathogen-free C57BL/6 mice were anaesthetized with isoflurane and placed on the surgery
table warmed to 37°C. Animals were shaved on one side to allow rapid and clean surgery.
Work was conducted in aseptic/sterile conditions. Briefly, the skin was disinfected with
Betadine and a 1-2 cm lateral midline skin incision was performed to access the left ovary
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and exteriorize the ovary and the oviduct. 1 x 106 ID8 cells were injected in 5-10 μL HBSS
under the bursa of the ovary of the mice, using a Hamilton syringe with a 26-gauge needle.
The ovary was replaced in the peritoneal cavity, the incision closed with surgical thread
and the skin with metal wound clips, then disinfected with Betadine (Decio and Giavazzi,
2016). Tumor formation was followed by magnetic resonance imaging (MRI), in
collaboration with the experts of the Laboratory of Biology of Neurodegenerative
Disorders of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (see Section
2.3.3.3).
2.1.4.3 Necropsy examination
Both for intraperitoneal and intraovarian tumor models, the peritoneal cavity was
macroscopically examined to ascertain the presence of tumor at necropsy (sacrifice and/or
prefixed end-points). Macroscopical analysis of the organs of the peritoneal cavity (liver,
diaphragm, omentum, pancreas, uterus/ovary, nodes) and lungs was performed by at least
two independent scientists and tumor dissemination was rated using an arbitrary score, as
reported:
Tumor burden was then calculated by summing the scores for each animal. The images of
the liver, diaphragm, omentum, pancreas, uterus/ovary, lungs and lymph nodes were
acquired with a macro-digital imaging system (MacroPATH; Milestone S.r.l.).
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2.1.5 The biobank of OC-PDX
2.1.5.1 Patients’ tumor collection
Patients’ original tumors were snap frozen then stored at -80°C and formalin fixed for
further analysis. When possible, patients’ tumors were frozen in a solution containing 50%
Cryoprotective Medium (Lonza) with 15% DMSO and 50% FBS and then stored in liquid
nitrogen as primary stocks.
2.1.5.2 Subcutaneous tumor specimen collection
Subcutaneous tumors were collected when they reached a volume of 1500 mm3. Mice were
sacrificed as previously described. A skin incision was then performed to access the tumor
mass, which was collected using sterile scissors and forceps.
2.1.5.3 Ascites collection
Ascitic fluid and subsequent peritoneal washings (3 mL 0.9% NaCl) were harvested using
a 5 mL syringe, collected separately in 15 mL tubes, and centrifuged at 8000 g for 10
minutes at 4°C. The volume of original ascites and pellet (representative of tumor burden)
were recorded for each animal.
2.1.5.4 Sample storage
After collection, s.c. and abdominal tumor masses were minced, placed into tubes and
immediately frozen in dry ice. Pellets and supernatants of ascites were separately collected
and snap frozen in dry ice. Samples were stored at -80°C until analysis. For
histopathological and immunohistochemical analysis, part of the subcutaneous tumor mass
and organs cavity (liver, diaphragm, omentum, pancreas, lungs and uterus/ovary) were
frozen in Optimal Cutting Compound (OCT) or fixed in 10% phosphate-buffered formalin
(Bio Optica) for 24h prior to embedding in paraffin. Prolonged contact with formalin
causes excessive crosslink formation and increasing loss of antigenicity. If samples could
not be processed to paraffin blocks after 24h in formalin, they were transferred to 70%
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ethanol for holding until the samples could be put on the processor. Samples were then
washed twice with 100% ethanol (absolute ethanol) and embedded in paraffin with the aid
of a microwave rapid tissue processor (Histos5, Milestone S.r.l.).
2.1.5.5 Blood sample collection and storage
Blood samples were collected from the retro-ocular plexus of anaesthetized mice. At the
end of the collection, mice were immediately sacrificed by cervical dislocation.
Plasma was collected using 10% EDTA disodium salt (1:50 final volume) and then
centrifuged at 12000 g for 10 minutes at 4°C. Blood serum was collected without any
anticoagulant, warmed at 37°C for 30 minutes and then centrifuged at 12000 g for 10
minutes at 4°C. The supernatant was collected and stored at -80°C.
2.2 MOLECULAR ANALYSIS
2.2.1 Nucleic Acid Extraction
RNA isolation
Frozen fragments of patients’ original tumors, ascites pellet and subcutaneous tumor
tissues were placed into 2 mL microcentrifuge tubes containing one stainless steel bead (5
mm mean diameter) and 1 mL QIAzol Lysis Reagent (Qiagen). QIAzol Lysis Reagent is a
monophasic solution of phenol and guanidine thiocyanate, which in addition to lysing
action prevents the activity of RNases. Tubes were then placed in the Tissuelyser LT
Adapter (Qiagen) and the instrument was switched on at 20-30 Hz until no tissue debris
was visible (about 2 minutes). Tubes containing the homogenates were placed on the bench
top at room temperature (25°C) for 5 minutes. The homogenates were then transferred to
new 2 mL microcentrifuge tubes and 200 μL chloroform were rapidly added. Tubes were
shaken vigorously for 15 seconds and left on the bench top for about 2 minutes to favour
the extraction of RNA. Tubes were then centrifuged at 12000 g for 15 minutes at 4°C to
separate the phases: an upper colourless aqueous phase containing RNA; a white
Chapter 2 Francesca Bizzaro
62
interphase (DNA); and a lower organic phase containing protein. The aqueous phase was
transferred into 2 mL collection tubes.
RNA purification was performed using the RNeasy® mini Kit along with the QIAcube®
robotic workstation (Qiagen). According to the RNeasy® mini Kit protocol, 350 μL of
ethanol 70% were added to the aqueous phase, creating conditions that promote selective
binding of RNA to the column. The samples were then applied to the RNeasy® mini spin
columns and centrifuged for 15 seconds at 8000 g. After centrifugation, contaminants were
washed away using RPE and RTW buffers and samples were again centrifuged. Finally,
the total RNA was eluted in 30 μL RNase-free water. At the end of the method, collection
tubes containing the purified RNA were securely capped and stored at -80°C until analysed.
DNA isolation
Genomic DNA from frozen fragments of patients’ original tumors, ascites pellets and
subcutaneous tumor tissues were extracted using Maxwell ® 16 Tissue DNA purification
kit, to be used with the Maxwell ® 16 Instrument for automated purification of genomic
DNA.
Frozen samples of approximately 30 mg were placed in the #1 well of the pre-dispensed
cartridge (Figure 2.1) after have removed the seal. In each cartridge, a plunger was placed
in the #7 well. Cartridges containing samples and plungers were transferred onto the
Maxwell ® 16 Instrument platform. In parallel, one blue elution tube for each cartridge
was placed into the elution tube slots at the front of the platform, with 300 ul of elution
buffer in each blue tube.
At the end of the automated run, genomic DNA of each sample was eluted in the elution
buffer and collected. DNA samples were stored at -20°C until analysed.
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Figure 2.1 Predispensed cartridge of Maxwell ® 16 Tissue DNA purification kit.
30 mg of tumor tissue were placed in Lysis Buffer in #1 well on the label side of the
cartridge, plunger in Wash Buffer in #7 well on the ridge side. #2 well from #6 well
contained different reagent buffers to perform the automated run of extraction.
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Analysis of DNA and RNA concentration and purity by Nanodrop® Spectrophotometer
Concentration and purity of nucleic acid samples were determined by spectrophotometric
analysis (Nanodrop® Spectrophotometer). Before starting the software module, both the
top and the bottom sensors of the Nanodrop® Spectrophotometer were cleaned with a tissue
moistened with ddH2O to remove any dried samples that might be present. Then 1 μL of
RNase-free water was pipetted onto the bottom sensor to calibrate the instrument. The
sensors were then wiped and 1 μL of purified DNA or RNA solution was loaded. The
absorbance of DNA and RNA samples was measured at 260 nm, 280 nm, and 230 nm. The
nucleic acid concentration was calculated using the Beer-Lambert law, which relates the
amount of light absorbed to the concentration of the absorbing molecule.
The 260/280 and 260/230 ratios were calculated to determine the purity of nucleic acids.
260/280 = nucleic acid and proteins/proteins only. 260/230 = nucleic acid and
contaminants/contaminants only. The optimum value for both 260/280 and 260/230 is
between 1,7 and 2,1.
Analysis of RNA integrity by Agilent Bioanalyzer®
The Agilent 6000 Nano Assay was used to check for RNA integrity (Agilent
Bioanalyzer®). This assay is similar to gel electrophoresis in concept, but it is more
efficient and only requires a very small amount of sample (25-500 ng). 1 μL of each total
RNA sample was loaded into each of the 12 sample wells in the RNA Nano Chip by
Agilent Technologies. The chip contains an interconnected set of microchannels in which
nucleic acid fragments are sieved by size as they are driven through it by an electrical
current. Results are either shown as an electropherogram image or as bands on a gel. To
determine RNA integrity, Agilent Technologies introduced the RNA Integrity Number
(RIN). Generally, RIN numbers greater than 6 are considered acceptable for further
RealTime PCR analyses.
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2.2.2 Next Generation Sequencing
Next Generation Sequencing was conducted on a panel of 26 OC-PDX, in collaboration
with AstraZeneca, Bioscience, Oncology Translational Sciences, IMED Biotech Unit,
Waltam, MA, US.
Library construction and next generation sequencing (NGS)
Two hundred nanograms of purified genomic DNA were used for NGS library
construction. Libraries were generated using the Kapa Biosystems HyperPrep kit following
the manufacturer’s protocol. All libraries were visualized on the Agilent TapeStation and
the concentration was determined using the Kapa Biosystems NGS Library Quantification
qPCR kit.
Exome sequencing and variant calling
Whole genome libraries were pooled together and used for the exome hybridization
capture using xGen®Exome Research Panel v1.0 (Integrated DNA Technologies).
Libraries were sequenced on the Illumina HiSeq 4000 platform (2 x 150) using TruSeq
SBS (sequencing by synthesis) reagents (Illumina). The NGS data were aligned and
analysed within the BCBio framework (https://bcbio-nextgen.readthedocs.org/en/latest/)
using an AstraZeneca-developed variant calling algorithm
(https://github.com/AstraZeneca-NGS/VarDict) (Lai et al., 2016).
For this PhD thesis the focus was on those aberrations and mutations in a set of genes
previously described as being mutated in ovarian cancer (e.g. TP53, KRAS, BRAF,
PIK3CA, CTNNB1, PTEN) and genes belonging to the HR DNA repair pathway (e.g.
BRCA1/2 and others from Coleman RL et al, Lancet 2017 and reported in Table 1.1
Introduction). For these genes, Sanger sequencing was performed to validate mutations.
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2.2.3 Sanger validation
To validate the results from the Next Generation Sequencing analysis, ad hoc Sanger
sequencing was performed for each mutation of interest, both on patients’ original tumors
and samples derived from OC-PDX.
PCR reaction
For each tumor model found to be mutated, 50 ng of DNA, extracted and quality checked
as reported in Section 2.2.1, was amplified by GoTaq ® PCR Core System (Promega),
accordingly to manufacturers’ instruction.
Ad hoc specific primer pairs tagged with M13F and M13R were chosen using PRIMER-3
software (https://primer3plus.com/).
The primer specificity for human DNA and not murine DNA was verified using NCBI
BLAST: Basic Local Alignment Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and
optimal cycling conditions were verified by detecting single-band amplicons of the PCR
products with a 1.5% agarose gel. PCR amplification of genomic DNA was done in a
thermocycler (2720 Thermal Cycler, Applied Biosystem) following the conditions reported
below.
PCR reaction mix components Single reaction (μL)
5X Colourless GoTaq® Flexi Buffer 10
10 uM specific forward primer 2
10 uM specific reverse primer 2
PCR Nucleotide Mix, 10 mM each 1
25 mM MgCl2 5
GoTaq® Hot Start Polymerase (5u/ul) 1
H2O 9
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PCR product purification
Amplified DNA was purified with IllustraTM GFX PCR DNA and Gel Band Purification
kit (GE Healthcare) following the manufacturer’s instructions. Briefly, 500 l of capture
buffer were added to each sample and transferred to a GFX column, centrifuged at 13000 g
for 30 seconds. The flow-through was discarded. Then 500 l of wash buffer were added
to each column, centrifuged at 13000 g for 30 seconds, the flow-through discarded and
each column placed into a new 1.5 ml collection tube. Elution buffer (20 l) was added to
each column directly to the top of the glass fibre matrix. Columns were finally centrifuged
at 13000 g for 1 minute to recover purified DNA.
DNA was then quantified with a Nanodrop® Spectrophotometer (see Section 2.2.1) and
prepared to be sequenced.
Sequencing of amplified DNA
The sequencing of PCR products was performed as a service by Microsynth SeqLab
(Switzerland). DNA was prepared at 6 ng/l, in a volume of 12 l, to obtain a total amount
of 72 ng.
Primer solution (3 l of 10 M primer) was added to the DNA template, keeping separate
the tube with DNA and forward primer and the tube with DNA and reverse primer.
Sequencing results consisted of an electropherogram for each reaction. Electropherograms
were then analysed and mutations confirmed using Sequencer 5.1 software and FinchTV
software.
All the genes and primer pairs sequenced are reported in Table 2.1.
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Table 2.1 Genes and primer pairs used in Sanger validation.
Most frequently mutated genes in ovarian carcinoma and belonging to the homologous
recombination deficiency (HRD) pathway were analysed.
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2.2.4 RealTime PCR
FLT1 gene (VEGFR1), KDR gene (VEGFR2), FLT4 gene (VEGFR3), KIT gene (c-Kit
protooncogene Receptor Tyrosine Kinase) and PDGFRA gene (PDGFR-Alpha) transcripts
were analysed by real-time reverse transcription-PCR (RT-PCR) using TaqMan® Gene
Expression Assay (Applied Biosystems, Monza, Italy).
Briefly, total RNA was extracted from tumor cells and tumor masses snap frozen in liquid
nitrogen with Trizol® protocol (Invitrogen, Life-Technologies, Monza, Italy) as described
in Section 2.2.1 then purified and reverse-transcribed with High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems™) to cDNA, according to manufacturer’s
instructions.
RT reaction
2 RT master mix was prepared following the instruction provided by the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems™), which is intended for the
quantitative conversion of up to 2 µg of total RNA to single-stranded cDNA for each
single reaction.
Component Volume/Reaction (μL)
10 RT Buffer 2.0
25 dNTP Mix 0.8
10 RT Random Primers 2.0
Multiscribe™ Reverse Transcriptase 1.0
Nuclease-free H2O 4.2
Total per Reaction 10.0
All required reagents were collected into a microcentrifuge tube and gently mixed. 10 μL
of 2 RT master mix were pipetted into each well of a 96-well reaction plate kept in a
tabletop cooler box. 500 ng – 1 μg of total RNA were pipetted into the 96-well reaction
plate containing the 2 RT master mix and enough nuclease-free water was added to
reach the final volume of 20 μL. The plate was then sealed, briefly centrifuged to spin
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down the contents and to eliminate any air bubbles, and finally load onto the thermal cycler.
Thermal cycler conditions were programmed as described below.
At the end of the procedure, the plate was stored at -20°C until used for PCR analysis. RT
reactions were diluted 1:20 in ddH2O before qPCR reactions.
qPCR reaction
The expression of human receptors VEGFR1, VEGFR2, VEGFR3, c-Kit and PDGFRA
was determined using qPCR and human ACTB (beta-actin) was chosen as a housekeeping
gene.
Experiments were run in triplicate.
For the amplification and quantification of a chosen target, the TaqMan® probes labelled
with FAM™ reporter dye on the 5’ end and the quencher dye on the 3’ end were purchased
from Applied Biosystems™ along with the primers and the Universal PCR Master Mix.
The qPCR reaction mix was prepared following the instructions provided by the TaqMan®
Gene Expression Assay protocol, as reported below.
* TaqMan® Universal PCR Master mix contains AmpliTaq Gold® Polymerase, Uracil-
DNA Glycosylate, dNTPs with dUTP, ROX™ dye (passive internal standard), and
optimized buffer components.
Step 1 Step 2 Step 3
Temperature (°C) 25 37 85
Time 10 min 120 min 5 min
PCR reaction mix components Single reaction (μL)
2 TaqMan®Universal PCR Master mix* 5
20 primers 0.5
RNase-free water 0.5
Total per Reaction 6
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The qPCR was run in a 384-well plate at a final volume of 10 μL in each well. To aid in
loading the plate, a robotic liquid handling system (epMotion® 5075 TMX) was used.
epMotion® 5075 transferred 6 μL of mix and 4 μL of diluted cDNA sample in each well of
384-well plate to reach the predetermined final volume of 10 μL.
The default thermal cycling protocol was used for all target and reference genes.
Amplification reactions were performed with the 7900HT Fast RealTime PCR System
(Applied Biosystems™). Quantitative PCR data were subsequently analysed using the
Sequence Detection System (SDS) version 2.3 (Applied Biosystems™).
VEGFR1, VEGFR2, VEGFR3, c-Kit and PDGFRA mRNA were normalized to beta-actin
housekeeping gene: ΔCt = Cttarget - Cthousekeeping (Schmittgen and Livak, 2008), mean ± SD
of three replicates from one experiment representative of three.
2.2.5 Fluidigm
The Fludigm platform allowed the analysis of expression levels of a broader panel of genes
of interest, using chip supports. Experiments were run in biological triplicates and
technical duplicates.
All the procedures were conducted in collaboration with AstraZeneca, Bioscience,
Oncology, IMED Biotech Unit at the CRUK Institute of Cambridge.
PreAmp pool and assay plate preparation
The panel of chosen genes was prepared in two 96-well plates assay (Table 2.2 and 2.3).
TaqMan ® Gene expression assays were supplied at 20x. The pooled assays were diluted
in 1x TE buffer so that each assay was run at a final concentration of 0.2x.
Step 1 PCR40 cycles
Temperature (°C) 95 95 60
Time 10 min 15 sec 1 min
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To prepare the PreAmp pool, 1 l of each TaqMan ® probe was added to a 1.5 ml tube and
made up to a volume of 100 l with TE buffer. 7.5 l of each assay mix was dispensed into
a 96 well plate following the assay scheme plate reported above.
cDNA preamplification
For each sample, cDNA was obtained as described in Section 2.2.4 and pre-amplified.
Briefly, 200 l of PreAmp TaqMan ® Master Mix was added to 100 l PreAmp pool+TE
and then dispensed into a 96 well plate. cDNA was added to each well, following the
designed sample plate layout. The plate containing cDNA was run on a thermal cycler as
previously reported.
Successively primed chip (IFC) was loaded.
Briefly, the control line fluid was injected into the two control line fluid reservoirs on the
IFC (see Figure 2.2). Then the chip was loaded into the instrument and the prime script run
for 10 minutes. At this point, the chip was ready to be loaded with samples and assays as
described in Figure 2.2.
Finally, the IFC was run on BioMark system as reported below.
Data analysis
For Fluidigm, data analysis was performed in collaboration with Dr. Paola Ostano and Dr.
Giovanna Chiorino of the Cancer Genomics Laboratory, Fondazione Edo and Elvo Tempia
Valenta, Biella, Italy.
Step 1 Step 214 cycles Step 3
Temperature (°C) 95 95 60 4
Time 10 min 15sec 4 min hold
Step Thermal Mix UNG Hot Start PCR40 cycles
Temperature (°C) 50 70 25 50 95 95 60
Time 2 min 30 min 10 min 2 min 10 min 15 sec 1 min
Chapter 2 Francesca Bizzaro
74
For each biological replicate, the technical replicate Ct mean was calculated. Then the
mean was normalized to housekeeping genes (IPO8 and HPRT1 for human; Hprt1 and
Ipo8 for mouse) and ΔCt = Cttarget- Cthousekeeping assessed.
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Figure 2.2 Diagram of a Fluidigm 96.96 primed chip (IFC) layout.
Control line fluid was injected into each of the control line fluid reservoirs and primed
using the IFC Controller (Control line fluid is pressurized causing it to enter the chip
allowing control of various valves). Ninety-six assays and 96 samples were then loaded
into their respective inlets. Assays and samples were then forced into the IFC chip using
the IFC controller.
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Table 2.2 Panel of genes for Fluidigm prepared in a 96-well plate assay.
Capital case letters: human genes; lower case letters: murine genes; red letters:
housekeeping genes.
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2.2.6 RNA sequencing
In collaboration with Novogene: Genome Sequencing Company (Chula Vista, California),
whole transcriptome shotgun sequencing was performed. Briefly, RNA sequencing uses
next generation sequencing techniques to reveal the presence and quantity of RNA in a
biological sample at a given moment. In this way, the continuous modifications of the
cellular transcriptome can be analysed, by looking at alternative gene spliced transcripts,
post-transcriptional modifications, gene fusions, mutations and changes in gene expression
over time in different groups of treatments. With this technique, it is possible also to
examine different populations of RNA (total and small RNA).
To perform this analysis, RNA samples, extracted and quality checked as reported in
Section 2.2.1, were prepared at 50 ng in 50 l and sent to Novogene for a 150 base pair-
paired end sequencing with 50 million reads per sample.
RNAseq data analysis was performed in collaboration with AstraZeneca, Bioscience,
Oncology Translational Sciences, IMED Biotech Unit, Waltam, MA, US.
2.3 IN VIVO PRECLINICAL STUDIES
2.3.1 Animals for preclinical studies
For preclinical testing, six- to eight-week-old female NCr-nu/nu mice or seven-week-old
pathogen-free C57BL/6 for the syngenic intraovarian model ID8 were obtained from
Envigo Laboratories. Mice were maintained under specific-pathogen-free conditions,
housed in isolated vented cages, and handled using aseptic procedures. Procedures
involving animals and their care were conducted in conformity with institutional guidelines
that comply with national (Legislative Degree 26, March, 2014) and international (EEC
Council Directive 2010/63, August, 2013) laws and policies, in line with guidelines for the
welfare and use of animals in cancer research (Workman et al., 2010). Animal studies were
approved by the Mario Negri Institute Animal Care and Use Committee and Italian
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Ministerial decree no. 84-2013.
2.3.2 Drug preparation and administration
Cisplatin (cis-diamminedichloroplatinum, DDP, Sigma-Aldrich, Milan, Italy) was
dissolved in 0.9% NaCl and administered intravenously (i.v) at the dose of 4 mg/kg, in a
volume of 10 ml/kg. DDP was administered every week for 3 cycles. DDP was used as a
reference drug.
Olaparib (OLA, AZD2281, AstraZeneca, Alderley Park, Macclesfield, UK) was dissolved
in 10%v/v DMSO in 10%w/v Kleptose (HP-β-CD) in purified deionized water and
administered by oral gavage (p.o) daily at the dose of 100 mg/kg, in a volume of 20 ml/kg.
Cediranib (CED, AZD2171, AstraZeneca, Alderley Park, Macclesfield, UK) was
suspended 0.5%w/v HPMC (hydroxyl propyl methyl cellulose) 0.1% Tween80 (Sigma-
Aldrich, Milan, Italy) in deionised water, vortexed and stirred overnight prior to dosing.
Cediranib was administered by oral gavage (p.o) daily at the dose of 3 mg/kg, in a volume
of 10 ml/kg.
For a particular set of experiments (see Section 4.5, Chapter 4, Results), bevacizumab
(Roche) and B20 4.1 (Genentech, provided by AstraZeneca) were tested along with the
PARP inhibitor olaparib. Bevacizumab is an antibody that recognized selectively human
VEGF, and B20 recognizes both human and mouse VEGF exhibiting with equal affinity
(EC50 0.17 nmol/L for h-VEGF and EC50 0.17 nmol/L for m-VEGF) (Liang et al., 2006).
Bevacizumab (BEV) was diluted in saline and administered at the dose of 5 mg/kg, i.v,
once a week for 4 cycles; B20 was diluted in saline and administered at the dose of 5
mg/kg, i.v, twice and once a week for short-term treatment of 4 cycles.
2.3.2.1 Schedule of treatments
Olaparib and cediranib, alone or in combination, were administered every day for 5 days
on and 2 days off (Q1x5), for four cycles (4 weeks, short-term treatment regimen) or until
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tumor progression (maintenance regimen). In models that were very responsive (regression
of tumor volume > -30%), treatments were stopped and tumor growth monitored.
2.3.3 Evaluation of treatment
2.3.3.1 Ectopic tumor models
For ectopic models (3-7 mice per group), tumor measurements were taken twice a week
during and after treatments. Tumor growth s.c. was measured with a Vernier caliper, and
tumor weight (mg=mm3) was calculated as [length (mm) x width2 (mm2)]/2.
Subcutaneous tumor-bearing mice were randomized at a calculated tumor volume of 280-
330 mm3 (300 mm3 average) and assigned to treatment groups. Animals were euthanized
when primary tumor volume reached approximately 1500mm3 and never beyond it
exceeded 15% of animal body weight. Tumor-free mice at approximately 200 days post
therapy were considered cured.
Treatment efficacy was expressed as best tumor growth inhibition: %T/C = (median weight
of treated tumors/median weight of control tumors) x 100, and evaluated also from the
tumor weight curve of individual mice using three independent parameters: the tumor
weight at nadir (TWnadir), the absolute growth delay (AGD) and the doubling time of
tumor regrowth (DTregrowth). TWnadir is the smallest tumor volume measured after
treatment. Where no regression was seen, TWnadir was set as the weight at the start of
treatment. AGD was calculated as the difference (in days) between the time to reach a
target size of 1500 mm3 in treated tumors and the average time to reach the same size in
the control group. DTregrowth was calculated from the exponential fit of the last part of
the growth curve when there was a frank and persisting increase in tumor size.
Treatment efficacy was also expressed as % tumor variation after 4 weeks (day 28) and 12
weeks (day 100) of treatment: %tumor variation = [(tumor volume day 28 or 100-tumor
volume day 0)/tumor volume day 0] x 100, considering day 0 as the day in which each
mouse was randomized to treatment. Disease was considered progressive: tumor variation
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> 20%; stable : -30% < tumor variation > 20%; regressive : tumor variation > -30%
(Fournier et al., 2014).
2.3.3.2 Intraperitoneal tumor models
For intraperitoneal models, mice (8-11 mice per group) were monitored and checked twice
a week for tumor formation (abdominal distension) in the peritoneal cavity. Mice were
randomized to treatment at an advanced stage of disease (i.e. 25% of expected median
survival time, MST) unless otherwise stated. For ethical reasons, survival was defined as
the day of appearance of signs of distress, at which time mice were euthanized (Garofalo et
al., 2003; Oliva et al., 2012; Ricci et al., 2014). At necroscopy, the peritoneal cavity was
macroscopically examined to ascertain the presence of tumor. Survival time was recorded
and increment of lifespan was calculated: %ILS = [(median survival day of treated group −
median survival day of control group) / median survival day of control group] x 100.
Results were plotted as the percentage of survival against days after tumor transplant.
Complete response, confirmed macroscopically at necropsy, was the absence of tumor in
animals still alive 200 days after transplant.
2.3.3.3 Intraovarian model ID8
For the intraovarian tumor model ID8, mice (5-10 per group) were randomized at an
advanced stage of disease (i.e. 25% of MST from previous experiments). In parallel two
randomly selected mice were scanned by MRI and sacrificed to ascertain the presence of
the tumor.
After 4 weeks of treatment, mice were scanned by MRI, and from that point on tumor
burden and progression were monitored every two-four weeks until the median survival
time was reached for each group. The appearance of signs of distress was considered as
survival and mice were immediately sacrificed; a complete necropsy was performed,
primary tumor in the ovary weighed and organs of the peritoneal cavity macroscopically
scored (see Section 2.1.4.3). Survival time was recorded and increment of lifespan was
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calculated: %ILS = [(median survival day of treated group − median survival day of
control group) / median survival day of control group] x 100. Results were plotted as the
percentage survival against days after tumor transplant.
Magnetic Resonance Imaging
Tumor formation was followed by MRI, in collaboration with the experts of the Laboratory
of Biology of Neurodegenerative Disorders of the Istituto di Ricerche Farmacologiche
Mario Negri IRCCS, Milan, Italy.
Briefly, animals were imaged under general gas anaesthesia (1.4% isoflurane in O2).
Respiratory rate and temperature were continuously monitored. Experiments were
performed on a 7T Bruker Biospin 70/30 Avance III system, equipped with a 12 cm
diameter gradient coil (400 mT/m maximum amplitude). A transmit cylindrical
radiofrequency (rf) coil (7.2 cm inner diameter) and a receive surface rf (2×2cm) coil array
positioned over the animal body were used.
In order to identify the tumor location, an initial axial image was first obtained using a
rapid acquisition with relaxation enhancement (RARE) sequence (TR/TE=2000/36ms,
RARE factor 8, Number of average 2, Field of View 30x30mm, Matrix 256x256, Slice
thickness 1mm, Number of slices 16). The anatomical image was then acquired using a
coronal RARE sequence triggered on respiration (TR/TE=4000/36ms, RARE factor 8,
Number of average 2, Field of View 30x20mm, Matrix 256x176) with a different slice
thickness from 0.8 to 1.1 mm depending on the extension of the tumor. Tumor volumes
were manually calculated by an expert tracer using ITK-SNAP software (Yushkevich et al.,
2006).
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2.4 EX VIVO ANALYSIS
2.4.1 Histological and immunohistochemical analysis on hypoxia and tumor-
associated vasculature
Histological and immunohistochemical analyses were performed in collaboration with an
expert pathologist of the Department of Veterinary Medicine of the University of Milan
and Mouse and Animal Pathology Lab (MAPLab) of the Fondazione Filarete, Milan.
Analyses were performed on subcutaneous tumors (s.c. models) and tumor masses at the
ovaries (i.p. models) collected at the end of short-term treatment (4 weeks, 5 days on and 2
days off), 6 hours after the last received dose of drugs.
Antibodies used are listed in the table below.
Pimonidazole and CA-9 were used to assess levels of hypoxia in the vehicle at random
(VH at random, when available), VH, OLA, CED and COMBO treatment group (n=2-
3/per group).
When possible, pimonidazole was administered 60 mg/kg, i.v, 30 minutes before the
sacrifice of the mice. Tumors and organs were fixed in 10% neutral buffered formalin and
paraffin embedded for histopathological analyses. 4 m serial sections from each sample
were routinely stained with Hematoxylin and Eosin for morphology and by
immunohistochemistry for features shown above.
For immunohistochemistry, deparaffinization, rehydration and antigen retrieval were
performed in a single step method: sections were immersed for 40’ at 94°C in a pH 9
buffer solution (Dewax and HIER Buffer H, Thermo Scientific). Endogenous peroxidase
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activity was blocked by incubating sections in 3% H2O2 for 15 min. To reduce nonspecific
background staining, slides were rinsed and treated, for 30 min, with 10% normal serum
from the species in which the secondary antibody was produced (rabbit serum for anti-
CD31 and goat serum for anti-pimonidazole and anti-CA9) and then incubated for 1 hour
at room temperature with the primary antibody.
An appropriate biotinylated secondary antibody (Vector Laboratories) was then added for
30 min and sections were labelled by the avidin-biotin-peroxidase (ABC) procedure with a
commercial immunoperoxidase kit (Vectastain Standard Elite, Vector Laboratories). The
immunoreaction was revealed with 3,3’-diaminobenzidine substrate (DAB, Vector
Laboratories) for 5 minutes and sections were counterstained with Mayer’s hematoxylin.
Digital Image Analysis.
The tumor-associated vasculature was evaluated by computing the number of CD31-
positive vessels (Microvessel Density, MVD) and by measuring the CD31-immunopositive
areas (Endothelial Area, EA, not considering vascular lumen) in 3 200x microscopic fields,
randomly selected throughout the neoplastic tissue, using ImageJ software (Schneider et al.,
2012). Tumor hypoxia was calculated by measuring the extension of pimonidazole- or
CA9- intensely stained area in 2 50x microscopic fields, with Orbit.bio software
(http://www.orbit.bio).
2.4.2 Histological and immunohistochemical analysis of HR DNA repair markers
Histological and immunohistochemical (IHC) analyses on H2AX were performed in
collaboration with AstraZeneca, Oncology iMed Translational Science, Molecular
Pathology Group at the Cambridge Science Park.
Briefly, subcutaneous tumors were collected at the end of short-term treatment (4 weeks, 5
days on and 2 days off), 6 hours after the last received dose of drugs. Tumors were fixed in
10% neutral buffered formalin and paraffin embedded for histopathological analyses. 4 m
serial sections from each sample were routinely stained with Hematoxylin and Eosin for
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morphology and by immunohistochemistry for features shown above. Subsequently,
sections were deparaffinized in xylene and rehydrated using graded ethanol and analyses
were performed with H2AX, using a Ventana BenchMark XT immunostainer.
Digital Image Analysis.
Foci of H2AX (% H2AX+ foci with a different pattern of expression) were evaluated 3
200x fields, randomly chosen across neoplastic tissue in VH, OLA, CED and COMBO
group (n=2-3/per group). Whole slide scans were analysed with Aperio ImageScope
Software.
2.5 STATISTICAL ANALYSES
Statistical analyses were done using Prism Software (Prism 7; GraphPad Software, La Jolla,
CA). Differences in Kaplan Meier survival curves were analysed by the Log-Rank test.
Differences in microvessel density (MVD), endothelial area (EA), foci of H2AX, gene
expression and - Ct values after treatment were analysed by the Kruskal Wallis test
followed by Dunn’s multiple comparison post-test.
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CHARACTERIZATION OF IN VIVO PATIENT-
DERIVED OVARIAN CANCER XENOGRAFTS
(OC-PDX)
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3.1 THE PLATFORM OF OC-PDX
Part of the data presented in this section is reported in the manuscript entitled “Patient-
Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic
Alterations”, by Ricci/Bizzaro et al, Cancer Res, 2014; DOI: 10.1158/0008-5472.CAN-14-
0274.
In the Department of Oncology, where this PhD research has been carried out, a platform
of transplantable patient-derived ovarian cancer xenografts (OC-PDX) has been
established over the last years. We have previously demonstrated that our bio-bank of OC-
PDX comprise all the main subtypes of human ovarian carcinomas and retain the features
of patients’ original tumors, in terms of biological behaviour, histopathological and
molecular profiling. Moreover, the availability of orthotopic intraperitoneally growing OC-
PDX, able to disseminate in the organs of the peritoneal cavity of mice, is a powerful tool
to resemble the typical pattern of dissemination seen in patients, with the formation of
ascites and carcinomatosis (Ricci et al., 2014).
One of the tasks of this PhD project was to establish new OC-PDX directly from patients’
fresh tumor tissue, thus enlarging the existing platform.
To date, the platform of OC-PDX available in the Department of Oncology of the Mario
Negri Institute includes 43 models, 34 previously described (Ricci et al., 2014) and 9
newly established, which I directly contributed to characterize during my PhD research
project.
Our collaboration with the San Gerardo Hospital in Monza (Italy) and IEO Hospital
(European Institute of Oncology) in Milan (Italy) is ongoing.
The 43 OC-PDX have been established and grow in immunodeficient mice, with different
routes of injection, as reported in Table 3.1.
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Table 3.1 The platform of OC-PDX: histopathology and route of engraftment.
Abbreviations: HGS, high grade serous; HGE, high grade endometrioid; LGE, low grade
endometrioid; CCC, clear cell carcinomas; MUC, mucinous; MMT, mixed Mullerian
tumor; UNDIFF., undifferentiated. S.C: subcutaneously growing OC-PDX.
I.P: intraperitoneally growing OC-PDX. Squared in red are the 26 OC-PDX selected to
perform molecular and pharmacological studies reported in this PhD research project.
$ OC-PDX reported in “Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and
Genetic Alterations”, by Ricci/Bizzaro et al, Cancer Res, 2014.
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Routinely, patients’ solid tumors from ovary and omentum, primary or relapsed, were
transplanted subcutaneously (s.c) in the flanks of mice, as reported in Materials and
Methods, Section 2.1.3.
Patients’ primary or relapsed ascites were injected directly into the peritoneal cavity (i.p)
of mice, as reported in Materials and Methods, Section 2.1.4.
Our pathologist, taking into account the available data of the corresponding patients,
confirmed the histotype of the 43 OC-PDX.
Half of the models (53%) were high grade serous, followed by 13% of high grade
endometrioid, 5% of high grade serous/endometrioid, 2% of high grade endometrioid/clear
cell, 2% of low grade endometrioid, 2% low grade serous/endometrioid, 6% of clear cell
carcinomas, 5% of mucinous, 5% of mixed Mullerian tumor and 6% of undifferentiated
ovarian carcinoma, mimicking the clinical pattern and frequency of human ovarian
carcinomas (Table 3.1).
The established platform of OC-PDX is an instructive framework that can be used to
perform characterization studies on generic molecular, morphological and biological
aspects and also to selected representative OC-PDX for drug testing (Figure 3.1).
Chapter 3 Francesca Bizzaro
90
Figure 3.1 The application of the platform of OC-PDX.
After patient surgery, tumor fragments or ascites were transplanted in
immunocompromised mice, without previous in vitro passage, obtaining different OC-
PDX models. After the in vivo establishment, OC-PDX were expanded and cryo-
preserved at different passages. In parallel, tumor samples were collected and stored
(formalin-fixed paraffin-embedded and snap-frozen) to constitute the bio-bank for
further studies. Pharmacological studies were performed on OC-PDX to test several
compounds and combination.
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To perform all the studies reported in this PhD research project, we decided to focus our
attention on 26 OC-PDX (Table 3.1), based on their biological behaviour and histological
features and analysed them with whole genome libraries sequenced on the Illumina HiSeq
4000 platform. The Next Generation Sequencing (NGS) data were aligned and analysed
within the BCBio framework (Lai et al., 2016) as reported in Materials and Methods,
Chapter 2.2.2. The ultimate goal was to select a smaller cohort of OC-PDX for drug testing
with the PARP inhibitor olaparib in combination with the angiogenesis inhibitor cediranib
(see Chapter 4, Results).
3.1.1 Characteristics of original patients’ tumors
Diagnosis (histotype, grade and stage), sample source and origin, patients’ treatments and
follow up of the 26 OC-PDX used in this PhD research project are reported in Table 3.2.
The origin and source of patients’ specimens included 3 primary ascites, 8 primary ovary,
3 primary tumors located in the omentum, 8 ascites and 4 omental metastasis collected at
relapse.
Patients experienced different treatments before primary surgery, peritoneal washing or
omentectomy, where tumor samples, from which OC-PDX derived, were collected.
Twelve patients were chemotherapy-naïve, 12 patients were treated with adjuvant
chemotherapy and 2 patients underwent neoadjuvant treatment.
Regardless of these aspects, all the patients were treated with a standard-of-care platinum-
taxane based chemotherapy, with the addition of bevacizumab in two cases. The patient
diagnosed with a mucinous carcinoma was not treated.
At the last recorded follow up, 8 patients were considered resistant to therapy, being in
progressive disease; 2 had stable disease and 5 had a partial response. After therapy, 4
patients experienced complete response and 5 did not show any evidence of disease. For
one patient no clinical records were available.
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Table 3.2 Patients’ tumors characteristics of the 26 OC-PDX used in this PhD
thesis.
Abbreviations: HGS, high grade serous; HGE, high grade endometrioid; LGE, low grade
endometrioid; CCC, clear cell carcinomas; MUC, mucinous.
Ov, ovary; Om, omentum; A, ascites.
CBDCA, carboplatin; EPI, epirubicin; DDP, cisplatin; PTX, paclitaxel; BEVA,
bevacizumab; PAC, cisplatin-adriamicin-cyclophosphamide; CP, cisplatin-
cyclophosphamide; CTX, cyclophosphamide; N.A, not available.
PR, partial response; PD; progressive disease; NED, non-evident disease; CR, complete
response; SD, stable disease; N.A, not available.
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3.1.2 OC-PDX recapitulate the morphology and histopathology of ovarian cancer
When available, the histology of OC-PDX was compared with the corresponding patient
original tumor; in all cases, morphology and tissue structure were retained (representative
histological section in Figure 3.2, panel A). In some cases, cytokeratin pool and CA-125
were assessed, resulting in a strong retention of positivity (Figure 3.2, panel B). The value
of OC-PDX as a model to study ovarian cancer was proved also by evaluating morphology
and histopathology after several in vivo passages (comparison between hematoxylin-eosin
section at passage I and higher than V); the architecture of the original tumor was
preserved even after several transplants in mice (Figure 3.2, panel C). The subset of
patients, from which the 26 OC-PDX were established, resembled the clinical
histopathological heterogeneity of ovarian cancer, thus being a powerful tool to study new
therapeutic strategies on a wider range of patients that could gain benefit.
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Figure 3.2 Representative histological section of subcutaneous OC-PDX and
corresponding patient tumor.
A) Sections from OC-PDX and the corresponding patient (hematoxylin and eosin).
B) Comparative immunohistological analysis of patient tumor and the corresponding
xenograft (cytokeratin pool and CA-125).
C) Comparative immunohistochemical analysis of xenografts at different passages.
Images partially reported in “Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology
and Genetic Alterations”, by Ricci/Bizzaro et al, Cancer Res, 2014.
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3.1.3 OC-PDX biological behaviour
Among the 26 OC-PDX chosen for this project, 16 models were transplanted
subcutaneously, 8 models were injected and grew in the peritoneal cavity and 2 grown in
both sites (Table 3.1, squared in red).
Subcutaneous models were a useful and easy-to-manage tool, especially to conduct
preclinical trials in a more simple and controlled environment, thus focusing only on the
effects of the therapy on tumor growth. Subcutaneous tumor growth was very variable,
from faster progressor OC-PDX, such as MNHOC 18 (approx. 17 days to reach 1200mm3),
to slower ones, such as MNHOC 125 (approx. 125 days to reach 1200mm3) (Ricci et al.,
2014).
Intraperitoneally growing OC-PDX were a unique and valuable tool to study the biological
behaviour and the ability to disseminate in the peritoneal organs, thus mimicking the
original patient tumors and allowing us to shed light on the effects of therapy in a more
complex microenvironment. Intraperitoneal OC-PDX closely reproduced the dissemination
patterns of human ovarian cancer, forming ascites and spreading diffusely through the
organs of the peritoneal cavity (ovary, uterus, diaphragm, pancreas, omentum and liver)
with various levels of carcinomatosis, ascites formation and median survival time (MST).
Ascites production and tumor dissemination were linear in some case, such as MNHOC
111/2 with high levels of fluid formation and carcinomatosis, or completely different, as
for MNHOC 8, with the highest levels of ascites among all and the lowest score of
dissemination and carcinomatosis (Ricci et al., 2014).
3.1.4 NGS to study the mutational landscape of OC-PDX
NGS on the whole genome was conducted in collaboration with AstraZeneca (see Section
2.2.2 and 2.2.3 Materials and Methods). Molecular characterization was undertaken on the
panel of 26 OC-PDX.
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For this project the focus was on aberrations and mutations in a set of genes involved in the
pathogenesis of ovarian cancer (Table 3.3, e.g. TP53, KRAS, BRAF, PIK3CA, CTNNB1,
PTEN, EGFR) and genes belonging to the HR DNA repair pathway (Table 3.4, e.g.
BRCA1/2, ATM, ATR, ATRX, BARD1, BLM, CHEK1, CHEK2, FANCA, FANCB, FANCC,
FANCD, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11A, NBN, PALB2,
RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RPA from (Coleman et
al., 2017) and reported in Table 1.1 Introduction).
Sanger sequencing was performed on OC-PDX DNA to validate mutations, designing ad
hoc primers pairs to amplify 100-200 bp around the region containing the mutation (see
Table 2.1, Materials and Methods, Chapter 2, for genes and primers pairs used in Sanger
validation). When possible, the same mutation found in OC-PDX was confirmed also in
the corresponding patient’s DNA.
The detailed mutational spectrum of the most common genes involved in the pathogenesis
of ovarian cancer is reported in Table 3.3.
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Table 3.3 Mutational spectrum of most commonly mutated genes in ovarian
cancer, verified by Sanger sequencing.
Data are from OC-PDX and corresponding patient (PZ) where available. Abbreviations:
HGS, high grade serous; HGE, high grade endometrioid; LGE, low grade endometrioid;
CCC, clear cell carcinomas; MUC, mucinous.
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Nonsynonymous TP53 mutations were found in all the high grade serous and endometrioid
tumors; clear cell (MNHOC 94/2-C and MNHOC 119), low grade endometrioid (MNHOC
109, synonymous TP53 mutation c.639A>G, p.R213R) and mucinous (MNHOC 182)
harboured wild type TP53, in line with clinical data (Ahmed et al., 2010).
All the mutations found in TP53 were located with a strong predominance in exons 4-9,
which encodes the DNA-binding domain of the protein, including the 6 main “hot-spot”
residues described (Cho et al., 1994), such as R175, G245, R248, R249, R273, and R282,
that are frequent in almost all type of cancer. The majority were missense substitutions,
with a pathogenic prediction score.
Among other genes, two cases of mutated KRAS were found both in the OC-PDX and
corresponding patient’s tumor, one high grade serous MNHOC 84 (p.G12A) and one
mucinous MNHOC 182 (p.G12D).
The clear cell MNHOC 94/2-C displayed a truncation/frameshift mutation in PTEN
(p.R130*), with a high pathogenic prediction score. EGFR carried two missense mutations
in MNHOC 508 (p.Y1110N) and MNHOC 18 (p.R962C, pathogenic).
The OC-PDX and the corresponding patient tumors whose DNAs were available always
displayed the same mutational status.
The detailed mutational spectrum of different HR DNA repair pathway genes is reported in
Table 3.4.
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Table 3.4 Mutational spectrum of different HR genes, verified by Sanger
sequencing.
Data are from OC-PDX and corresponding patient (PZ) where available. Abbreviations:
HGS, high grade serous; HGE, high grade endometrioid; LGE, low grade endometrioid;
CCC, clear cell carcinomas; MUC, mucinous.
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Sequencing of genes related to the HR DNA repair pathway revealed a disparate picture.
BRCA1 and BRCA2 were found mutated or lost in 11 OC-PDX, notably in the high grade
serous and endometrioid types.
Mutations in BRCA1 were mostly substitution/missense and truncation/frameshift, all
described as pathogenic accordingly to ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/).
Of note, MNHOC 513 carried a deletion on the exon 23 of BRCA1, an event that caused a
frameshift leading to a loss of function (LoF) at the protein level (Table 3.4).
Mutations in BRCA2 included one frameshift described as pathogenic (p.L1908fs on
MNHOC 508) and one missense mutation with conflicting interpretation (p.S2071T on
MNHOC 511). Interestingly MNHOC 18 exhibited a missense mutation, predicted as
neutral non-pathogenic (FATHMM score 0,15) on BRCA2 (p.T1067A). The mucinous
MNHOC 182 displayed a truncation/frameshift mutation in BRCA2, despite the low
mutation rate described for this type of tumor (Pennington et al., 2014; Soegaard et al.,
2008; Zhang et al., 2011). The mutation (p.E2391EX) led to the formation of a stop codon.
In both the cases, the mutation induced an absence of locus-specific loss of heterozygosity
(LOH), meaning that one allele is wild type and the other is mutated, so functional protein
is still produced. This was confirmed also with ad hoc Sanger sequencing on cDNA, retro-
transcribed from RNA. The homologous recombination pathway was thus functional.
Of note, MNHOC 154 carried a pathogenic amplification of BRCA2 (Table 3.4).
Among other genes of the HR DNA repair pathway, PARP4, PALB2, ATM, ATRX, FANCA
and FANCB were found altered. Mutations were unknown missense with uncertain clinical
significance accordingly to ClinVar, except for PARP4 (p.R958Q) substitution missense
described as pathogenic in MNHOC 10, PALB2 (p.T284P) substitution missense likely
benign in MNHOC 22, FANCB (p.G335E) and ATRX (p.H865Q) substitutions missense
described as benign in MNHOC 508 and MNHOC 154 respectively (Table 3.4).
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Interestingly, OC-PDX and the corresponding patient’s tumor -where human DNA was
available- displayed the same somatic mutations.
3.1.5 Gene expression profile analysis to characterize OC-PDX
Gene expression analysis on selected genes was performed using different techniques,
including RealTime-PCR (RT-PCR), genome-wide gene expression, fluidigm and RNAseq
(see Chapter 2.2, Molecular analysis, Materials and Methods).
The results herein presented a focus on the expression levels of BRCA1 and BRCA2 across
the 26 OC-PDX selected to perform this PhD research project.
Firstly, absolute copy numbers of mRNA were determined by RT-PCR (ABI-7900,
Applied Biosystems) with the SYBR Green technique, using an EPMotion 5075 robot
(Eppendorf). Standard curves for each gene were included for absolute quantification of
mRNA. Primers for BRCA1 were designed to cover exons 16-17, and reported in the
following table.
RT-PCR analysis showed that MNHOC 8 and MNHOC 8Y (respectively primary and
relapsed ascites of the same patient), MNHOC 149 and MNHOC 182 displayed the lowest
levels of BRCA1 expression. In MNHOC 125, MNHOC 22, MNHOC 18, MNHOC 111/2
and MNHOC 508, BRCA1 levels of expression were the highest (Figure 3.3).
BRCA1 ex.16-17 Forward GCCAGAAAACACCACATCAC
BRCA1 ex.16-17 Reverse CAGTGTCCGTTCACACACAA
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Figure 3.3 Gene expression analysis of OC-PDX from RT-PCR: BRCA1 level
of expression.
Absolute copy numbers of mRNA were determined by RT-PCR (ABI-7900, Applied
Biosystems) with the SYBR Green technique, using an EPMotion 5075 robot
(Eppendorf). Standard curves for each gene were included for absolute quantification
of mRNA. Data are expressed as ratio between BRCA1 and actin (housekeeping gene).
Chapter 3 Francesca Bizzaro
103
Results were then re-confirmed with genome-wide gene expression analysis, focusing our
attention both on BRCA1 and BRCA2.
Briefly, arrays were scanned and images analysed by the Feature Extraction Software from
Agilent Technologies; raw data were then processed using the LIMMA (LInear Models for
Microarray Analysis) package from Bioconductor (Smyth, 2004). Background correction
was performed with the normexp method with an offset of 50. Normalization was carried
out using the quantile method. Data were expressed as log2 normalized Intensities (Figure
3.4, panel A and B).
Evaluation of Log2 Intensity demonstrated that MNHOC 8 and MNHOC 8Y expressed the
lowest level of BRCA1, with barely detected values compared to the other OC-PDX. High
levels of expression were confirmed in MNHOC 111/2 and MNHOC 125, as from RT-
PCR data.
Differences in BRCA2 expression were less pronounced, with Log2 Intensity values being
quite uniform across OC-PDX. BRCA2 expression appeared to be the lowest in MNHOC
182, MNHOC 10 and MNHOC 8, and the highest in MNHOC 154, due to the pathogenic
amplification found in NGS (Figure 3.4, panel A and B).
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Figure 3.4 Gene expression analysis of OC-PDX from genome-wide gene
expression.
A) BRCA1 and B) BRCA2 levels of expression from genome-wide gene expression
analysis. Arrays were scanned and images analysed by the Feature Extraction Software;
raw data were processed using the LIMMA (LInear Models for Microarray Analysis)
package from Bioconductor (Smyth, 2004). Background correction was performed with
the normexp method with an offset of 50. Normalization was carried out using the
quantile method. Data are expressed as Log2 Intesity and represented on graph as
mean±SD. Abscissa intercepts ordinate axis at the mean value of Log2 Intensity
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Levels of BRCA1 and BRCA2 expression were further evaluated with fluidigm (see
Chapter 2.2.5 Materials and Methods). To summarize, the mean of Ct values of each
replicate was calculated. Then the mean was normalized to housekeeping genes and ΔCt =
Cttarget- Cthousekeeping assessed (Figure 3.5, panel A and B). For convenience, values were
reported as -ΔCt, being the lowest value corresponding to the lowest expression.
Results confirmed what was previously assessed by RT-PCR and genome-wide gene
expression analysis: MNHOC 8 expressed the lowest and MNHOC 125 the highest values
of BRCA1, while BRCA2 was poorly and highly expressed in MNHOC 182 and MNHOC
154 respectively. Results from Fluidigm (Figure 3.5, panel A and B) mirrored what was
already highlighted with genome-wide gene expression analysis.
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Figure 3.5 Gene expression analysis of OC-PDX at baseline from Fluidigm.
A) BRCA1 and B) BRCA2 levels of expression from Fluidigm analysis.
Briefly, Ct = Ct target - Ct housekeeping was calculated (housekeeping genes were IPO8 and
HPRT1) for each gene under investigation and reported as -ΔCt, being the lowest value
corresponding to the lowest expression Abscissa intercepts ordinate axis at the average
value of - ΔCt obtained from all the samples.
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RNAseq analysis further strengthened previous results. Log2*PCM (count per million)
values showed that levels of BRCA1 were the lowest in MNHOC 8 and MNHOC 8Y,
while the highest levels of BRCA2 were detected in MNHOC 154 (Figure 3.6, panel A and
B).
Of note, MNHOC 154 was the model with the highest level of expression of BRCA2 across
every gene expression profile analysis performed, confirming NGS results, that indicated a
pathogenic amplification in BRCA2 (as described above in Section 3.1.3 and reported in
Table 3.4).
Interestingly, MNHOC 513 carried a deletion in exon 23 of BRCA1 (as described above in
Section 3.1.3 and reported in Table 3.4). However, levels of expression of BRCA1 were
among the highest in MNHOC 513, meaning that the transcript was still produced. The
deletion in exon 23 of BRCA1 led to frameshift and LoF at the protein level.
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Figure 3.6 Gene expression analysis of OC-PDX from RNAseq.
A) BRCA1 and B) BRCA2 levels of expression from RNAseq analysis.
Data are expressed Log2*CPM (count per million) and represented on graph as
mean±SD. Abscissa intercepts ordinate axis at the mean value of Log2*PCM
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3.2 THE COHORT OF OC-PDX SELECTED TO PERFORM PRECLINICAL
DRUG TESTING
The extensive characterization on the 26 OC-PDX chosen to perform this PhD project,
based on biological behaviour, histopathological and molecular (mutational landscape and
levels of expression of selected genes) aspects, gave us the opportunity to carefully select
13 OC-PDX to perform preclinical testing (Figure 3.7).
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Figure 3.7 The cohort of OC-PDX selected for drug testing.
no locus-specific Loss Of Heterozygosis (LOH)
no mutation detected
HGS, high grade serous; HGE, high grade endometrioid; CCC, clear cell carcinomas; MUC, mucinous.
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In particular, 3 orthotopic intraperitoneal OC-PDX were chosen: MNHOC 8, MNHOC 22
and MNHOC 506. Among subcutaneously growing tumors, 10 models were selected,
MNHOC 143, MNHOC 500, MNHOC 508, MNHOC 511, MNHOC 513, MNHOC 124,
MNHOC 18, MNHOC 154, MNHOC 94/2-C and MNHOC 182.
The cohort included 8 high grade serous (HGS), 1 mixed high grade serous/endometrioid
(HGS/HGE), 2 high grade endometrioid (HGE), 1 clear cell (CCC) and 1 mucinous
(MUC). Mutational spectrum and levels of expression of BRCA1 and 2 were carefully
considered for these OC-PDX. Particularly, 6 OC-PDX carried mutations or loss of BRCA1
and 2, and of other genes related to HR (MNHOC 22, MNHOC 500, MNHOC 508,
MNHOC 511, MNHOC 513, MNHOC 154); MNHOC 8 was the model with the lowest
expression of BRCA1 and one of those with low levels of BRCA2 expression, verified with
several experiments and with different techniques (RT-PCR, genome-wide gene expression,
fluidigm and RNAseq).
Among OC-PDX that harboured no mutation or absence of locus-specific loss of
heterozygosity (LOH) in BRCA1 and BRCA2, 6 OC-PDX were chosen: MNHOC 143,
MNHOC 506, MNHOC 124, MNHOC 18, MNHOC 94/2-C and MNHOC 182.
We decided to classify the 13 OC-PDX, selected ad hoc for testing drugs, as BRCAness or
Not BRCAness, not only considering the mutational status and pathogenicity of BRCA1
and 2, but also the levels of expression and any aberration on other genes involved in the
HR DNA repair pathway, as reported in Figure 3.7.
3.3 SUMMARY OF RESULTS AND DISCUSSION
OC-PDX were obtained by transplanting tumor samples, freshly obtained from patients at
surgery, subcutaneously and orthotopically in immunocompromised mice.
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The choice of the appropriate strain of mice is a critical issue to achieve a high engraftment
rate, especially in the first in vivo passage. We estimated that the take rate at the first
passage after injection is around 50/60% using athymic nude mice (Masazza et al., 1991;
Massazza et al., 1989; Ricci et al., 2014). However, accordingly to published data (Shultz
et al., 2012), engraftment rate could be improved with the use of NGS mice.
The benefit of OC-PDX models is the limited diversity shown from patient’s original
tumor (Sausville and Burger, 2006; Siolas and Hannon, 2013; Tentler et al., 2012),
compared with the use of an established cell line, which can result in a selected population
not truly representative of the original tumor, thus producing responses that are different
from those seen in patients.
On the other hand, the biggest issue with PDX as preclinical models is the lack of a murine
immune system that makes it impossible to study the effect of the immune system to boost
therapy. In fact, it is nowadays well recognized that the immune system plays a critical role
in cancer initiation and expansion (Colvin, 2014; Hansen et al., 2016; McLean and Mehta,
2017; Pogge von Strandmann et al., 2017).
This problem/limitation could be overcome thanks to the recent development of
“humanized xenograft” models, which are created by co-engrafting patient’s tumor
fragments with hematopoietic stem cells or human peripheral blood mononuclear cells
(Siolas and Hannon, 2013), ideally derived from the same patient to avoid allogenic and
graft-versus-host phenomena (Shultz et al., 2012).
A platform of patient-derived ovarian cancer xenografts has been established in the
Department of Oncology (Ricci et al., 2014), and new models have been added during this
PhD research project (Table 3.1).
Among these, 26 OC-PDX were characterized in depth from the biological,
histopathological and molecular point of view (protocol of the study as in Figure 3.1). The
panel of the 26 OC-PDX reproduced the plethora of human ovarian carcinomas with all the
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different subtypes. OC-PDX, growing both subcutaneously and orthotopically in the
peritoneal cavities of mice, maintained the original histotype and tissue architecture even
after several passages in vivo (Figure 3.2), harboured mutations in genes mostly involved
in ovarian cancer disease and progression (TP53, KRAS, BRAF, PIK3CA, CTNNB1, PTEN,
EGFR) and in HR DNA repair pathway genes (Table 3.3 and Table 3.4). Accordingly to
the literature, all the high grade serous and endometrioid OC-PDX harboured mutations on
TP53, while the clear cell (i.e. MNHOC 94/2-C) and the mucinous (i.e. MNHOC 182)
harboured mutations in PTEN and KRAS. MNHOC 508 and MNHOC 18 carried a
missense mutation in EGFR. The selected platform of 26 OC-PDX was a useful tool to
perform gene expression analysis, with different techniques, leading to reproducible and
consistent results (Figure 3.3 – 3.6).
Recently one issue with the use of PDX has been highlighted: Golub and colleagues (Ben-
David et al., 2017) have suggested that genomic instability of PDX is underestimated and
that the variation in copy number alteration is continuously changing, leading to genetic
drift of PDX from the original patient’s tumor. De novo events during several passages in
vivo limit the prediction value of these models.
In our platform, when the comparison was possible, OC-PDX showed a strong consistency
with the patient’s tumor from which they derived, at least in the histopathological and
molecular aspect. For this reason, our collection offers an instructive framework to perform
preclinical drug testing that could be translated into the clinic (Figure 3.2, Table 3.3 and
Table 3.4), as long as OC-PDX are used within a minimum number of in vivo passages.
Taking together the data obtained from the NGS and gene expression analysis and
considering the histopathology, we further selected 13 OC-PDX for preclinical therapy
testing (see Chapter 4, Results). This cohort included mostly high grade serous and
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endometrioid ovarian carcinomas (Figure 3.7), with one clear cell and one mucinous model
(MHOC 94/2-C and MNHOC 182, as in Figure 3.7).
To resemble the clinical situation and patient stratification, OC-PDX carrying somatic
mutations and loss of BRCA1/2 on both the alleles of the gene were defined as BRCAness
types (Figure 3.7); low levels of expression of BRCA1 and BRCA2 allowed us to define
one particular model, MNHOC 8, as BRCAness, even though no mutations were detected
with Sanger sequencing (Figure 3.7). Of note, MNHOC 154, carrying a mutation in
BRCA1, was defined as BRCAness, even though a high level of expression of BRCA2,
attributable to an amplification, was described as pathogenic.
OC-PDX that did not carry mutations on BRCA1 and BRCA2 or absence of locus-specific
loss of heterozygosity (LOH) (such as MNHOC 18 and MNHOC 182) were defined as Not
BRCAness (Figure 3.7).
A variety of other genes linked to the HR DNA repair pathway was found mutated across
the OC-PDX. The majority of these mutations were reported as non-pathogenic or of
uncertain clinical significance.
The panel of 13 OC-PDX offered a useful platform for preclinical testing therapy with
cediranib and olaparib, being a powerful tool to study mechanisms of action underlying the
effect of the combination (see Chapter 4, Results).
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4.1 CORRELATION BETWEEN THE BRCANESS STATUS AND RESPONSE
TO OLAPARIB MONOTHERAPY
PARP inhibitor (PARPi) olaparib was the first molecularly targeted agent validated for
high grade ovarian cancer (Ledermann et al., 2012).
To classify the cohort of OC-PDX selected to perform preclinical testing, we used the
following criteria:
 OC-PDX carrying somatic mutations and loss of BRCA1/2 on both the gene alleles
were defined as BRCAness. In addition, low expression levels of both BRCA1 and
BRCA2 allowed us to define one particular model, MNHOC 8, as BRCAness, even
though no mutations were detected with Sanger sequencing.
 OC-PDX that did not carry mutations on BRCA1 and BRCA2 or did not display
locus-specific loss of heterozygosity (LOH) (such as MNHOC 18 and MNHOC
182) were defined as Not BRCAness.
A cohort of 10 subcutaneous OC-PDX was first selected to assess the responsiveness to
olaparib monotherapy. Tumor-bearing mice were randomized at an estimated tumor
volume of 280-330 mm3 (300 mm3 average) and assigned to treatment groups (see Section
2.3.2 and 2.3.3 Materials and Methods).
Olaparib was administered as a single therapy every day for 5 days on and 2 days off
(Q1x5), in a short-term treatment regimen of 4 weeks or in a maintenance schedule (until
partial regression - 30% of the tumor volume at random - or complete progression).
Results are shown as waterfall plots, in which each bar represents the course of the disease
for each mouse (Figure 4.1).
The BRCAness tumors MNHOC 500, 508, 511, 513 and 154 showed statistically
significant responses to olaparib in a short-term regimen (Figure 4.1, panel A) and
continued to regress under maintenance treatment (Figure 4.1, panel C), with complete
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responses and animals considered cured when tumor-free for approximately 200 days post
therapy.
Only a few cases differed from this trend (one MNHOC 508, one MNHOC 511 and two
MNHOC 154 tumors), which progressed under treatment, enabling the future possibility of
investigating potential mechanisms of resistance to olaparib (beyond the scope of this
thesis).
Olaparib was poorly active or inactive in tumor models that were classified as Not
BRCAness, such as MNHOC 18, 124, 143, 94/2-C and 182. In each case the course of the
disease was progressive after a short-term treatment (Figure 4.1, panel A), and tumor
growth also increased markedly (similar to vehicle controls) in a maintenance regimen
(Figure 4.1, panel C).
These results confirmed that our OC-PDX models enabled us to recapitulate the drug
profile sensitivity seen in patients from which they derived, making them a reliable tool for
drug discovery.


































Figure 4.1 Correlation between BRCAness status and response to olaparib
monotherapy in a short-term versus maintenance regimen.
Olaparib (100 mg/kg) was administered by oral gavage every day for 5 days on and 2
days off (Q1x5), for four cycles (short-term regimen) or until tumor progression
(maintenance regimen).
Treatment efficacy was expressed as % tumor variation after (A – B) short-term (4
weeks, day 28) and (C –D) maintenance (12 weeks, day 100) regimen.
%tumor variation = [(tumor volume day 28 or day 100-tumor volume day 0)/tumor
volume day 0] x 100, considering day 0 randomization time.
Disease was considered progressive = tumor variation > 20%; stable = -30% < tumor
variation > 20%; regressive = tumor variation > -30%. * Complete responses = tumor
free mice at day 200.
N= 4-7 tumors per model.
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4.2 THE IMPORTANCE OF THE COMBINATION OF OLAPARIB AND
CEDIRANIB
Interest in adding cediranib, an anti-angiogenic agent with activity against VEGF receptors
(VEGFR1, 2, 3), c-KIT and PDGFR-alpha, to olaparib has increased recently. Both oral
agents have displayed antitumor activity in women with recurrent ovarian cancer
(Kaufman et al., 2015; Ledermann et al., 2016) and the combination is ongoing in clinical
trials (Liu et al., 2013, 2014).
Olaparib (100 mg/kg) and cediranib (3 mg/kg) in combination were administered orally,
every day for 5 days on and 2 days off (Q1x5) with the same doses and scheduled as the
single agents, in a short-term treatment regimen of 4 weeks or in a maintenance regimen
(until partial regression – 30% of the tumor volume at random - or progression).
After 4 weeks of treatment, the number of progressing single tumors was lower compared
to single drug administration (Figure 4.2, panel A), including Not BRCAness tumors that
were not responsive to olaparib or cediranib single therapy (all the cases of MNHOC 94/2-
C, three MNHOC 124 and one MNHOC 18 tumor).
Of note, the combination increased the number of stable and regressing tumors, most
remarkably among the Not BRCAness (most of the MNHOC 18 and 124, all MNHOC 182
and 143) and also those BRCAness cases that marginally responded to olaparib single
therapy benefitted from the combination (such as MNHOC 508 and 154) (Figure 4.2, panel
A). Moreover, the combination also increased tumor regression rates in those BRCAness
tumors that were sensitive to olaparib single therapy (Figure 4.2, panel A).
The long-term administration (maintenance regimen) of the combination possibly boosted
the outcome, increasing the number of regressions, equally affecting the BRCAness and
Not BRCAness tumors and leading to some complete responses with cured mice (Figure
4.2, panel D).
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The short-term (4 weeks) administration of cediranib single therapy caused a
heterogeneous response within the OC-PDX. Stable disease and regressions were achieved
both for Not BRCAness (MNHOC 124 and MNHOC 143) and almost all the BRCAness
models (MNHOC 500, 508, 511, 513 and 154) (Figure 4.2, panel C). Progressive disease
was evident especially among Not BRCAness OC-PDX (MNHOC 18, 94/2-C and 182),
but also in BRCAness cases (two MNHOC 513, one MNHOC 154 and one MNHOC 508)
(Figure 4.2, panel C). The administration of the anti-angiogenic agent in a maintenance
regimen resulted in stable disease and regressions in those tumors that already benefitted
from the short-term treatment, leaving the not responsive progressing under treatment
(Figure 4.2, panel F).
Chapter 4 Francesca Bizzaro
122
Figure 4.2 The combination of olaparib and cediranib in a short-term and in
mainteinance (until tumor progression) regimen.
Olaparib (100 mg/kg) and cediranib (3 mg/kg), alone or in combination, were administered
by oral gavage every day for 5 days on and 2 days off (Q1x5). Treatment efficacy was
expressed as % tumor variation after (A – C) short-term (4 weeks, day 28) and (D – F)
maintenance (12 weeks, day 100) regimen. Disease was considered progressive = tumor
variation > 20%; stable = -30% < tumor variation > 20%; regressive = tumor variation > -
30%. * Complete responses = tumor free mice at day 200. N= 4-7 tumors per model.
Waterfall B and E as in Figure 4.1.
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Summary of results
 OC-PDX, classified as BRCAness types and carrying mutations or loss of BRCA1
and 2, responded to olaparib single therapy, both after a short-term treatment and
even more notably after a maintenance regimen, with complete responses: there
was a strong correlation between homologous recombination deficiency and
sensitivity to PARP inhibition.
 OC-PDX displayed a heterogeneous response to cediranib, independent of the
homologous recombination status: sensitivity to the anti-angiogenic drugs was
dependent on intrinsic features of the tumor or tumor microenvironment.
 The antitumor activity was improved when cediranib was added to olaparib. The
superiority of the combination was especially evident for those models that were
poorly responsive to the single treatment with olaparib, such as the Not BRCAness
types: the results suggested a possible additivity between the two drugs.
4.3 THE COMBINATION OF OLAPARIB AND CEDIRANIB IN ECTOPIC
MODELS OF OVARIAN CANCER
To investigate the relevance of the effect of the combination of these two agents, a case-
report analysis was performed on the most representative models of OC-PDX, both Not
BRCAness and BRCAness
4.3.1 Case-report: MNHOC 18, Not BRCAness
MNHOC 18 was established from a high grade endometrioid primary tumor at the ovary.
The activity of olaparib and the addition of cediranib was tested in a short-term regimen (4
weeks) in the first experiment (Figure 4.3, panel A). Doses, schedules and evaluation of
treatment as in Section 2.3.2 and 2.3.3 Materials and Methods.
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Tumors progressed rapidly under treatment with olaparib single therapy (T/C 59%), with
no significant difference from vehicle-treated controls. Absolute growth delay was 9 days,
with a doubling time of 10 days compared to 8 days for the vehicle-treated controls.
Cediranib alone was no different from olaparib monotherapy (T/C 57%), with an absolute
growth delay and a doubling time of 12 and 13 days respectively (Figure 4.3, panel A).
The combination of olaparib plus cediranib was the most effective treatment (T/C 29%),
inducing stable disease until the end of the 4 weeks of administration. As soon as the
treatment was stopped, tumors started to re-grow, with an absolute growth delay increased
up to 53 days and regrowth doubling time of 51 days compared to vehicle (Figure 4.3,
panel A).
The fast regrowth of tumors at the termination of treatment prompted us to investigate the
effect of the maintenance regimen (Figure 4.3, panel B). As above, olaparib alone was
inactive in reducing or delaying tumor growth (T/C 62%), with the same doubling time as
vehicle controls (24 days). The addition of cediranib to olaparib in combination stabilized
and controlled tumor progression during 18 weeks of daily administration (T/C 33%).
Eventually, tumors progressed under treatment, with an absolute growth delay of 92 days
compared to vehicle and 2/7 mice were tumor-free at day 150.
Cediranib in a maintenance regimen was slightly more effective in delaying tumor
progression (T/C 41%) than in the short-term treatment, with an absolute growth delay of
55 days.
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Figure 4.3 The combination in maintenance regimen: the case of MNHOC
18, Not BRCAness.
Mice were randomized to treatment at an average tumor volume of 300 mm3
(subcutaneously growing tumor), doses and schedule as in Materials and Methods
(Chapter 2). Responses were A) tumor growth after olaparib, cediranib and the
combination in a short-term regimen (4 weeks), B) tumor growth after olaparib,
cediranib and the combination in a maintenance regimen (until tumor progression).
Data are mean ± SD.
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4.3.2 Case-report: MNHOC 182, Not BRCAness
MNHOC 182 was established from a mucinous primary tumor in the ovary.
Olaparib slightly reduced tumor growth (T/C 41%), with an absolute growth delay of 14
days; the addition of cediranib to olaparib induced a significant stabilization of tumor
volume (T/C 17%), with an absolute growth delay of 276 days. As soon as the therapy was
terminated at day 210 (after 30 weeks of treatment), tumors progressed rapidly, with a
regrowth doubling time of approximately one month (Figure 4.4).
Cediranib alone was moderately active in delaying tumor progression (T/C 27%), with
values of absolute growth delay of 176 days (Figure 4.4).
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DAYS POST THERAPY
MNHOC 182 maintenance treatment
Figure 4.4 The combination in maintenance regimen: the case of MNHOC
182, Not BRCAness.
Antitumor activity of olaparib, cediranib and the combination was evaluated in
MNHOC 182, growing subcutaneously. Mice were randomized to treatment at an
average tumor volume of 300 mm3, doses and schedule as in Materials and Methods
(Chapter 2). Responses were shown as tumor growth after olaparib, cediranib and






Chapter 4 Francesca Bizzaro
128
4.3.3 Case-report: MNHOC 508, BRCAness
MNHOC 508 was established from a high grade serous primary tumor in the omentum.
The activity of olaparib and cediranib combination was tested in a short-term regimen (4
weeks) in the first experiment (Figure 4.5, panel A) and in a maintenance regimen (Figure
4.5, panel B). Doses and schedules were described in Section 2.3.2 and 2.3.3, Materials
and Methods.
Olaparib and cediranib single agents induced a stabilization of tumor growth under
treatment compared to vehicle (T/C 26% and 36% respectively), with olaparib being
slightly more effective in delaying tumor growth than cediranib (absolute growth delay -
AGD- 46 days and 30 days respectively) (Figure 4.5, panel A).
The combination was more effective in reducing and delaying tumor growth (T/C 14%
compared to vehicle, 23% compared to cediranib and 40% compared to olaparib); tumor
volume reduction reached its nadir at day 28, concomitantly with the end of the short-term
treatment. The regression was maintained for approximately one month from the
conclusion of treatment. The delay in tumor growth was 60 days from therapy initiation. In
all treatment arms tumors regrew at the end of 4 weeks treatment, with a comparable
doubling time (29 days for olaparib, 25 days for cediranib, 25 days for the combination)
(Figure 4.5, panel A).
When drugs were given in a maintenance regimen (Figure 4.5, panel B), the effect was
more pronounced: cediranib stabilized tumor growth (T/C 34%), both olaparib and the
combination induced sustained tumor regressions (T/C 4% and 6% respectively), with
tumors reaching their smallest volume at day 63. This prompted us to interrupt all the
treatments after 9 weeks of daily administration.
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Soon after the suspension of treatment, tumors started to re-grow, reaching the target
volume of 300 mm3 in about 35 days for olaparib and 51 days for the combination, while
cediranib treated tumors remained stable. Tumors were thus rechallenged to treatment at
day 98 with cediranib, olaparib or the combination.
All the treatments delayed tumor growth compared to vehicle (AGD 160 days, 130 days
and 176 days respectively), but after treatment restarted the responses were heterogeneous.
At rechallenge, 4/6 tumors progressed rapidly under treatment with olaparib alone; these
tumors were no longer responsive to treatment. The potential mechanisms of the resistance
to olaparib at relapse would be of interest but are beyond the scope of this PhD research.
However, single cell analysis (DNA and RNA sequencing) could be performed, in order to
assess if a sub-clonal cell population arise capable of growing under drug pressure in those
tumors that progressed at rechallenge, and if tumor cells are enriched in some particular
mutation, genomic alteration or change in gene expression induced by the treatment, that
could explain the acquired resistance.
When olaparib was administered in combination with cediranib, a more pronounced
regression was induced at rechallenge, with tumors reaching the lowest volume at day 147;
2/4 tumors progressed under treatment, with a regrowth doubling time of 45 days (Figure
4.5, panel B).
Cediranib stabilized tumor growth for a longer period (until day 161); then 3/4 tumors
progressed under treatment, with a regrowth doubling time of 48 days.
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Figure 4.5 The combination in maintenance regimen: the case of MNHOC
508, BRCAness.
Mice were randomized to treatment at an average tumor volume of 300
mm3(subcutaneously growing tumor), doses and schedule as in Materials and
Methods (Chapter 2). Responses were A) tumor growth after olaparib, cediranib and
the combination in a short-term regimen (4 weeks), B) tumor growth after olaparib,
cediranib and the combination in a maintenance regimen (until tumor progression).
Data are mean ± SD.
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4.3.4 Cases-report: MNHOC 511 and MNHOC 513, BRCAness
Having demonstrated the superiority of the maintenance regimen, MNHOC 511 (Figure
4.6, panel A) and MNHOC 513 (Figure 4.6, panel B) bearing mice were treated until
complete regression or progression.
MNHOC 511 was derived from a high grade serous primary tumor from the omentum.
Olaparib itself was very active, such that the combination with cediranib only marginally
improved response and treatment was stopped after 9 weeks (day 63).
After treatment suspension, tumors slowly progressed, reaching 300 mm3 in 56 and 84
days for olaparib and the combination respectively. Tumors were then rechallenged at day
119 and day 147 respectively. In both arms a significant regression was induced, that led to
complete responses and tumor-free mice at day 200 (Figure 4.6, panel A).
MNHOC 511 proved moderately responsive to cediranib (T/C 33%), with tumors that
progressed under treatment and continued to grow after treatment cessation at day 63. The
absolute mean tumor growth delay in the group was 45 days and the doubling time 82 days
(Figure 4.6, panel A).
Interestingly in this case, treatment information on the corresponding patient, from which
MNHOC 511 was established, were available. The MNHOC 511 patient relapsed after
first-line chemotherapy and was treated with olaparib; at present, she is still under
treatment and showing a complete response. This OC-PDX could be considered a powerful
example of perfect correlation between the biological and pharmacological behaviour of
the OC-PDX and the corresponding patient, once again stressing the predictive value of
xenografts to study the more appropriate treatment for patients (Figure 4.6, panel A).
MNHOC 513 was derived from a high grade serous primary tumor from the omentum.
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Olaparib and cediranib single agents were active, inducing tumor regressions when
administered in a maintenance regimen (T/C 2% and 4% respectively; AGD 168 and 139
days respectively). At this time point treatment was interrupted (day 84), after 12 weeks,
but tumors regrew immediately, reaching a volume of 300 mm3 in 63 days (Figure 4.6,
panel B).
At variance of MNHOC 511, tumors progressed rapidly despite re-challenge (day 147),
with doubling times of 28 days and 23 days respectively.
When olaparib was administered in combination with cediranib, a stronger tumor
regression occurred and treatment was stopped at day 81. After the end of treatment, no
regrowth was detected, with complete responses and 3/3 mice considered cured at day 200
(Figure 4.6, panel B).
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Figure 4.6 The combination in maintenance regimen: the cases of MNHOC
511 and MNHOC 513, BRCAness.
Antitumor activity of olaparib, cediranib and the combination was evaluated in
MNHOC 511 and MNHOC 513, growing subcutaneously. Mice were randomized to
treatment at an average tumor volume of 300 mm3, doses and schedule as in Materials
and Methods (Chapter 2). Responses were shown as tumor growth after olaparib,
cediranib and the combination in a maintenance regimen (until tumor progression) for
A)MNHOC 511 and B)MNHOC 513. Data are mean ± SD.
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4.3.5 Case-report: MNHOC 154, BRCAness
MNHOC 154 was established from a relapsed tumor at the omentum of a high grade
endometrioid patient.
From studies previously carried out in the laboratory, MNHOC 154 was moderately
sensitive to cisplatin, with a T/C of 39% (Ricci et al., 2014).
Although MNHOC 154 carried a mutation in BRCA1, thus of BRCAness phenotype, the
activity of olaparib was heterogeneous, with 2/4 tumors that did not respond and continued
to grow under treatment, 1/4 long responder started to regrow at day 150 post therapy and
1/4 was stabilized by the treatment (Figure 4.7). This heterogeneity in olaparib sensitivity
could be due to the presence of the amplification in BRCA2 (see Table 3.4 and Figure 3.4-
3.6, Chapter 3).
When cediranib was added to olaparib, tumor regression was induced in all mice (T/C 3%),
with treatment being stopped after 13 weeks (day 91). The effect of the combination
continued even when treatments were discontinued, with a stabilization of tumor growth
and only 3/6 tumors that slowly regrew at day 158 (Figure 4.7). The activity of the
combination was more pronounced compared to cediranib single agent, reaching the
smallest tumor volume at day 84 (mean tumor volume 125 mm3).
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Figure 4.7 The combination in maintenance regimen: the case of MNHOC
154, BRCAness.
Antitumor activity of olaparib, cediranib and the combination was evaluated in
MNHOC 154, growing subcutaneously. Mice were randomized to treatment at an
average tumor volume of 300 mm3, doses and schedule as in Materials and Methods
(Chapter 2). Responses were shown as tumor growth after olaparib, cediranib and
the combination in a maintenance regimen (until tumor progression). Data are mean
± SD for vehicle, cediranib and combination. Data are single tumor volume for
olaparib.
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Summary of results
 In Not BRCAness models of OC-PDX, olaparib was inactive or very poorly active,
with tumors progressing rapidly under treatment, in both MNHOC 18 and MNHOC
182.
When cediranib was added to olaparib, the effect of the combination remarkably
improved the outcome. In MNHOC 18, the short-term regimen of 4 weeks induced
stable disease while drugs were administered. The cessation of treatment led to a
rapid progression.
The maintenance administration of the combination boosted the outcome, manly
stabilizing tumor growth for several weeks (18 weeks for MNHOC18 and 30 weeks
for MNHOC182), and then tumors progressed rapidly under treatment. The effect
of the combination in a maintenance regimen in MNHOC 182 suggested a greater
synergism for all the subtypes of ovarian cancer, not only serous and endometrioid,
but also mucinous.
Taken together, these results indicate the importance of adding cediranib to
olaparib, especially in a maintenance regimen, as was evident in the waterfall plot
(Figure 4.2, panel A and D), analysing the whole panel of Not BRCAness models.
Cediranib was variously effective in delaying tumor growth, with MNHOC 18
being the most resistant. We hypothesise that the effect of the anti-angiogenic is
likely linked to the intrinsic microenvironmental features within each model.
 In BRCAness models of OC-PDX, olaparib, in general, stabilized tumor growth
when administered in a short-term regimen of 4 weeks. Immediately after removing
the drug, tumors progressed. A marked and persistent regression was obtained
when the regimen was maintained. When tumors were rechallenged by
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monotherapy with olaparib, the responses were heterogeneous: in MNHOC 508
and MNHOC 513, a linear progression under treatment was induced, while in
MNHOC 511 regression was again achieved. In MNHOC 154, previously reported
as moderately sensitive to platinum, a heterogeneous response to olaparib was
observed, with 2/4 single tumors that continued to grow under treatment and 2/4
sustainably inhibited.
The combination of olaparib plus cediranib proved to be the most active regimen,
by inducing tumor regression - even after a short-term treatment, as in MNHOC
508 - and further delaying tumor regrowth in a prolonged regimen - as for MNHOC
508 and MNHOC 511. The combination showed the best outcome for MNHOC
513 and MNHOC 154, with complete responses that persisted several weeks after
treatment suspension.
Taken together, these results indicate the advantage of adding cediranib to olaparib
also in OC-PDX that already gained a benefit from olaparib single therapy, such as
the BRCAness types. The results supported the waterfall plot analysis (Figure 4.2,
panel A and D) considering all the BRCAness models.
Cediranib was variably effective in delaying (MNHOC 513 and MNHOC 154) or
stabilizing (MNHOC 508) tumor growth, except for MNHOC 511, which
progressed under treatment.
Ectopic models represent a powerful tool to study pharmacological activity, being easier to
continuously monitor over time and being quite reproducible.
However, ectopic models do not reproduce the biology of the disease, lacking, for example,
of the ability to disseminate, invade organs of the peritoneal cavity and forming ascites.
To gain further insight into a more “close-to-patient” setting, we studied the effect of the
combination on tumor models growing orthotopically in the peritoneal cavity of mice.
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4.4 THE COMBINATION OF OLAPARIB AND CEDIRANIB IN ORTHOTOPIC
MODELS OF OVARIAN CANCER
4.4.1 Case-report: MNHOC 8, BRCAness
MNHOC 8 was derived from ascites of a patient diagnosed with high grade serous ovarian
carcinoma and established as ascites in the mouse peritoneal cavity.
The combination administered in a short-term regimen (4 weeks).
In the first experiment, we assessed the response of MNHOC 8 to olaparib and the addition
of cediranib in combination in a short-term regimen (4 weeks), starting treatment at an
advanced stage of disease (day 10 after transplantation).
Olaparib increased survival (MST 61 days; ILS 74%) and a similar effect was observed
with cediranib (MST 61 day; ILS 71%) (Figure 4.7, panel A).
The addition of the antiangiogenic to olaparib marginally improved the outcome (MST 68
days; ILS 95%), with 1/9 mice alive at day 200, considered cured by necropsy (Figure 4.8,
panel A).
At the end of 4 weeks treatment, ascites was present only in vehicle-treated mice, while
was almost absent in treated groups, comparable to the level recorded at the beginning of
treatment (random group) (Figure 4.8, panel B)
Dissemination to the organs of the peritoneal cavity, assessed using an arbitrary score (see
Section 2.1.4.3 Materials and Methods), was diminished in olaparib treated animals, and
significantly more when in combination with cediranib, compared to vehicle controls
(Figure 4.8, panel B).
The analysis at survival off treatment showed increased ascites, especially in the olaparib
group. Cediranib and the combination inhibited ascites formation compared to vehicle
controls and olaparib single agent groups (Figure 4.8, panel C).
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A macroscopical analysis in the organs of the peritoneal cavity at survival indicated that,
despite the effect of olaparib in controlling tumor burden, the combination with cediranib
somewhat impaired the outcome, with mice living longer, but dying with a more
aggressive disease (Figure 4.8, panel C).
These results suggested that the effectiveness of the combination was present during
treatment and was lost when therapy ceased.
The combination administered in a maintenance regimen.
To confirm the efficacy of the combination with a continuous exposure, in a second
experiment cediranib was added to olaparib in a maintenance regimen, until survival.
Treatment started at an advanced stage of disease (20 days after transplantation). An
additional group was included, in which the combination was terminated on day 142, after
approximately 20 weeks of drug administration (COMBINATION stop day 142), as
reported in Figure 4.8, panel D.
Olaparib, significantly prolonged survival (MST 56 days and ILS 100%) when given for
approximately 13 weeks, until each mouse progressed and was culled. When cediranib was
added to olaparib in a maintenance regimen, the outcome was significantly enhanced
(MST 105 days and ILS 275%), with 1/6 mice alive at day 300, considered cured. Of note
is the fact that when the combination was interrupted at day 142, tumors progressed rapidly
and mice were culled within two weeks (MST 148 days and ILS 427%) (Figure 4.8, panel
D). At necropsy, olaparib slightly reduced ascites, while cediranib and the combination in
maintenance significantly inhibited ascites formation (Figure 4.8, panel E).
However, in contrast, tumor dissemination was significantly affected by olaparib.
Interestingly, as observed in the experiment above, the addition of cediranib prolonged
survival, despite an apparently increased tumor dissemination (Figure 4.8, panel E).
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Figure 4.8 The combination in the orthotopic model MNHOC 8, BRCAness.
Doses and schedule as in Materials and Methods (Chapter 2).
A) Survival in a short-term regimen (4 weeks).
Volume of ascites and dissemination were evaluated B) at 4 weeks and C) at progression-off
treatment (survival). Representative images of invaded pancreas at the end of treatment.
D) Survival in a maintenance regimen (until progression) and E) volume of ascites and
dissemination evaluated at progression under treatment. Representative images of invaded
ovaries and uterus are reported.
VH, vehicle; Cstop, cediranib 4 weeks; Cmaint, cediranib in maintenance; Ostop, olaparib 4
weeks; Omaint, olaparib in maintenance; C+O, combination; C+Omaint, combination in
maintenance; C+O 142, combination stopped at day 142 MST, median survival times (days).
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.
Pellet Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGutAscites
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The importance of drug sequence in the combination.
To shed light on which of the two players, the PARP inhibitor olaparib or the angiogenesis
inhibitor cediranib, was the key effector of the combination, a third experiment was
performed (Figure 4.9), with different sequences of the two drugs.
The combination was given for 4 weeks. Then mice were randomized to continue
combination (COMBINATION maint) or switched to olaparib (COMBINATION
stop/OLAPARIB maint) or cediranib (COMBINATION stop/CEDIRANIB maint).
The combination (COMBINATION stop) was effective in prolong animal survival even
after only 4 weeks of treatment (MST 71 days and ILS 109%); the switch to olaparib
prolonged survival (MST 98 days and ILS 188% compared to vehicle and 38% compared
to COMBINATION stop), with 3/7 long responding mice, culled at day 200. The switch to
cediranib increased survival although mice ultimately did not respond to treatment and
were culled (MST 101 days and ILS 197% compared to vehicle and 42% compared to
COMBINATION stop). The combination of the two inhibitors given in a maintenance
regimen (COMBINATION maint), from randomization until progression, was the most
effective treatment, strongly increasing survival (MST 142 days and ILS 316%), with 3/8
cured mice culled at day 200 (Figure 4.9, panel A).
Necropsy revealed that the combination administered for 4 weeks (COMBINATION stop)
was not sufficient to affect ascites and tumor dissemination, probably explaining the worse
survival compared to the other treatment groups (Figure 4.9, panel B).
The switch to olaparib (COMBINATION stop/OLAPARIB maint) decreased ascites and
tumor dissemination. The switch to cediranib (COMBINATION stop/CEDIRANIB maint)
significantly reduced ascites but was unable to control tumor dissemination, which could
explain the rapid loss of response. The combination of the two drugs maintained until
Chapter 4 Francesca Bizzaro
142
progression (COMBINATION maint) reduced ascites and tumor dissemination (Figure 4.9,
panel B).
Chapter 4 Francesca Bizzaro
143
Figure 4.9 The importance of drug sequence in the combination olaparib
plus cediranib.
A) Mice bearing intraperitoneal MNHOC 8 were treated with the combination
olaparib plus cediranib in short-term regimen (4 weeks), then switched to olaparib
or cediranib in maintenance, or maintained until tumor progression under treatment,
and survival was evaluated.
B) Volume of ascites and dissemination were evaluated at progression under
treatment.
VH, vehicle; C+Ostop, 4 weeks combination; C+Omaint, combination in
maintenance; C+O/Omaint, 4 weeks combination then olaparib in maintenance;
C+O/Cmaint, 4 weeks combination then cediranib in maintenance.
MST, median survival times (days). *P<0.05; ****P<0.0001.
Pellet Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGutAscites
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Summary of results
 The orthotopic model MNHOC 8 could be considered a robust tool to study the
effect of drug treatment, due to the resemblance to the original biological features
of the patient’s tumor.
 In the BRCAness orthotopic model MNHOC 8, olaparib significantly increased
survival, mainly when administered in a maintenance regimen until tumor
progression
The PARP inhibitor was primarily active on solid “primary” tumors, decreasing
dissemination and carcinomatosis. Median survival time was doubled compared to
vehicle controls, and mice were culled due to the degree of ascites but with a lower
tumor burden.
The combination of olaparib plus cediranib performed better, both in a short-term
treatment and even more when administered in a maintenance regimen until tumor
progression. Of relevance, the cessation of drug treatment led animals to the need
for culling in less than two weeks, endorsing the necessity of the treatment to be
maintained, as also demonstrated in different drug sequences. Survival was
significantly prolonged to the detriment of a more aggressive disease (tumor
dissemination), counteracted by the inhibition of ascites.
This particular effect could be explained by the presence of cediranib, which
continued to limit ascites; animals lived longer but suffered from solid masses that
compromised the vital function of the peritoneal organs.
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4.5 THE COMBINATION OF OLAPARIB WITH OTHER ANGIOGENESIS
INHIBITORS
To confirm that the advantage of the combination of olaparib plus cediranib was not
related to the pharmacological profile of the angiogenesis inhibitor, we investigated the
addition of different angiogenic inhibitors (i.e. bevacizumab and B20) in the ectopic (s.c)
MNHOC 18 (Figure 4.10) and orthotopic (i.p) MNHOC 8 model (Figure 4.11).
Bevacizumab is an antibody that recognizes human VEGF, and B20 recognizes both
human and mouse VEGF exhibiting an equal affinity (EC50 0.17 nmol/L for h-VEGF and
EC50 0.17 nmol/L for m-VEGF) (Liang et al., 2006).
4.5.1 Case-report: MNHOC 18, Not BRCAness
Tumors progressed rapidly under bevacizumab single agent therapy, as well as under
bevacizumab added to olaparib (T/C 46% and 36% respectively), with a doubling time of
15 days and 24 days respectively (Figure 4.10, panel B).
Similarly, B20 (B20 TWICE) caused a modest tumor growth delay (T/C 51%) and did not
give any advantage when added to olaparib, neither administered once (B20 ONCE+OLA)
nor twice a week (B20 TWICE+OLA) (T/C 53% and 60% respectively), with comparable
doubling times (18 days, 16 days and 13 days respectively) (Figure 4.10, panel C).
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Figure 4.10 Olaparib in combination with different angiogenesis inhibitors: the
case of the ectopic MNHOC 18, Not BRCAness.
Mice bearing MNHOC 18 subcutaneously were treated in a short-term regimen (4
weeks) with olaparib (100mg/kg) in combination with:
A) Cediranib (3mg/kg, p.o, daily), same graph of Figure 4.3, panel A;
B) Bevacizumab (5mg/kg, i.v, once a week), the antibody anti-human VEGFA;
C) B20 (5mg/kg, i.v, once or twice a week), the antibody recognising both human and
murine VEGFA. Data are mean ± SD.
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4.5.2 Case-report: MNHOC 8, BRCAness
To assess if the effect of the combination was a general phenomenon achievable with other
angiogenesis inhibitors in orthotopic OC-PDX, the activity of olaparib was evaluated in
combination with bevacizumab in a maintenance regimen in MNHOC 8 (Figure 4.11).
Olaparib plus bevacizumab (COMBINATION BEV+OLA) was slightly less effective in
prolonging survival (MST 107 days and ILS 213%) compared to olaparib plus cediranib
(COMBINATION CED+OLA), even if not significantly different (Figure 4.11, panel A).
A similar pattern of tumor dissemination and ascites were observed with the two
combinations at progression (Figure 4.11, panel B).
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Figure 4.11 Olaparib in combination with a different angiogenesis inhibitor,
bevacizumab: the case of the orthotopic MNHOC 8, BRCAness.
A) Effect of the combination olaparib (100mg/kg, p.o, daily) plus cediranib (3mg/kg,
p.o, daily) and bevacizumab (5mg/kg, i.v, once a week) in maintenance until tumor
progression under treatment in mice bearing intraperitoneal growing MNHOC 8.
Vehicle and combination with cediranib as in Fig. 4.9.
B) Volume of ascites and dissemination were evaluated at progression under
treatment.
VH, vehicle; C+Omaint, cediranib plus olaparib combination in maintenance;
B+Omaint, bevacizumab plus olaparib combination in maintenance. MST, median
survival times (days). *P<0.05; ****P<0.0001.
Pellet Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGutAscites
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Summary of results
 No differences were highlighted comparing the two angiogenesis inhibitors
affecting VEGFA, bevacizumab and B20, and the results confirmed the
combination of olaparib plus cediranib as the best possible treatment (Figure 4.10).
 The activity of the combination is evident also with other angiogenesis inhibitors
(i.e bevacizumab in the orthotopic MNHOC 8, Figure 4.11), although in our OC-
PDX models the addition of cediranib to olaparib appeared as the most efficacious
in delaying tumor progression (Figure 4.10, the case of the ectopic MNHOC 18)
compared with the addition of bevacizumab or B20.
4.6 THE ADVANTAGE OF THE COMBINATION IN OLAPARIB RESISTANT
BRCANESS MODELS
4.6.1 Case-report: MNHOC 22, BRCAness
MNHOC 22 was derived from primary ascites of a patient diagnosed with high grade
serous ovarian carcinoma; the OC-PDX was established as ascites, growing orthotopically
in the peritoneal cavity.
MNHOC 22 was extensively characterized for its responsiveness to cisplatin, proving to be
very sensitive (ILS >150%, at 4 mg/kg), as previously reported (Ricci et al., 2014).
In this model, a truncation/frameshift mutation in BRCA1 was detected.
Olaparib and the combination with cediranib were administered in a short-term regimen (4
weeks), starting treatment at an advanced stage of disease (6 days after transplant). The
engraftment of tumor was verified with necropsy on additional mice (N=3) at the day of
randomization; at this point, ascites was barely detected but low levels of carcinomatosis
were present in ovaries, liver and gut.
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Olaparib single agent therapy was ineffective on survival (ILS 10%), compared to vehicle.
The administration of cediranib significantly increased survival (ILS 120%) and the
combination performed additively (ILS 159%) (Figure 4.12. panel A).
Tumor burden was evaluated at the end of treatment (Figure 4.12, panel B); at this time
vehicle-treated mice had already been culled due to the presence of ascites and
dissemination across the organs of the peritoneal cavity (MST 21 days).
Animals which received olaparib single therapy were also culled (MST 21 days as for
vehicle), due to the high levels of ascites; however, interestingly, the macroscopical
analysis of tumor dissemination revealed a significantly lower burden in term of solid
masses and carcinomatosis, compared to vehicle and cediranib treated mice. The effect of
the combination of olaparib plus cediranib was “additive”: survival (MST 53 days) was
significantly increased, and at the end of treatment ascites and dissemination were
undoubtedly reduced compared to vehicle and olaparib. The combination added together
effects of cediranib on ascites formation and olaparib action on the formation of tumor
masses. Cediranib (MST 46 days) inhibited ascites formation but did not affect tumor
dissemination (Figure 4.12, panel B).
The substantial effect of the treatment in reducing ascites formation and dissemination
displayed at the end of treatments was completely reversed at progression, after treatment
interruption (Figure 4.12, panel C).
The increment of lifespan was however associated with a more aggressive disease. The
effect in increasing survival was not associated with tumor burden inhibition (but rather
with an aggressive disease), but could be explained by the strong activity of the angiogenic
inhibitor in keeping under control the formation of ascites, barely affecting tumor
dissemination (as previously reported in MNHOC 8 case with all the schemes of treatment
used). On the contrary, the PARP inhibitor displayed a strong action in reducing tumor
dissemination.
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Figure 4.12 The advantage of the combination in olaparib-resistant BRCAness
model: the case of the orthotopic MNHOC 22, BRCAness.
Doses and schedule as in Materials and Methods (Chapter 2).
A) Effect of olaparib, cediranib and the combination on survival in a short-term treatment
(4 weeks);
B) Volume of ascites and dissemination were evaluated at the end of treatment (4 weeks).
Representative images of invaded diaphragm and ovaries at the end of treatment;
C) Volume of ascites and dissemination at progression off treatment (survival).
VH, vehicle; C, cediranib 4 weeks; O, olaparib 4 weeks; C+O, combination.MST, median
survival times (days). *P<0.05; **P<0.01; ****P<0.0001.
Pellet Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGutAscites
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Summary of results
MNHOC 22, an orthotopic model of OC-PDX, despite the presence of a
truncation/frameshift mutation on BRCA1, proved to be resistant to olaparib single
agent therapy. A deeper investigation revealed that the PARP inhibitor was not
effective in prolonging overall survival, but displayed a great effect in reducing
tumor dissemination across the organs of the peritoneal cavity. Cediranib prolonged
survival in MNHOC 22 bearing mice, here mainly acting on ascites formation.
The combination of the two drugs was the most active regimen, significantly
prolonged survival in MNHOC 22 bearing mice and most actively reduced levels of
ascites and dissemination. The short-term effect of the combination on tumor
burden was lost at progression off treatment.
4.7 MODELS NOT RESPONSIVE TO THE COMBINATION TO STUDY NEW
TREATMENT MODALITIES
Only two OC-PDX among those selected to perform this project did not gain significantly
greater advantage from the combination, one ectopic model MNHOC 94/2-C (Figure 4.13)
and one orthotopic model MNHOC 506 (Figure 4.14), both Not BRCAness subtypes.
4.7.1 Case-report: MNHOC 94/2-C, Not BRCAness
MNHOC 94/2-C, diagnosed as clear cell carcinoma, was derived from the ascites of a
patient at relapse.
MNHOC 94/2-C was moderately sensitive to cisplatin (T/C 34%), but the short-term
administration of olaparib had no effect on tumor growth (T/C 54%), with a doubling time
comparable to vehicle-treated controls (10 days). Cediranib and the combination with
olaparib marginally reduced tumor burden (T/C 36% and 35% respectively), with an
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absolute growth delay of 20 days and no differences between the two treatments (Figure
4.13).
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Figure 4.13 The resistance to the combination: the case of the subcutaneous
MNHOC 94/2-C, Not BRCAness.
Antitumor activity of olaparib, cediranib and the combination were evaluated in
MNHOC 154, growing subcutaneously. Mice were randomized to treatment at an
average tumor volume of 300 mm3, doses and schedule as in Materials and Methods
(Chapter 2). Responses were shown as tumor growth after olaparib, cediranib and
the combination in a maintenance regimen (until tumor progression).
Data are mean ± SD.
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4.7.2 Case-report: MNHOC 506, Not BRCAness
MNHOC 506, diagnosed as a high grade serous carcinoma, was derived from a primary
ascites of a patient, who was treated in a neoadjuvant setting with carboplatin and
paclitaxel. MNHOC 506 responded to cisplatin (ILS 98%). Short-term administration (4
weeks) of olaparib did not prolong survival compared to vehicle (MST 49 days, ILS 5%),
and neither did cediranib (MST 63 days, ILS 16%). The addition of cediranib to olaparib
was not more advantageous than single agents (MST 56 days, ILS 20%) (Figure 4.14,
panel A).
At necropsy at the end of treatment (4 weeks), the level of ascites and dissemination were
reduced by cediranib and the combination (Figure 4.14, panel B). However, at progression,
these differences disappeared and necropsy showed a comparable level of ascites and
tumor dissemination (Figure 4.14, panel C).
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Figure 4.14 The resistance to the combination: the case of the orthotopic
MNHOC 506, Not BRCAness.
Doses and schedule as in Materials and Methods (Chapter 2).
A) Effect of olaparib, cediranib and the combination on survival in a short-term
treatment (4 weeks); B) Volume of ascites and dissemination were evaluated at the
end of treatment (4 weeks) and C) at progression off treatment (survival).
VH, vehicle; C, cediranib 4 weeks; O, olaparib 4 weeks; C+O, combination. MST,
median survival times (days). *P<0.05.
Pellet Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGutAscites
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Summary of results
Olaparib was inactive on two Not BRCAness OC-PDX, one orthotopic and one
subcutaneous model.
The combination of olaparib with cediranib did not result in a better outcome than
single agents; however, a marginal effect on ascites reduction and dissemination at
the end of treatment was observed in MNHOC 506 bearing mice and on tumor
growth in MNHOC 94/2-C. The fact that this effect was obtained also with
cediranib alone suggested that no benefit was gained by olaparib treatment.
These two OC-PDX could be useful to study other treatment modalities when the
combination is not significantly advantageous.
4.8 A SYNGENEIC MODEL OF OVARIAN CANCER IN
IMMUNOCOMPETENT MICE
In this experiment, we used an orthotopic model of ovarian cancer, designing a complex
preclinical trial, with the possibility to follow the response to therapy using magnetic
resonance imaging (MRI) analysis. That allowed us to obtain information at different time-
points, avoiding the sacrifice of animals.
Briefly, 1 x 106 syngeneic ID8-luc cells were injected in the ovary bursa of pathogen-free
C57BL/6 mice (see Section 2.1.4.2 Materials and Methods). The protocol of the study was
as reported in Figure 4.15, panel A.
MRI was used to confirm tumor engraftment in 5 random mice; 2 mice were culled to
perform gross dissemination analysis (Figure 4.15, panel C, Random group). Animals
(N=10) were then assigned to vehicle, cediranib, olaparib and the combination based on
primary tumor volume at the ovary, assessed with MRI, and considering body weight.
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Treatments started at day 31 from tumor injection, at an advanced stage of disease (1/4 of
median survival time - MST - of vehicle-treated controls, inferred from previous
experiments carried out in the laboratory). Differences in the ovary injected with the tumor
compared to the contralateral normal ovary were not macroscopically evident, but signs of
tumor dissemination were present mainly at the uterus and gut. Ascites was not yet formed.
Olaparib and cediranib single agents were administered every day for 5 days on and 2 days
off (Q1x5), for 4 weeks (short-term treatment) to perform interim analysis, and in
maintenance (13 weeks treatment) (Figure 4.15, panel A).
Survival analysis did not show significant differences among the vehicle and cediranib
treated mice in terms of median survival time (MST vehicle 129 days, cediranib 129 days),
with olaparib being slightly, but not significantly, more active (MST olaparib 171 days).
No significant advantage was observed combining the two drugs (Figure 4.15, panel B).
However, interim analysis after a short-term treatment (4 weeks, day 54 from tumor
transplant) showed that olaparib and the combination with cediranib were the most active
in reducing tumor in the ovary, with volume and weight comparable to those registered at
random (day 31 from tumor transplant) (Figure 4.15, panel C). The effect of short-term
treatment on tumor in the ovary was appraised with MRI and confirmed with necropsy;
tumor dimension assessed with MRI (volume, mm3) or weighting the injected ovary
(precision balance, mg), was comparable and consistent using the two different
methodologies (Figure 4.15, panel C). Ascites was not yet formed, thus peritoneal washout
(3 ml NaCl, 0,9%) was performed; pellets were 50 l on average (Figure 4.15, panel C).
Dissemination score analysis showed a strong effect of the combination olaparib plus
cediranib in reducing tumor masses and carcinomatosis formation, with a dissemination
score comparable to the one registered at random (day 31 from tumor transplant) (Figure
4.15, panel C).
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Figure 4.15 The combination in a syngeneic orthotopic model: the intraovarian
ID8.
ID8 was injected in the ovary bursa in syngeneic C57 mice. Treatment started at day 31
post transplant.
A) Protocol of the study. B) Effect of olaparib, cediranib and the combination on survival.
C) Evaluation of short-term treatment (4 weeks) on primary tumor volume (assessed with
MRI), injected ovary weight, volume of ascites and dissemination (N=5 mice/group).
VH, vehicle; C, cediranib; O, olaparib; C+O, combination; MST, median survival times
(days). *P<0.05
LungPellet Contralateral Ovary Uterus Pancreas CarcinomatosisDiaphragm LiverGut
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The other halves of each olaparib, cediranib and the combination group (N=5) were treated
in a maintenance regimen for an additional 9 weeks and mice monitored with MRI every
two/four weeks (Figure 4.15, panel A). Necropsy was performed on each mouse at survival.
MRI scans at different time points (day 54, day 68, day 84 and day 116 from injection as
latest time point) enabled us to follow tumor burden and plot growth curves (Figure 4.16,
panel A). Olaparib monotherapy was active in stabilizing tumor growth compared with
vehicle and cediranib (Figure 4.16, panel B). When cediranib was added to olaparib, the
combination significantly slowed tumor progression under treatment, with 5/5 tumor with a
volume under 100 mm3 and animals still alive at day 114 after transplant, thus indicating
the greater effect of the combination in a maintenance regimen in delaying tumor growth
(Figure 4.16, panel B).
Eventually, when treatments were terminated at day 121, ascites had developed and tumor
had disseminated across the peritoneal cavity, explaining the lack of difference in survival
(Figure 4.15, panel B). Nevertheless, the effect of the combination on primary tumor
growth was evident at necropsy: injected ovary weights were significantly lower in the
combination group, with 4/5 tumors under 400 mg and 1/5 at 1200 mg. Thus, the
combination was the most effective regimen in reducing primary tumor growth (Figure
4.16, panel C).
Chapter 4 Francesca Bizzaro
161
Figure 4.16 The combination in a syngeneic orthotopic model: the intraovarian
ID8.
A) Tumor growth in the ovary was evaluated with MRI scans at different time points after
the end of the short-term treatment (4 weeks).
B) Single tumor growth curve of vehicle, olaparib, cediranib and the combination are
reported.
C) Injected ovary weight for each mice at survival (N=5 mice/group).
VH, vehicle; C, cediranib; O, olaparib; C+O, combination; MST, median survival times
(days). *P<0.05, **P<0.01.
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Summary of results
The syngeneic Not BRCAness model of ovarian cancer ID8, injected orthotopically
in the ovaries of immunocompetent mice, helped us to better understand the effect
of olaparib in combination with cediranib.
Olaparib marginally improved survival and slowed tumor progression, mainly at
the end of the 4 weeks of treatment (Figure 4.15, panel C). At the end of the study
primary tumor weights (Figure 4.16, panel C), levels of ascites, tumor
dissemination and carcinomatosis were increased as for vehicle-treated controls.
Cediranib was not active in prolonging survival and marginally in delaying tumor
growth; an effect of the angiogenesis inhibitor was just detectable immediately
after the end of the 4 weeks treatment (Figure 4.15, panel C), but tended to
disappear at tumor progression and when mice were culled (Figure 4.16, panel B
and C).
The combination of the two drugs was the most active regimen, not so much in
survival, but rather in delaying tumor progression. Primary tumor growth and
dissemination were clearly reduced after 4 weeks of treatment (Figure 4.15, panel C)
and through the length of the maintenance treatment (13 weeks), as shown by the
growth curve inferred by MRI scan (Figure 4.16, panel B). At cull, after the
interruption of treatment, the combination affected tumor dissemination and most
evidently primary tumor weight (Figure 4.16, panel C).
4.9 MOLECULAR CHARACTERIZATION AFTER TREATMENT
At the beginning of Chapter 4, the 13 OC-PDX selected for testing drug, were classified in
BRCAness or Not BRCAness, not only considering the mutational status and pathogenicity
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of BRCA1 and 2, but also the levels of expression and any aberration on other genes
involved in HR DNA repair pathway.
Briefly, OC-PDX carrying somatic mutations and loss of BRCA1/2 on both the gene alleles
were defined BRCAness. Low expression levels of both BRCA1 and BRCA2 allowed to
define one particular model, MNHOC 8, as BRCAness, even though no mutations were
detected with Sanger sequencing; OC-PDX that did not carry mutations on BRCA1 and
BRCA2 or absence of locus-specific loss of heterozygosity (LOH) (such as MNHOC 18
and MNHOC 182) were defined Not BRCAness.
In order to define whether the short-term treatment (4 weeks) with olaparib, cediranib and
the combination has or not changed the classification of the OC-PDX models in
BRCAness or Not BRCAness, we investigated the mutational landscape and expression of
BRCA1 and BRCA2 (NGS and gene expression with fluidigm) at the end of treatment
(Figure 4.17).
BRCA1 (c.1687C>T, p.Q563* truncation/frameshift, described as pathogenic) was found
mutated in MNHOC 22 after cediranib, olaparib and combination treatment, as for vehicle;
MNHOC 508 carried one frameshift described as pathogenic on BRCA2
(c.5722_5723delCT, p.L1908fs) maintained after treatment with cediranib, olaparib and
combination. MNHOC 506, MNHOC 18 and MNHOC 94/2-C were defined as Not
BRCAness, and no additional mutations harboured on these genes after treatment (Figure
4.17, panel A).
All the pathogenic mutations described for TP53 were preserved and not changed by
treatment (substitution missense c.514G>T, p.V172F for MNHOC 8; c.993+1G>A and
c.782+1G>A at splice site for MNHOC 22 and MNHOC 508 respectively; truncation
frameshift c.796G>T p.G266* for MNHOC 506; substitution missense c.527G>T p.C176F
for MNHOC 18). The clear cell MNHOC 94/2-C did not harbour any alteration in TP53 as
when tested at baseline but maintained PTEN truncation frameshift (c.388C>T, p.R130*)
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after short-term treatment. In MNHOC 18, EGFR carried a substitution missense
(c.2884C>T, p.R962C) described as pathogenic and preserved in tumor cells after
treatment (4.17, panel A).
MNHOC 8 harboured wild type BRCA1 and BRCA2 at baseline and was classified as
BRCAness due to the low level of the two genes observed with gene expression analysis
with different techniques (Real Time PCR, genome-wide gene expression, Fluidigm and
RNAseq, Chapter 3, Figure 3.3 - 3.6). BRCA1 low expression was retained even after
treatment. Of note, short-term treatment of olaparib and the combination with cediranib
significantly increased level of expression of BRCA1 compared to vehicle and cediranib
treatment (Ct -15.4 vehicle; -15.4 cediranib; -11.4 olaparib; -11.6 combination), but
values were still under the mean value of all the models tested (mean Ct -6.2) (Figure
4.17, panel B). For convenience, values were reported as -ΔCt, being the lowest value
corresponding to the lowest expression.
BRCA2 expression in MNHOC 8 was not different compared to the other models, but still
under the mean value (mean Ct -7.6). No significant differences were pointed out in
BRCA2 among different treatment (Ct -10.8 vehicle; -9.4 cediranib; -8.5 olaparib; -8.4
combination) (Figure 4.17, panel B).




Figure 4.17 OC-PDX classification after treatment.
A) Mutational landscape after treatment with cediranib, olaparib and combination in 6 OC-
PDX selected for preclinical testing therapy.
B) BRCA1 and BRCA2 level of expression in 8 OC-PDX selected for preclinical testing
therapy after four weeks of treatment with cediranib, olaparib and combination.
Data are ΔCt = Cttarget- Cthousekeeping. and reported as - ΔCt, being the lowest value
corresponding to the lowest expression. Red line ( ) mean value of - ΔCt for each gene
tested.
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4.10 DISCUSSION
Preclinical tumor models recapitulate many aspects of the genesis and progression of
human cancers, thus they are valuable resources to investigate the mechanisms of cancer
and to predict clinical behaviour, in terms of tumor biological features (i.e. dissemination
and ascites formation) and response to therapy.
In particular, patient-derived ovarian tumor xenografts (OC-PDX) are a useful tool to test
new therapeutic strategies and efficacy can be determined by mimic the response of the
patients (Weroha et al., 2014). A strong correlation between patient and OC-PDX
responsiveness to therapy has been demonstrated in ovarian cancer, thus endorsing the
reliability of the model to lead translational preclinical and co-clinical trials (Ricci et al.,
2014; Masazza et al., 1991; Massazza et al., 1989; Fiebig et al., 1984).
A platform of transplantable OC-PDX has been established in the Department of Oncology
(Ricci et al., 2014), and a cohort of 13 OC-PDX was used to perform the preclinical studies
reported in Chapter 4.
Firstly, the response to olaparib single therapy was assessed in 10 models of OC-PDX
growing subcutaneously, both in a short-term (4 weeks) and in a maintenance regimen
(Figure 4.1). Results showed that BRCAness tumors responded to olaparib single therapy,
after a short-term treatment and even more so in a maintenance regimen, with complete
responses, as seen in the clinic (Fong et al., 2010; Kaufman et al., 2015). Aberrations in
BRCA1/2 are a good predictor for olaparib response. Interestingly, MNHOC 154 was an
exception in this context; despite a pathogenic mutation in BRCA1, the presence of an
amplification in BRCA2 (confirmed also by high level of gene expression, as reported in
Figure 3.4-3.6, Chapter 3, Results) induced a heterogeneous response to olaparib
Chapter 4 Francesca Bizzaro
167
monotherapy (Figure 4.7), thus MNHOC 154 was a good model to study combination
regimens.
In general, the entire cohort of OC-PDX could be considered a reliable tool to deeply
analyse the combination of olaparib and other drugs, such as angiogenesis inhibitors.
Genomic instability and induced angiogenesis are two of the hallmarks of cancer (Hanahan
and Weinberg, 2011), thus targeting both of them could boost the therapeutic outcome.
Clinical trials have investigated the combination of olaparib and cediranib (Liu et al., 2013,
2014) in recurrent ovarian cancer patients, showing PFS increase in patients with germline
mutations in BRCA1/2, but also in homologous recombination proficient patients.
Our models of OC-PDX displayed a heterogeneous response to the angiogenesis inhibitor,
both in a short-term and maintenance regimen (Figure 4.2). The response to cediranib
seemed to be dependent on the intrinsic features of each single tumor, such as vasculature,
factors that determine the metabolic status of the tumor (i.e. fibroblasts), stroma and levels
of VEGF. The heterogeneity and diversity of responses seen in our OC-PDX models
mimic the clinical scenario, in which patients show different profiles of responsiveness to
the anti-angiogenic treatment.
The addition of cediranib to olaparib was favourable for those OC-PDX that were poorly
responsive to the olaparib single agent therapy, especially the Not BRCAness subtypes,
promoting a stabilization of disease in case of short-term treatment and a strong regression
in maintenance regimens, as for MNHOC 18 and MNHOC 182 (Figure 4.3 and 4.4).
The combination was beneficial also for BRCAness models, increasing the number of
complete responses and cured mice (Figure 4.2, panel A and D).
Our preclinical data advanced the idea that the combination is worth administering
especially in Not BRCAness patients, but also in the BRCAness types to induce more
durable and stable effects, persistent several weeks after treatment suspension, as for
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MNHOC 511 and MNHOC 513 (Figure 4.6). In particular, the BRCAness MNHOC 511
was a powerful example of the clinical translational impact of these preclinical studies. The
patient, from which the OC-PDX was derived, is still under treatment with olaparib and in
a complete response. Since MNHOC 511 gained an advantage from the addition of
cediranib to olaparib, the combination could be an appropriate treatment if the patient
would eventually relapse.
The effect of the combination was evaluated in a case-report fashion, taking into advantage
the orthotopic (intraperitoneal) set of available OC-PDX, due to their resemblance to the
original biological features of the patient’s tumor.
Timing and sequence of angiogenesis and PARP inhibition is an issue that calls for
consideration. The BRCAness MNHOC 8 model, for instance, enabled us to analyse in
detail the importance of sequence in the combination of cediranib and olaparib. In this
model too, the combination was more active than single drugs in increasing survival of
mice, particularly when administered in a maintenance regimen (Figure 4.8, panel A and
panel D). The gain in survival was accompanied by a substantial control in the levels of
ascites; however, dissemination increased, leading mice to live longer, but with the
detriment of a more aggressive disease.
The escape from antiangiogenic treatments has been well documented in preclinical studies,
including in our models of OC-PDX treated with the anti-VEGFA bevacizumab, which
under certain circumstances increased survival but also tumor dissemination (Bizzaro et al.,
2018; Decio et al., 2015).
The evidence that cediranib and olaparib should be administered together was obtained
when different sequences of drugs were administered (Figure 4.9). The administration of
the combination until progression reduced ascites and was more effective in keeping tumor
spread across the organs of the peritoneal cavity under control. The combination followed
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by a switch to cediranib or olaparib single agent was not effective in increasing survival
compared with continuing the combination in maintenance; the switch to olaparib
marginally decreased ascites and dissemination; the switch to cediranib significantly
reduced ascites, but markedly increased dissemination (Figure 4.9, panel B). The activity
of adding cediranib to olaparib, even when treatment was started at a late stage of disease,
could be explained as a two-compartment effect, with the effect on the microenvironment
produced by the first, and the inhibition of DNA repair system generated by the latter (see
also Chapter 5 and Chapter 6, Results).
The benefit of the combination of olaparib and cediranib was further evident when the
PARP inhibitor was combined with bevacizumab, the first anti-VEGFA approved for
ovarian cancer treatment. A phase III clinical trial, PAOLA-1, is currently testing olaparib
versus placebo combined with bevacizumab as maintenance treatment in patients with
advanced ovarian cancer following first-line platinum-based chemotherapy plus
bevacizumab. In our OC-PDX models, the administration of the combination bevacizumab
plus olaparib was ineffective in the case of MNHOC 18 (Figure 4.10, panel B), with
subcutaneous tumors progressing rapidly under treatment. A similar outcome was observed
when B20, the antibody recognising both human and murine VEGFA, was used (Figure
4.10, panel C).
The effect of the addition of bevacizumab to olaparib was more evident in the orthotopic
model MNHOC 8, but not different from the combination with cediranib (Figure 4.11). We
could speculate that differences in response between the two OC-PDX tested could be
related to the site of growth (subcutaneously growing MNHOC 18 versus intraperitoneally
growing MNHOC 8). Moreover, the lack of differences between the combination with
cediranib or bevacizumab in the intraperitoneal MNHOC 8 model could be linked to the
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effect of the two angiogenic inhibitors on ascites - both reducing it - and on dissemination -
both increasing it-, resulting into an equal outcome in survival.
In addition, MNHOC 18 expressed high levels of all the receptors of cediranib, while
MNHOC 8 did not (Figure 6.5 and Figure 6.6, Chapter 6); this could explain why there is
such a great benefit in combining olaparib with cediranib instead of bevacizumab, at least
in MNHOC 18.
Intraperitoneal MNHOC 22 tumor, carrying a mutation in BRCA1, was resistant to olaparib
single agent, showing no increase in host survival and remarkable production of ascites.
The addition of cediranib increased survival and promoted a strong decrease of ascites and
dissemination at the end of treatment (Figure 4.12, panel A and B). The additive effect of
the combination could be explained by the efficacy of cediranib in controlling ascites
formation and olaparib in reducing tumor masses and dissemination. However, after
treatment suspension, tumors progressed and mice succumbed with a heavy tumor burden
into the peritoneal organs (Figure 4.12, panel C). Thus, the increment of lifespan came
along with a more aggressive disease, confirming our previous finding (Bizzaro et al., 2018;
Decio et al., 2015; Oliva et al., 2012). However, results obtained on MNHOC 22 (BRCA1
mutated) and on MNHOC 154 (BRCA1 mutated but amplified BRCA2) suggested that the
combination of olaparib with cediranib could be considered the best therapeutic option also
for BRCAness platinum-sensitive patients, which are moderately responsive or resistant to
olaparib single agent therapy.
If the majority of the selected OC-PDX benefitted from the combination of olaparib with
cediranib, cases of poor response need to be taken into consideration and carefully
addressed. Poorly responsive OC-PDX, such as the orthotopic MNHOC 506 (Figure 4.14)
and the ectopic MNHOC 94/2-C (Figure 4.13), are fundamental tools to study other
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treatment modalities for patients in whom the combination would not be so advantageous.
A marginal effect could be claimed in reducing ascites and dissemination immediately
after the end of treatment in MNHOC 506 bearing mice and marginally in reducing tumor
growth in MNHOC 94/2-C.
One last aspect that should be taken into account using OC-PDX, especially to test target
therapies, is the fact that the tumor (human) and the host (murine) are different. To address
this issue, the orthotopic transplant in the bursa of the ovary of syngeneic murine tumor
cells, such as ID8, may enable us to study key aspects of the biological features of the
ovarian disease in immunocompetent host, since cancer progression, metastasis formation
and response to therapy are similar to those seen in the clinic. Syngeneic murine models
provide the opportunity to study the tumor microenvironment, stroma, infiltrating host
cells, secreted factors and vasculature. Moreover, in this particular case, we followed
disease progression with MRI, a non-invasive imaging technique, that allowed us to obtain
several pieces of information, at different time-points, without the need for a sequential
culling of animals (Figure 4.16, panel A and B).
The effect of olaparib and the combination with cediranib was tested both in a short-term
(4 weeks) and in maintenance regimen (Figure 4.15, panel A). The combination of the two
drugs was the most active, not increasing survival in mice, but mostly delaying tumor
progression and affecting primary tumor growth at the ovary, both in the short-term
treatment (Figure 4.15, panel C) and even after several weeks from treatment suspension
(Figure 4.16, panel C).
To summarize, results obtained from preclinical testing trials described in Chapter 4, lead
us to believe that the addition of cediranib to olaparib is advantageous in many cases,
notably when administered until tumor progression.
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Mutational landscape and BRCA1 and BRCA2 expression were not modified by short-term
treatment (4 weeks) (Figure 4.17, panel A and B). However, preliminary data (not shown)
extrapolated from NGS analysis showed that olaparib single agent and the combination
with cediranib induced the highest number of novel mutations (as the total number of
single-nucleotide-polymorphisms count) in post-treated samples, not observed in vehicle-
and cediranib-treated samples at the same time point. This suggested that olaparib is
inducing DNA damages in tumor cells during administration.
Biomarkers of response and preliminary data on molecular characterization after short-
term treatment described in Chapter 5 and Chapter 6 have the aim to further shed light on
the possible mechanisms underlying the biological and pharmacological effects
demonstrated in combination treatments.
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5.1 EFFECTS OF THE COMBINATION ON THE TUMOR
MICROENVIRONMENT AND HR DNA REPAIR MARKERS
Cediranib binds the three VEGF receptors, with marked selectivity for VEGFR2, together
with c-Kit (KIT) and PDGFRPDGFRA) (Sahade et al., 2012), and the use of VEGFR
inhibitors can cause local tumor hypoxia. On the other hand, evidence supports the idea
that angiogenesis inhibitors can normalize the structure and function of tumor-associated
vasculature, thus reducing levels of hypoxia (Jain, 2005).
As a marker of cediranib activity on tumor vasculature, CD31 positive vessels
(microvessel density, MVD) and endothelial area (EA) were evaluated; hypoxia was
evaluated with CA-9 and pimonidazole. Representative staining showed that both are
comparable in formalin-fixed sections of tumors and colocalization is observed, even
though differences were highlighted: CA-9 staining tended to be more localized at cell
membranes away from vessels, while pimonidazole contributed to a more diffuse signal
(Figure 5.1).










Figure 5.1 Tumor hypoxia: CA-9 vs Pimonidazole representative staining on
MNHOC 513.
CA-9 and Pimonidazole staining were evaluated in parallel on the same OC-PDX, to
assess that results are comparable.
N: necrosis; T: neoplastic tissue; S: stroma.
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Acute and chronic hypoxia can lead to a DNA repair-deficient phenotype and genetic
instability (Bristow and Hill, 2008; Pires et al., 2010), with decreased expression of
proteins involved in the HR DNA repair pathway, leading to an increased sensitivity to
DNA cross-linking agents such as Poly(ADP-ribose) polymerase (PARP) inhibitors (Chan
et al., 2008, 2010). PARP inhibitors, such as olaparib, are able to induce an increase in
DNA damage by “trapping” PARP on DNA single strand breaks, thus inducing the block
of replication forks, leading to an evolution and accumulation of double strand breaks.
When DNA damage forms double strand breaks (DSBs), it is always followed by the
phosphorylation of the histone H2AX. Newly phosphorylated protein, H2AX, is the first
step in recruiting and localizing DNA repair proteins. Thus, evaluating levels of expression
of H2AX within neoplastic tissue could be considered a marker of DNA damage, induced
by olaparib.
Analyses were performed on subcutaneous tumors (s.c models) and tumor masses at the
ovaries (i.p models) collected at random days (VH at random -when available-) and at the
end of short-term treatment (4 weeks, 5 days on and 2 days off), 6 hours after the last dose
of vehicle (VH), cediranib (CED), olaparib (OLA) or the combination (COMBO) (n=2-
3/per group). Details are reported in Section 2.4, Chapter 2, Materials and Methods.
5.1.1 Subcutaneous tumor models
5.1.1.1 MNHOC 18, Not BRCAness
Administration of the PARP inhibitor olaparib in MNHOC 18 tumor-bearing mice failed in
delay tumor progression in a short-term regimen. Lack of responsiveness was displayed
with the angiogenesis inhibitor cediranib. The combination was active in stabilizing tumor
growth until treatment was ended (Figure 5.2, panel A).
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Changes in tumor vasculature indicated that MVD was reduced after cediranib treatment
and maintained with the combination (mean number of CD31+ vessels = 12 for cediranib;
14 for the combination), compared with vehicle or olaparib (mean number of CD31+
vessels = 22 for vehicle; 19 for olaparib) (Figure 5.2, panel C).
The same trend was observed on endothelial area (EA) measurements. The PARP inhibitor
olaparib induced a modest reduction of the CD31+ area compared with vehicle (mean EA
= 2,4% olaparib; 3,9% vehicle). The angiogenesis inhibitor cediranib reduced the CD31+
area compared with vehicle (mean EA = 1,6%) and no further reduction was observed with
the combination (mean EA = 1,8%) (Figure 5.2, panel D and representative images in
panel E).
This evidence supported results on the level of hypoxia. At randomization, hypoxia was
almost undetectable in vehicle-treated tumors (mean of group = 2,5% vehicle at random).
The hypoxic area was similarly increased by cediranib and olaparib after 4 weeks of
treatment, with no further improvement by the combination (mean of group = 10% vehicle;
30% cediranib; 20% olaparib; 24% combination) (Figure 5.2, panel B).
Additional analysis on the level of CA-9 mRNA, assessed by fluidigm, showed that
cediranib induced an increase in levels of expression (mean -Ct = -5.14). Levels in
olaparib treated animals were comparable with vehicle-controls (mean -Ct = -7.59 vehicle;
-7.27 olaparib). Accordingly, the addition of cediranib to olaparib did not further increase
the expression (mean -Ct = -5.77).
For immunohistochemical analysis of H2AX, the same samples used for hypoxia and
tumor-associated vasculature determination were evaluated. Cediranib and olaparib
slightly reduced foci formation compared with vehicle (mean of group = 31% vehicle; 15%
cediranib; 13% olaparib), and the combination of the two inhibitors induced a significant
increase in foci formation (mean of group = 56%) (Figure 5.2, panel F and representative
images in panel G).
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Figure 5.2 Analysis on subcutaneous MNHOC 18.
A) Samples were collected at the end of short-term treatment (- - -), from figure 4.3 A.
B) % CA-9+ area, C) MVD (microvessel density, n° of CD31+ vessels), D) EA
(endothelial area, CD31 positive area not considering vascular lumen, % of CD31+ area)
are reported as the mean±SD of 3 200X randomly selected fields in neoplastic tissue. E)
Representative sections of CD31+ vessels (200X magnification).
F) H2AX foci (% H2AX+ foci with different patterns) are reported as the mean±SD of 3
200X randomly selected fields in neoplastic tissue.G) Representative sections of H2AX+
cells (200X magnification). *P<0.05.
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5.1.1.2 MNHOC 182, Not BRCAness
Short-term administration (4 weeks) of olaparib slightly reduced tumor growth in MNHOC
182 bearing mice and cediranib induced a moderate stabilization of tumor growth. The
combination was remarkably active in stabilizing tumor growth, maintaining mean tumor
volume closer to values at random day (Figure 5.3, panel A).
Changes in tumor-associated vasculature were estimated. MVD was significantly reduced
by cediranib and the combination treatment, compared with vehicle or olaparib (mean n° of
CD31+ vessels = 20 for vehicle; 5 for cediranib; 16 for olaparib; 6 for the combination)
(Figure 5.3, panel C).
Cediranib reduced EA (mean EA = 0,6%) as much as the combination (mean EA = 0,7%),
compared with vehicle (mean EA = 4,3%) or olaparib (mean EA = 4%) (Figure 5.3, panel
D).
Of note, evaluation of CD31 stained slides pointed out ectasia of vessels present in vehicle
and olaparib groups (Figure 5.3, panel E, black arrows), completely absent after short-term
treatment with cediranib and the combination.
Levels of hypoxia were evaluated by assessing the percentage of pimonidazole-positive
area (% Pimo+ area) in 2 fields (50x magnification), randomly chosen across the neoplastic
tissue. Cediranib induced a reduction of hypoxic area compared with vehicle at random
and vehicle after 4 weeks of treatment, but not different from olaparib (mean of groups =
45% vehicle at random; 43% vehicle; 21% cediranib; 21% olaparib). The combination
improved the reduction compared to vehicle (mean of group = 12% combination) (Figure
5.3, panel B).
In this model, the formation of H2AX foci was in general very low, compared to the other
subcutaneous models. No significant differences in foci formation were highlighted among
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the different groups (mean of group = 0% vehicle; 1% cediranib; 0% olaparib; 1%
combination) (Figure 5.3, panel F).
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Figure 5.3 Analysis on subcutaneous MNHOC 182.
A) Samples were collected at the end of short-term treatment (- - -), from figure 4.4.
B) % Pimo+ area, C) MVD (microvessel density, n° of CD31+ vessels), D) EA
(endothelial area, CD31 positive area not considering vascular lumen, % of CD31+ area)
are reported as the mean±SD of 3 200X randomly selected fields in neoplastic tissue. E)
Representative sections of CD31+ vessels (200X magnification).
F) H2AX foci (% H2AX+ foci with different patterns) are reported as the mean±SD of 3
200X randomly selected fields in neoplastic tissue.*P<0.05.
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5.1.1.3 MNHOC 508, BRCAness
Short-term treatment (4 weeks) with olaparib and cediranib induced a stabilization of
tumor growth in the MNHOC 508 OC-PDX model. Soon after the end of treatment, tumors
regrew again. The combination of the PARP inhibitor with the angiogenesis inhibitor
induced a significant regression in tumor growth, maintained for approximately one month
after the end of treatment (Figure 5.4, panel A).
MVD analysis revealed a significant reduction in the number of vessels induced by
cediranib and the combination compared with vehicle or olaparib alone (mean n° of
CD31+ vessels = 12 for vehicle; 15 for olaparib; 3,5 for cediranib; 7 for the combination)
(Figure 5.4, panel C).
Analysis of EA showed a decreasing trend of endothelial area driven by cediranib
compared with vehicle (mean EA = 0,7% vehicle; mean EA = 0,4% cediranib). Olaparib
induced instead a marked increase in EA (mean EA = 1,5% olaparib). The effect of the
combination mirrored the situation of vehicle-treated samples (mean EA = 0,8%
combination) (Figure 5.4, panel D).
Evaluation of % CA-9+ area confirmed that hypoxic areas were comparable between
vehicle at random day and vehicle after 4 weeks (mean of group = 16% vehicle at random;
20% vehicle). Levels of hypoxia were slightly increased after cediranib and reduced by the
treatment with olaparib and the combination (mean of group = 30% cediranib; 14%
olaparib; 17% combination) (Figure 5.4, panel B and representative images in panel E).
Additional analysis on levels of CA-9 mRNA, assessed by fluidigm, showed comparable
values in vehicle and cediranib treated tumors (mean Ct = - 4.1 vehicle; -3.6 cediranib)
and a decrease in level of CA-9 after olaparib and the combination (mean Ct = -7.5
olaparib; -5.2 combination). For convenience, values were reported as -ΔCt, being the
lowest value corresponding to lowest expression.
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Evaluation of DNA damage, assessing % H2AX foci formation, showed that cediranib
administration did not influence H2AX foci formation compared with vehicle (mean of
group = 11% vehicle; 11% cediranib), while olaparib and the combination induced a
significant increase in DNA damage (mean of group = 48% olaparib; 30% combination)
(Figure 5.4, panel F and representative images in panel G).
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Figure 5.4 Analysis on subcutaneous MNHOC 508.
A) Samples were collected at the end of short-term treatment (- - -), from figure 4.5 A.
B) % CA-9+ area, C) MVD (microvessel density, n° of CD31+ vessels), D) EA
(endothelial area, CD31 positive area not considering vascular lumen, % of CD31+ area)
are reported as the mean±SD of 3 200X randomly selected fields in neoplastic tissue. E)
Representative sections of CA-9+ area (50X magnification).
F) H2AX foci (% H2AX+ foci with different patterns) are reported as the mean±SD of 3
200X randomly selected fields in neoplastic tissue. G) Representative sections of H2AX+
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5.1.2 Intraperitoneal models
5.1.2.1 MNHOC 8, BRCAness
Analysis of changes in tumor-associated vasculature and hypoxia induced by treatment
were performed in one intraperitoneal OC-PDX, taken as an illustrative example; the
biomarkers of responses were evaluated in neoplastic tissue invading the ovaries.
For the intraperitoneal model MNHOC 8, analyses were carried out taking into
consideration two different time points: samples were collected at the end of short-term
treatment (4 weeks) (Figure 5.5, panel A) and at progression under treatment (Figure 5.6,
panel A).
At short-term treatment (4 weeks), the angiogenesis inhibitor cediranib, PARP inhibitor
olaparib and the combination induced a strong reduction in levels of ascites compared with
vehicle-treated mice. The combination further improved the outcome, significantly
reducing levels of tumor dissemination in the organs of the peritoneal cavity (Figure 5.5,
panel A).
MVD and EA evaluation did not show a clear variation in the number of vessels and
percentage of CD31+ area detected within the neoplastic tissue, just a general, treatment-
independent, decreasing trend in cediranib, olaparib and the combination group compared
with vehicle (MVD mean of group = 15 vehicle; 5 cediranib; 8 olaparib; 4 combination.
EA mean of group = 1% vehicle; 0,4% cediranib; 0,6% olaparib; 0,5% combination)
(Figure 5.5, panel B and C).
Basal levels of hypoxia were assessed evaluating % of CA9+ area in vehicle at random
(day 10 after tumor injection) (mean of group = 5%). After 4 weeks, tumor masses in the
ovaries were hardly measurable, resulting in poor evaluable hypoxic areas (mean of group
= 30% vehicle; 25% cediranib; 30% olaparib; 17% combination) (Figure 5.5, panel D).
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Figure 5.5 Analysis on intraperitoneal MNHOC 8.
Levels of ascites and carcinomatosis at A) short-term treatment sample collection time
point.
B) MVD (microvessel density, n° of CD31+ vessels), C) EA (endothelial area, CD31
positive area not considering vascular lumen, % of CD31+ area) and D) %CA-9+ area are
reported as the mean±SD of 3 200X randomly selected fields in neoplastic tissue.
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At progression under treatment (after more than 20 weeks of treatment administration),
cediranib and the combination remarkably controlled ascites formation compared with
vehicle or olaparib, nevertheless inducing a substantial spread of carcinomatosis
throughout the organs of the peritoneal cavity, especially ovaries. In contrast, olaparib
monotherapy did not affect ascites formation, even though it induced a strong reduction in
solid tumor masses formation in the ovaries (Figure 5.6, panel A).
At this time point, MVD was halved by cediranib and the combination, compared with
vehicle controls or olaparib monotherapy (mean n° of CD31+ vessels = 21 for vehicle; 10
for cediranib; 20 for olaparib; 12 for the combination). The same results were obtained
analysing the % CD31+ area (mean of group = 1% vehicle; 0,4% cediranib; 2% olaparib;
0,4% combination) (Figure 5.6, panel B, C and representative images in panel D).
Pimonidazole was used to assess levels of hypoxia (% Pimo+ area). Levels of hypoxia
increased significantly at progression under treatment, particularly in vehicle, cediranib
and olaparib groups (mean of group = 7% vehicle; 7% cediranib; 9% olaparib). Continuous
administration of the combination remarkably diminished % Pimo+ area (mean of group =
1,6% combination) compared to other treatments: despite the fact that tumor masses were
larger in animals treated with the combination and changes in tumor-associated vasculature
were not further intensified by the combination, hypoxia levels were significantly reduced
(Figure 5.6, panel E).
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Figure 5.6 Analysis on intraperitoneal MNHOC 8.
Levels of ascites and carcinomatosis at A) progression under treatment sample collection
time point. B) MVD (microvessel density, n° of CD31+ vessels), C) EA (endothelial area,
CD31 positive area not considering vascular lumen, % of CD31+ area) and D) % Pimo+
area are reported as the mean±SD of 3 200X randomly selected fields in neoplastic tissue.
E) Representative sections of CD31+ vessels (200X magnification). *P<0.05.
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5.2 SUMMARY OF RESULTS AND DISCUSSION
It is well recognized that angiogenesis inhibition, using drugs such as the tyrosine-kinase
inhibitor cediranib, could lead to a normalization of structure and function of tumor-
associated vasculature, reducing hypoxia (Jain, 2005). Nonetheless, there is evidence to
support the idea that the use of therapeutic strategies to inhibit angiogenesis can cause local
hypoxia in tumors, reducing the number, maturation, patterning and function of vessels and
therefore level of oxygen (Liao and Johnson, 2007).
Modification in levels of hypoxia can lead to a DNA repair-deficient phenotype, causing
increased genetic instability, with a decrease in the level of expression of HR DNA repair
pathway proteins. In this context, tumor cells should be more sensitive to DNA cross-
linking agents, such as PARP inhibitors, including olaparib (Bristow and Hill, 2008; Pires
et al., 2010).
Moreover, changes in level of hypoxia induced HIF-1 stabilization and activation, and
this might enhance tumor cell dissemination. Enhanced angiogenesis is associated with
metastasis, due to the fact that permeable and heterogeneous vasculature facilitates the
extravasion and circulation of tumor cells to distant and unaffected organs, thus escaping
the hypoxic microenvironment in the primary tumor. Hypoxic cells are indeed more
aggressive and invasive, with a better ability to metastatize. Hypoxia influence invasive
and migratory behaviour via epithelial-to-mesenchimal transition (EMT), that it is
characterized by a decrease in epithelial-associated genes, such as E-cadherin, -catenin,
and an increase in mesenchymal associated gene, such as N-cadherin, vimentin and -
SMA. Tumor cells that undergo EMT are resistant to chemo and radiotherapy.
Changes that the tumor microenvironment and hypoxia cause at a genetic level, could in
part explain the promising results of olaparib combined with cediranib in OC-PDX models.
For these reasons, changes in tumor-associated vasculature (using CD31 and evaluating
vessels number and area), hypoxia (using CA-9 or Pimonidazole staining) and DNA
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damage markers (such as H2AX foci formation) were evaluated in a limited number of
OC-PDX used for preclinical drug testing (see Chapter 4, Results).
In particular, treated samples from 3 subcutaneous (MNHOC 18, MNHOC 182 and
MNHOC 508) and one intraperitoneal (MNHOC 8) models were analysed after the end of
treatment (4 weeks) and at progression under treatment (only for MNHOC 8).
Results reported in Chapter 5 indicated a general heterogeneity amongst the models, with
different levels of hypoxia detected within each model at baseline (vehicle at random and
vehicle at short-term treatment), and different baseline expression of H2AX.
For example, in the Not BRCAness MNHOC 182, cediranib and the combination reduced
hypoxia, with a diminution in vessel number and area, indicating also a normalization of
tumor vasculature compared to the ectatic (dilated) vessels present in vehicle and olaparib
treated samples (Figure 5.3, panel B, C, D and E). The effect of olaparib and the
combination on H2AX foci formation was limited, with no significant differences
between the groups (Figure 5.3, panel F).
In contrast, in the subcutaneous model MNHOC 18, the number and area of vessels and
hypoxia level were mostly affected by cediranib and the combination (Figure 5.2, panel B,
C and D). Olaparib induced a slight increase of H2AX foci formation (Figure 5.2, panel
F). This moderate effect could be linked to the fact that this model is Not BRCAness, so
mechanisms of damage repair are functional. Rather, H2AX foci formation was
significantly increased by the combination with cediranib (Figure 5.2, panel F).
In addition, in the BRCAness MNHOC 508 tumor model, no significant changes in levels
of hypoxia were detected, despite a decreased number of vessels induced by cediranib and
the combination (Figure 5.4, panel B, C and D). The PARP inhibitor itself induced an
increase in H2AX foci, and the effect was not further enhanced by the combination, thus
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indicating the already strong effect of the PARP inhibitor in boosting genetic instability in
this DNA-repair deficient model (Figure 5.4, panel F and G).
In the context of combination therapy, it would be reasonable to hypothesize that i)
cediranib played a key role in modifying tumor-associated vasculature and local hypoxia, ii)
olaparib caused an enhancement of DNA damage, iii) the combination of the effects
sustained the strong stabilization (MNHOC 18, Figure 5.2, panel A) or regression
(MNHOC 508, Figure 5.4, panel A) of tumor growth, as long as the therapy is
continuously administered.
The intraperitoneal MNHOC 8 model provided the opportunity to study the short and long-
term activity of the combination. After only 4 weeks of therapy, minimal changes in
tumor-associated vasculature and hypoxia were detected (Figure 5.5, panel B, C and D). At
this time point, neoplastic tissue in the ovaries was barely detectable, and that could
explain the lack of differences, even with a general reduction in the level of dissemination
at necropsy induced by the combination (Figure 5.5, panel A).
When analyses were performed at tumor progression under maintenance treatment (after
more than 20 weeks of treatment), vessel number and area were reduced by cediranib and
the combination (Figure 5.6, panel B, C and E), but only the latter induced a strong
reduction of hypoxia (Figure 5.6, panel D). It is known that long-term exposure to
angiogenesis inhibitors can results in tumor growth reduction and in parallel in a more
malignant and invasive phenotype (Mountzios et al., 2014). In MNHOC 8 the maintenance
treatment with the combination reduced ascites production to the detriment of an increased
tumor dissemination through the organs of the peritoneal cavity (Figure 5.6, panel A).
Increased aggressiveness could in part be explained by the fact that angiogenesis inhibitor
administration prolong survival in mice, mainly because ascites is drained off and, without
it, tumor cells “fall” directly in contact with the surrounding healthy tissues. It is possible
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to speculate that the prolonged survival allows resistant and malignant tumor cells to
survive and grow, in a microenvironment rich of oxygen and with the correct levels of
nutrient.
Correlating results on biomarkers of response, in term of immunohistochemical analysis,
with molecular changes (see Chapter 6, Results), in terms of gene expression after
treatment, could help to reveal possible mechanisms of action underlying the advantage of
adding cediranib to olaparib in both BRCAness and Not BRCAness tumors.
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In an attempt to investigate mechanisms of action underlying the combination of olaparib
(PARP inhibitor) with cediranib (angiogenesis inhibitor), analyses were performed, taking
into consideration several complementary aspects of the tumor’s biological behaviour.
In Chapter 6 preliminary data on gene expression modulation at the end of 4 weeks of
treatment are reported.
6.1 GENE EXPRESSION ANALYSIS AFTER TREATMENT: FLUIDIGM DATA
Cediranib, an oral inhibitor of VEGF signaling, that binds VEGFR1, VEGFR2, VEGFR3,
c-Kit and PDGFR-alphashown to inhibit blood vessel growth and sprouting both in vivo
and in vitro (Wedge et al., 2005).
Olaparib, an oral inhibitor of PARP, shown a dual activity in preventing DNA damage
repair and “trapping” PARP on DNA, thus creating complexes that impair the progression
of replication forks (Lord and Ashworth, 2017).
It has been suggested that the use of VEGFR inhibitors (e.g. cediranib) can cause changes
in the microenvironment (e.g. local tumor hypoxia, tumor-associated vasculature
remodelling) that could lead to a DNA repair-deficient phenotype on tumor cells (Bristow
and Hill, 2008; Pires et al., 2010), with a decreased expression of proteins involved in the
HR DNA repair pathway. This can increase sensitivity to DNA cross-linking agents such
as PARP inhibitors (e.g. olaparib) (Chan et al., 2008, 2010).
As previously reported in the laboratory where this PhD project has been performed,
cediranib also caused vascular regression and inhibition of VEGFR3 mediated
lymphangiogenesis in ovarian cancer models (Decio et al., 2014). Lim and colleagues (Lim
et al., 2014) reported that VEGFR3 inhibition in ovarian cancer cells leads to a decrease in
the levels of BRCA1 and BRCA2, both at the mRNA and protein levels of expression.
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These multiple findings gave us the rationale to analyse changes induced by the treatment
in different classes of genes.
Specifically, gene expression was investigated after 4 weeks of treatment on three OC-
PDX: MNHOC 18, MNHOC 182 and MNHOC 124. The three OC-PDX were
subcutaneously growing tumors, Not BRCAness, olaparib resistant, but all gained a
significant advantage in terms of growth delay when olaparib was administered together
with cediranib (Figure 6.1; see also Chapter 4, Results, for details).
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Figure 6.1 OC-PDX models selected to perform gene expression data
analysis.
A) MNHOC 124, B) MNHOC 182 and C) MNHOC 18 were Not BRCAness
models, resistant to olaparib and gained advantages from the combination.
Samples were collected at the end of 4 week treatment (- - -).
Not BRCAness models
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Gene expression analysis was carried out with RealTime PCR. Ad hoc murine and human
primers were designed, allowing us to consider changes both in the murine (e.g.
angiogenesis, cytokine/chemokine, hypoxia, metabolism, immune-stimulatory and
suppressive genes) and in the human compartments (e.g. DDR and EMT genes).
Changes in gene expression were initially assessed to identify which classes of genes were
overall modulated by the combination treatment.
Modulations at gene expression levels were induced in both cancer cells and tumor
microenvironment.
In particular, angiopoietin-2 (m_Angpt2), delta-like protein 4 (m_Dll4), VEGF receptor 2
(m_Kdr) and placental growth factor (m_Pgf) were significantly downregulated, indicating
the inhibition of angiogenesis (Figure 6.2, panel A).
Transcript levels (mRNA) of thioredoxin-interacting protein (m_Txnip), an inhibitor of the
thioredoxin antioxidative function that leads to the accumulation of reactive oxygen
species and cellular stress, were significantly upregulated, suggesting a modulation also in
metabolism-associated genes in the microenvironment (Figure 6.2, panel A).
Human XRCC3, which belongs to the DDR pathway and participates in homologous
recombination to maintain chromosome stability and repair DNA damage, was
significantly upregulated in cancer cells (Figure 6.2, panel B).
Thus, given these overall results, OC-PDX specific changes induced by treatments were
then analysed, with a particular focus on all the genes belonging to metabolism and
angiogenesis (murine compartment) and DDR (human compartment), comprised in the
panel of genes selected for Fluidigm (for the complete list see Section 2.2.5 and Tables 2.2
and 2.3, Materials and Methods, Chapter 2).
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Figure 6.2 Gene expression analysis after 4-week treatment with the
combination.
Overall A) murine and B) human genes, of which levels of expression were
significantly modulated by the combination of olaparib and cediranib in responsive
tumors undergoing treatment. Briefly Ct = Ct target - Ct housekeeping was calculated
(housekeeping genes were IPO8 and HPRT1) for each gene under investigation.
Changes in levels of expression (FC=fold change) were calculated by the 2-Ct
method (comparator were the untreated tumors) (Schmittgen TD and Livak KJ, Nat
Protoc, 2008). Then the Log2FC values were analysed for statistical significance.
Shown are the significantly modulated genes. * P<0.01. N=9 (3 ≠ models).
DDR
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Murine compartment.
Changes in gene expression induced by the treatment were in general moderate in
MNHOC 124 and MNHOC 182 (Figure 6.3, panel A and B). All the treatments induced a
significant gene expression modulation in MNHOC 18.
Among genes belonging to metabolism, m_Phgdh (phosphoglycerate dehydrogenase) was
significantly upregulated by the three treatment, m_Keap1 (substrate adapter protein for
the E3 ubiquitin ligase complex), m_Pfkfb3 (phospho-fructo-kinase/fructose-
diphosphatase 3), m_Scd1 (endoplasmic reticulum enzyme Stearoyl-CoA desaturase),
m_Slc25a10 (mitochondrial dicarboxylate carrier) and m_Txnip were modulated by
olaparib and the combination with cediranib (Figure 6.3, panel C).
The combination of olaparib with cediranib reduced the expression of angiogenesis-related
genes, such as m_Angpt2, m_Dll4 and m_Kdr in both MNHOC 124 and MNHOC 182.
Unexpectedly, cediranib monotherapy did not modulate gene expression either in
metabolism-, or in angiogenesis-related genes (Figure 6.3, panel A and B).
Different angiogenesis genes were downregulated by olaparib, cediranib and the
combination in MNHOC 18.
Interestingly, m_Tek (the tyrosine kinase receptor for angiopoietin-1) was significantly
upregulated by olaparib, cediranib and the combination (Figure 6.3, panel C).
Chapter 6 Francesca Bizzaro
202
Figure 6.3 Heatmap of relative gene expression (-Ct values) induced by 4-
week treatment.
Relative expression (-Ct) of murine genes associated with metabolism and
angiogenesis in A) MNHOC 124, B) MNHOC 182 and C) MNHOC 18 after treatment
with cediranib, olaparib and the combination. Treated samples were compared with
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Human compartment.
Results obtained from the analyses on tumor microenvironment (murine compartment)
indicated a significant downregulation of angiogenesis induced by treatments. Since it has
been reported that changes in the microenvironment (e.g. local hypoxia and changes in
tumor-associated vasculature) could induce a downregulation of protein involved in the
DNA damage repair system, we analysed gene expression changes on tumor cells (human
compartment).
When genes belonging to the DDR pathways were analysed, no significant downregulation
was identified (Figure 6.4, panel A and B). On the opposite, a larger number of genes were
upregulated in MNHOC 18, mostly when olaparib monotherapy and the combination were
administered. Interestingly, also cediranib monotherapy affected the expression levels of
DDR genes (Figure 6.4, panel C).



















Figure 6.4 Heatmap of relative gene expression (-Ct values) induced by 4-
week treatment.
Relative expression (-Ct) of human genes associated with DDR in A) MNHOC 124,
B) MNHOC 182 and C) MNHOC 18 after treatment with cediranib, olaparib and the
combination. Treated samples were compared with untreated samples. * P <0.05.
N=3
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6.2 CEDIRANIB TARGET BASELINE LEVELS OF EXPRESSION
Given the unexpected modulation induced by cediranib of genes belonging to the DDR
(human compartment), we investigated whether cediranib could act directly on the tumor
cell.
Genome-wide gene expression analyses had previously been carried out on a wider panel
of OC-PDX (Ricci et al., 2014). Given the availability of these data, expression levels of
cediranib targets, VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), c-Kit (KIT) and
PDGFR-alphaPDGFRA) (Sahade et al., 2012) were analysed on tumor cells.
Results showed that VEGFR1, VEGFR3 and PDGFR-alpha were significantly more highly
expressed in MNHOC 18, compared with the other models. Indeed VEGFR1 was scarcely
expressed (range 6.1-6.8 Log2 Intensity) across OC-PDX (n=19), except for MNHOC 18
(7.7 Log2 Intensity) (Figure 6.5, panel A). Similar results were obtained analysing
VEGFR3 and PDGFR-alpha, with MNHOC 18 expressing higher levels (8.9 and 10.2
Log2 Intensity for VEGFR3 and PDGR-alpha respectively) compared to the other OC-
PDX models (range VEGFR3 7-7.9 Log2 Intensity and range PDGFR-alpha 6.4-10 Log2
Intensity) (Figure 6.5, panel B and C). No significant differences were seen comparing
VEGFR2 and c-KIT levels of expression in MNHOC 18, MNHOC 182 and MNHOC 124
(Figure 6.5, panel D and E).
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Figure 6.5 Cediranib-target expression level of OC-PDX.
A) FLT1, B) FLT4, C) PDGFRA, D) KDR and E) KIT levels of expression from
genome-wide gene expression analysis.
Arrays were scanned and images analysed by the Feature Extraction Software; raw
data were processed using the LIMMA (LInear Models for Microarray Analysis)
package from Bioconductor (Smyth, 2004). Background correction was performed
with the normexp method with an offset of 50. Normalization was carried out using
the quantile method. Data are expressed as Log2 Intensity and represented on graph












Genome-wide gene expression analysis
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Thus, to confirm the results obtained from these analyses, ad hoc Real-Time PCR assays
were performed specifically to study the panel of the13 OC-PDX used for this PhD
research project (see Chapter 3 and Chapter 4, Results). Human-specific primers for
VEGFR1, VEGFR2, VEGFR3, c-Kit and PDGFR-alpha were used (Taqman Assay).
VEGFR1 was weakly expressed across all samples (mean ΔCt -15); nevertheless, levels of
expression were higher in MNHOC 18 (ΔCt -11.6) compared with MNHOC 124 and
MNHOC 182 and above the confidence interval (Figure 6.6, panel A). VEGFR3 and
PDGFR-alpha levels of expression were higher in MNHOC 18 (ΔCt -9.5 for VEGFR3 and
ΔCt -5.6 for PDGFR-alpha) compared with MNHOC 124 and MNHOC 182 and the other
models (mean ΔCt -13 for VEGFR3 and ΔCt -10 for PDGFR-alpha) (Figure 6.6, panel B).
MNHOC 18 expressed also the highest level of c-KIT (ΔCt -7.8; mean ΔCt -11) (Figure
6.6, panel E). VEGFR2 levels were within the confidence interval for MNHOC 18 (ΔCt -
9.8), but higher compared with the mean of the group (ΔCt -12.3) and different than
MNHOC 124 and MNHOC 182 (Figure 6.6, panel D).
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Figure 6.6 Cediranib-target expression level in 13 OC-PDX from RT-PCR.
A) FLT1, B) FLT4, C) PDGFRA, D) KDR and E) KIT were normalized to beta-actin
housekeeping gene and ΔCt calculated.
Reported are results for three biological replicates (mean of three technical replicates
each). Data are reported as - ΔCt, such that the lowest value corresponds to the
lowest expression. Abscissa intercepts ordinate axis at the average value of - ΔCt











RealTime gene expression analysis
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When data were analysed considering only MNHOC 18, MNHOC 124 and MNHOC 182
together, the comparison showed that expression of cediranib targets was always higher in
MNHOC 18, with the three receptors of VEGF and c-Kit being significantly higher
compared with MNHOC 182 (Figure 6.7). Thus, it is conceivable that, particularly in
MNHOC 18, cediranib could act not only on the tumor microenvironment but also directly
on tumor cells.
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Figure 6.7 Cediranib-target level in MNHOC 18, MNHOC 124 and MNHOC
182.
Reported are results for three biological replicates (mean of three technical replicates
each). Data are reported as -ΔCt, such that the lowest value corresponds to the lowest
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6.3 SUMMARY OF RESULTS AND DISCUSSION
Cediranib (Ledermann et al., 2016) and olaparib (Pujade-Lauraine et al., 2017) have shown
promising therapeutic activity in ovarian cancer as single agents. The activity of the
combination has led to the two drugs now being considered for a maintenance therapy in
patients with ovarian cancer (Liu et al., 2013, 2014).
Preclinical tests with PARP inhibitors combined with angiogenesis inhibitors have
suggested that downregulation of homologous recombination repair genes, such as BRCA1
and RAD51, occurs with hypoxia, with an enhancement sensitivity to PARP inhibitor in the
hypoxic setting (Bindra et al., 2005; Chan et al., 2008; Scanlon and Glazer, 2015).
Lim and colleagues suggested that VEGFR3 inhibition results in downregulation of both
BRCA1 and BRCA2 in cancer cells (Lim et al., 2014), and additional preclinical studies
indicated that PARP inhibition could increase cytotoxicity in cancer cells under hypoxic
compared with normoxic conditions (Lu et al., 2011).
Given these findings, our initial working hypothesis was that the angiogenesis inhibitor
cediranib could cause hypoxia, which in turn could induce a downregulation of genes
involved in the DNA repair pathway and consequently lead to a “DNA damage repair
system-deficient phenotype”, rendering tumor cells more responsive to olaparib.
In this context, the cross talk between an altered microenvironment and tumor cells no
longer able to repair DNA damage would lead to synthetic lethality and provide the
rationale to the therapeutic advantage of the two drugs administered together.
Indeed, our preclinical testing trials confirmed that the administration of the combination
was the regimen with the best outcome, both in models with an impairment in DNA
damage repair system (BRCAness) and, most importantly, in those with a proficient
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system of repair (Not BRCAness), delaying tumor progression and increasing survival in
subcutaneous and in orthotopic OC-PDX.
For these reasons, we investigated changes in gene expression after 4 weeks of treatment in
three Not BRCAness models, in which the therapeutic advantage of the combination of
olaparib with cediranib was more evident (Figure 6.1).
A panel of both murine and human genes was simultaneously investigated with RealTime
PCR gene expression analysis, giving us the opportunity to assess changes in the tumor
microenvironment/stroma (murine compartment, cediranib primary target) and in the
tumor cell (human compartment, olaparib primary target).
Results indicated that the combination of olaparib with cediranib caused changes in the
tumor microenvironment, in particular inducing a significant downregulation of
angiogenesis-related genes across the three OC-PDX analysed (Figure 6.2, panel A). Of
note, the significant upregulation of m-Tek, the tyrosine kinase receptor (that acts as a cell-
surface receptor for angiopoietin-1, angiopoietin-2 and angiopoietin-4) in MNHOC 18,
could also support the inhibition of angiogenesis by endorsing vascular instability and
vessel quiescence when angiopoietin-2 competes with angiopoietin-1 for binding (Figure
6.3, panel C).
When analyses on changes induced by the treatment on tumor cells (human compartment)
were performed, our initial hypothesis that cediranib, by inhibiting angiogenesis, would
lead to a decreased expression of proteins involved in the DDR, rendering the tumor cells
more sensitive to olaparib, was not confirmed.
No significant downregulation occurred in DDR genes when the combination of olaparib
with cediranib was administered; on the contrary and unexpectedly, the treatments induced
a significant upregulation of DDR genes in MNHOC 18 (Figure 6.4).
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This upregulation could be partially explained by the fact that we have only examined
changes in gene expression after 4 weeks of continuous treatment, hence we are likely
analysing not the “responder cells” but rather the “survivor cells”.
Thus, it would be better to perform gene expression analyses at different time points to
take in consideration changes after a few doses of treatment, when it is reasonable to
assume that the treatment has not yet selected resistant cells, could help to better define
possible mechanism of action underlying the observed advantage of the combination, both
in BRCAness and Not BRCAness tumors.
Olaparib causes DNA damage, due to its “trapping” activity, inducing replication forks to
stall. The increased DNA damage is supported by the significantly higher expression of
H2AX foci detected after the administration of the combination in MNHOC 18 (see
Figure 5.2, Chapter 5, Results).
Thus, tumor cells that survived such damage were those able to overcome the insult by
increasing the expression of proteins involved in DNA damage repair, and the same occurs
in cells that do not respond, explaining also the resistance to olaparib monotherapy.
The fact that the treatments could have induced a clonal selection of cells that have
acquired a BRCAness phenotype, thus becoming more sensitive to the combination of
olaparib and cediranib, can be excluded. Indeed, mutational analyses at the end of the
treatments indicated no acquisition of novel mutations, nor the selection of subclones
mutated in BRCA1, BRCA2 or other genes involved in the DNA repair pathway, as
reported in Figure 4.17, Chapter 4 of Results.
One last aspect that should be taken into account is the modulation induced by the
angiogenesis inhibitor, which led us to investigate the expression of cediranib targets
directly on tumor cells across our platform of OC-PDX. Results showed that, especially in
MNHOC 18, levels of expression of the three VEGF receptors, c-KIT and PDGFR-alpha,
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were higher compared with the other models (Figure 6.5, 6.6 and 6.7), which could explain
the modulation of DDR-related genes induced by cediranib monotherapy.
Despite the fact that these preliminary results did not completely clarify the role of
cediranib in the beneficial combination with olaparib, it appears not to be linked only to a
“general antiangiogenic modulation” on the microenvironment through the inhibition of
the VEGFA pathway. Indeed, when bevacizumab or B20 (bevacizumab is an antibody that
recognizes human VEGF, and B20 recognizes both human and mouse VEGF exhibiting
equal affinity) were administered in combination with olaparib on MNHOC 18 tumor-
bearing mice, no tumor growth delay was achieved (as reported in Figure 4.10, Chapter 4,
Results).
However, it may be assumed that the growth delay induced by the combination could be
due to the sum of the effects given by the single drug; cediranib and olaparib together
perturbed the host microenvironment, modulating angiogenesis, and furthermore both
directly influenced tumor cells as long as the treatment is administered. In fact, in the
MNHOC 18 model, as soon as the combination treatment was interrupted, tumors regrew
with the same doubling time as olaparib and vehicle control group.
More detailed analyses are needed to better clarify these preliminary results.
For instance, to mitigate the bias of using only a small panel of selected genes, whole
transcriptome (RNA sequencing) analysis is being performed (collaboration with
AstraZeneca). Expert bioinformatics colleagues are currently analysing data, taking into
consideration changes induced by treatment in each model used in the preclinical testing
trials, BRCAness and Not BRCAness, considering both the human and murine
compartments.
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CHAPTER 7.
Conclusions and Future Perspective
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7.1 CONCLUSIONS AND FUTURE PERSPECTIVES
This project was aimed to investigate the effect of the combination therapy of PARP (i.e.
olaparib) with angiogenesis inhibitors (i.e. cediranib) in the treatment of ovarian cancer,
taking advantage of a platform of established and well characterized (histopathology,
biological behaviour and molecular profile) ovarian cancer patients-derived xenografts
(OC-PDX).
To this purpose, OC-PDX previously established in the Department of Oncology (Ricci et
al., 2014), together with new models established during this PhD research project, as
described in Chapter 3, have been used.
Among these, 26 OC-PDX were selected, that reproduced the plethora of ovarian
carcinomas with all the different subtypes, growing subcutaneously or orthotopically in the
peritoneal cavity of mice. The OC-PDX were deeply characterized for their biological,
histopathological and molecular features. Results showed that OC-PDX retained the
histotype and tissue architecture even after several in vivo passages, harboured mutations
in genes mostly involved in ovarian cancer disease and progression (TP53, KRAS, BRAF,
PIK3CA, CTNNB1, PTEN, EGFR) and in some HR DNA repair pathway genes. Moreover,
when a comparison was possible, OC-PDX showed a strong consistency with the patient’s
tumor they derived from, maintaining the same histotype and mutations. For these reasons,
our collection offered an instructive framework to perform preclinical drug testing that
could be translated into the clinic.
Taking together data obtained from the Next Generation Sequencing and gene expression
analysis and considering their histopathological origin, 13 ad hoc OC-PDX models were
further selected to preclinical therapy testing with olaparib combined with cediranib, as
reported in Chapter 4. This cohort of OC-PDX included mostly high grade serous and
endometrioid ovarian carcinomas, with one clear cell and one mucinous model.
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OC-PDX carrying somatic mutations and loss of BRCA1/2 on both gene alleles or
expressing low levels of BRCA1 and BRCA2 were defined as BRCAness. OC-PDX that did
not carry mutations on BRCA1 and BRCA2 or did not display locus-specific loss of
heterozygosity (LOH) were defined as Not BRCAness.
The response to olaparib monotherapy was assessed in 10 OC-PDX growing
subcutaneously, both in a short-term (4 weeks) and in a maintenance regimen, until tumor
regression or progression.
Results showed that BRCAness tumors responded to olaparib monotherapy after a short-
term treatment and even more in a maintenance regimen, with complete responses. As seen
in the clinic, aberrations in BRCA1/2 were predictive for olaparib response also in our
platform of OC-PDX (Fong et al., 2010; Kaufman et al., 2015), increasing the predictive
value of these models.
However, some OC-PDX were an exception. The subcutaneous MNHOC 154 carried a
pathogenic mutation in BRCA1, but the presence of an amplification in BRCA2 (confirmed
also by the high level of gene expression) induced a heterogeneous response to olaparib
monotherapy.
The molecular heterogeneity within an individual model is an issue that call for
consideration. In this sense, the identification of sub-clone populations of cells within each
single tumor of each OC-PDX model and consequently single cell analyses with optimized
next generation sequencing technologies, both on DNA, RNA and proteomics could
provide a better understanding of the function of an individual cell in the context of its
microenvironment. Sequencing the DNA of individual cell clones could provide
information about carrier and non-carrier mutations and genomic alteration, while
sequencing the RNA could give insight into the differences in gene expression. Taken
together, all these aspects could deeply influence the response to targeted therapies, such as
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PARP inhibitors and explain the observed heterogeneous responses within one single OC-
PDX, as for MNHOC 154.
Similarly, to MNHOC 154, the intraperitoneal MNHOC 22 was resistant to olaparib,
showing no increase in host survival and remarkable production of ascites, although
carrying a mutation in BRCA1.
Not BRCAness and olaparib resistant OC-PDX were good models to study combination
regimens and specifically the advantage of adding cediranib to olaparib. Genomic
instability and induced angiogenesis are two of the cancer hallmarks (Hanahan and
Weinberg, 2011), thus targeting both of them could boost the therapeutic outcome. Clinical
trials have investigated the combination of olaparib with cediranib (Liu et al., 2013, 2014)
in recurrent ovarian cancer patients, showing an increased PFS in patients with germline
mutations in BRCA1/2, and most interestingly in homologous recombination proficient
patients.
Our preclinical trials indicated that the combination was beneficial for the BRCAness
models, inducing more durable and stable effects, persisting several weeks after treatment
suspension, and increasing the number of complete responses and cured mice. Most
importantly, the combination of olaparib with cediranib was favourable for those OC-PDX
that were poorly responsive to olaparib single agent, especially the Not BRCAness
subtypes, promoting a stabilization of disease in case of short-term treatment and a
regression in maintenance regimens.
Several aspects of the therapeutic advantage of the combination were considered in the
orthotopic OC-PDX models, that grow in the peritoneal cavity of immune-deficient mice,
resembling the biological features of the patient’s tumor.
In particular, the BRCAness MNHOC 8 model enabled us to analyse the importance of
drug sequence in the combination of olaparib with cediranib. Survival was increased when
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the combination was administered in a maintenance regimen. The gain in survival was
accompanied by a substantial control in the ascites levels; however, dissemination
increased, leading mice to live longer, but with the detriment of a more aggressive disease.
The escape from antiangiogenic treatments has been well documented in preclinical studies,
including in our OC-PDX models treated with bevacizumab, which under certain
circumstances increased survival but also tumor dissemination (Bizzaro et al., 2018; Decio
et al., 2015).
The benefit of the combination of olaparib with cediranib was further supported when the
PARP inhibitor was combined with other angiogenesis inhibitors. In our OC-PDX models,
the administration of olaparib with bevacizumab or B20, two anti-VEGF antibodies, was
ineffective or not different from the combination with cediranib. Despite the fact that these
results did not completely clarify the role of cediranib added to olaparib, its effect appears
not to be linked only to a “general antiangiogenic modulation” on the microenvironment
through the inhibition of VEGFA pathway.
In this regard, further experiments on the VEGFC/VEGFR3 assay could be of interest,
since it has been reported that tumor tissue overexpressing VEGFR3 are characterized by
aggressiveness and ability to spread. VEGFC binds VEGFR3, and its expression has been
associated with peritoneal and lymph node metastases, since it is the main promoter of
lymphangiogenesis and has regulatory functions in tumor progression and dissemination. It
has been reported that cediranib caused vascular regression and inhibition of VEGFR3
mediated lymphangiogenesis in ovarian cancer models (Decio et al., 2014). In this context,
the effect of adding cediranib to olaparib on the VEGFC/VEGFR3 mediated
lymphangiogenesis and dissemination could provide insight into the prolonged survival
and the reduced ascites production with the combination treatment, to the detriment of an
increased tumor dissemination through the organs of the peritoneal cavity.
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In addition, the combination of olaparib with cediranib was the regimen with the best
outcome also in the ID8 model, a syngeneic murine ovarian cancer, transplanted in the
bursa of the ovary of mice. The combination of olaparib with cediranib did not increase
survival in mice, but mostly delayed tumor progression and affected primary tumor growth
at the ovary, both in the short-term and in maintenance regimen, inducing stable disease
even after several weeks from treatment suspension.
Efforts to determine possible biomarkers of response and to carry out the molecular
characterization of OC-PDX after 4 weeks of treatment were described in Chapter 5 and
Chapter 6.
Preclinical in vitro tests have suggested that downregulation of homologous recombination
repair genes, such as BRCA1 and RAD51, occurs with hypoxia, with an enhancement of
PARP inhibitor sensitivity in the hypoxic setting (Bindra et al., 2005; Chan et al., 2008;
Scanlon and Glazer, 2015).
Lim and colleagues suggested that VEGFR3 inhibition results in downregulation of both
BRCA1 and BRCA2 in cancer cells (Lim et al., 2014), and additional preclinical studies
indicated that PARP inhibition could increase cytotoxicity in cancer cells under hypoxic
compared with normoxic conditions (Lu et al., 2011).
Given these, our initial working hypothesis was that the angiogenesis inhibitor cediranib
could cause hypoxia, which in turn induced a downregulation of genes involved in the
DNA repair pathway and consequently lead to a “DNA damage repair system-deficient
phenotype”, thus rendering more responsive to olaparib also DNA repair-proficient tumors.
In this context, the cross-talk between an altered microenvironment and tumor cells no
more able to repair DNA damage would have led to synthetic lethality and provided the
rationale to the therapeutic advantage of the two drugs administered together.
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Changes in tumor-associated vasculature (CD31 positive), hypoxia and DNA damage
markers (such as H2AX foci formation) were evaluated in a limited number of OC-PDX
after drug testing, as reported in Chapter 5.
Results indicated a general heterogeneity amongst the models, with different levels of
hypoxia and different expression of H2AX, detected at baseline.
However, after 4 weeks of treatment, the addition of cediranib to olaparib reduced tumor-
associated vasculature and modified hypoxia (microenvironment, cediranib most intended
target) and enhanced DNA damage, with H2AX foci increased (tumor cells, olaparib most
intended target). The double-side effect of the combination sustained the stabilization or
regression of subcutaneous tumor growth, as long as the therapy was administered.
When analyses were performed at tumor progression under maintenance treatment in the
intraperitoneal MNHOC 8 (after more than 20 weeks of treatment administration), vessel
number, vessel area and hypoxia were reduced by the combination. Long-term exposure to
angiogenesis inhibitors could result in tumor growth reduction, paralleled by a more
malignant and invasive phenotype (Mountzios et al., 2014). In MNHOC 8 the maintenance
treatment with the combination reduced ascites production to the detriment of an increased
tumor dissemination through the organs of the peritoneal cavity.
Changes in gene expression were analysed after 4 weeks of treatment in three
subcutaneously growing Not BRCAness models, in which the therapeutic advantage of the
combination of olaparib with cediranib was more evident, as reported in Chapter 6. A
panel of both murine and human genes was simultaneously investigated, giving us the
opportunity to assess changes in the tumor microenvironment/stroma (murine compartment,
cediranib most intended target) and in the tumor cells (human compartment, olaparib most
intended target).
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Results indicated that the combination of olaparib with cediranib caused changes in the
tumor microenvironment, inducing a significant downregulation of angiogenesis-related
genes across the three OC-PDX analysed.
However, when changes induced by the treatment on tumor cells were analysed, our initial
hypothesis that cediranib, by inhibiting angiogenesis, would have led to a decreased
expression of proteins involved in the DDR, rendering the tumor cells more sensitive to
olaparib, was not confirmed. On the contrary and unexpectedly, the combination treatment
induced a significant upregulation of DDR genes.
These preliminary results could be partially explained by the time-point selected to collect
samples for analyses.
Since we looked at changes in gene expression after 4 weeks of continuous treatment, we
were likely analysing the “survivor cells”. In these tumor cells, olaparib caused DNA
damage, due to its “trapping” activity, inducing replication forks to stall, and that was
supported by the significantly higher expression of H2AX foci detected after the
administration of the combination. Thus, tumor cells that survived such damage were those
able to solve the insult by increasing the expression of proteins involved in DNA damage
repair, and the same occurs in cells that do not respond, explaining also the resistance to
olaparib monotherapy.
Given these, it might be assumed that the effect on growth delay induced by the
combination is due to the sum of the effects given by the two single drugs; cediranib and
olaparib perturbed together host microenvironment, modulating angiogenesis, and
furthermore, both influenced directly tumor cells as long as the treatment was administered.
In conclusion, the results obtained in this PhD thesis compel us to believe that the addition
of cediranib to olaparib is advantageous both for BRCAness and Not BRCAness models.
The therapeutic effect of the combination in delaying tumor growth, the induction of more
durable and stable effects, even several weeks after treatment suspension, and the increased
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number of complete responses, is particularly evident when the combination is
administered in maintenance.
However, the attempt to investigate possible mechanisms of action underlying the
therapeutic effect of the combination of olaparib with cediranib, by immunohistochemical
and gene expression analyses, led us to preliminary results that need to be better clarified.
To this purpose, whole transcriptome (RNA sequencing) analysis has been performed, to
overcome the bias of using only a small panel of selected genes, as we did with RealTime
PCR.
RNA sequencing has been carried out in collaboration with AstraZeneca, on samples
collected from subcutaneously and intraperitoneally growing OC-PDX (n=8 both
BRCAness and Not BRCAness) after 4 weeks of treatment.
Data are currently under investigation, taking in consideration changes in both the human
and murine compartment induced by treatments.
From this genome-wide analysis, more focused gene expression analyses will be
performed, to take in consideration changes after a few doses (e.g. 2, 5 and 7 days from
treatment initiation), when it would be conceivable to think that the treatment has not
selected resistant cells. Looking at cells that are responding to treatment could help to
better understand possible mechanisms of action underlying the observed advantage of the
combination, both in BRCAness and Not BRCAness tumor.
In this respect performing ad hoc preclinical trials, increasing the number of tumors per
treatment group (N=8-10) would strengthen the significance of the analyses performed in
this PhD project and provide additional material for multiple end-points, both in terms of
molecular, such as RNA sequencing, and immunohistochemical analysis.
In terms of immunohistochemical analysis, several other biomarkers of accumulating
DNA damage could be investigated in addition to those reported, such as ROS (reactive
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oxygen species) production, that is one of the pathway regulated by hypoxia, and also
levels of CHECK, ATM, ATR and CASP3.
Vascular architecture is one aspect that could influence drug distribution and response.
In this context, other immunohistochemical analysis could be performed on OC-PDX
tumor samples, to assess SMA expression, and also to consider EMT (epithelial to
mesenchymal transition) status, evaluating E-cadherin and vimentin expression. This
evaluation could help to better stratify OC-PDX accordingly to the response to cediranib,
olaparib and the combination, and possibly to reveal some mechanism of action underlying
to advantage of adding cediranib to olaparib both in BRCAness and Not BRCAness tumor.
Doses of olaparib and cediranib used to perform preclinical therapy testing reported in this
PhD project were selected on the basis of those used in clinical trials and converted from
human to animal administration. Indeed, in the phase II clinical trial (Liu et al., 2014),
olaparib and cediranib were administered as capsule and tablets at the dose of 200 mg and
30 mg; mouse equivalent dose conversion based on FDA Draft Guidelines, led us to select
100 mg/kg and 3 mg/kg respectively. Furthermore, data from clinical trials supported daily
oral dosing for both the drugs, that were thus administered with oral gavage in mice.
However, no studies to exclude plasma pharmacokinetic interactions between the two
inhibitors and examine whether there is any influence of the combination on drug
accumulation in the tumor were performed in OC-PDX.
The collection of a higher number of tumor samples and biological fluids (plasma, serum
and ascites) per treatment group, at different time-points from treatment initiation (e.g. 2, 5,
7 and 28), would allow to evaluate steady-state concentrations of the two inhibitors,
together with clearance and potential accumulation phenomena.
In this regard, it is known that tyrosine kinase inhibitors, such as cediranib, impair the
ATP-ase functionality of the p-glycoprotein (ABCB1), expressed by tumor endothelial
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cells, increasing intracellular drug accumulation of different compound that are ABCB1
substrates (doxorubicin, vincristine and paclitaxel).
Ad hoc Real-Time PCR assays or Western Blot analysis could be performed in order to
assess level of ABCB1 expression across our OC-PDX.
The availability of AZD2281-BODIPY FL, a modified olaparib in which the cyclopropane
group is replaced by the green fluorescent dye boron-dipyrromethene (BODIPY)
fluorophore (FL), with potential fluorescent imaging activity, would be useful to determine
if the administration of cediranib will allow the accumulation of olaparib in the tumor cells
of those OC-PDX in which ABCB1 is mostly expressed.
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